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Abstract 
So-called “targeted therapeutics”, agents with tumour-selective action, promise to 
revolutionise treatment of specific malignancies; however, realisation of the 
therapeutic promise of such drugs requires new methods of rapidly distinguishing 
patients who will derive treatment benefit.  Tyrosine Kinase Inhibitors (TKIs), a 
group of small molecule therapeutics, inhibit specific aspects of the phosphorylation-
mediated intracellular signalling pathways commonly altered in cancer. 
Overexpression of one such pathway, initiated by the HER2 growth factor receptor, 
occurs commonly in breast cancer. Lapatinib, a HER2 TKI, has been used in 
combinations with other cancer drugs for treating HER2 overexpressing breast 
cancer. The aim of this study was to evaluate gene expression changes in response to 
these targeted therapies to examine their ability to predict treatment response.  
In this thesis, microarray data from lapatinib-treated drug sensitive breast cancer cell 
lines was interrogated using an emerging bioinformatic technique, Co-inertia 
analysis (CIA). Using this technique, 512 genes were found to be altered in a specific 
response to lapatinib treatment in the cell lines. 27 gene targets were chosen for more 
detailed analysis using Taqman RT-PCR, of which five showed predictive response 
in a broader panel of breast cancer cell lines treated with lapatinib.  
Expression of the five genes was further examined in response to other HER2 
targeted therapies and the analysis indicated that the gene expression changes 
remained consistent with these other treatments, demonstrating a more broadly 
representative anti-HER2 response pattern. An in vivo study sought to evaluate these 
gene expression responses in a more in vivo-relevant scenario and found that they 
were also conserved in this model.  
Our research indicates that there are commonalities among the gene expression 
response to HER2-targeting therapeutics in responsive cells which may extrapolate 
to HER2-amplified patient tumours and more broadly suggests that characterisation 
of gene changes shortly after treatment may provide a valuable rapid predictor of 
inhibitor response, potentially guiding a more specific use of such agents by 
identifying patients that will benefit from these therapies. 
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1.1 Cancer 
1.1.1 History  
 
Commonly thought to be one single malady, cancer is in fact a highly complex group 
of diseases. It can originate and affect any organ and system in the body and affects 
men and women of all ages. In the developed world it is one of the biggest killers 
and it is becoming more prevalent in the developing world. Of the 7.6 million deaths 
in 2008 associated with cancer, 4.8 million of those occurred in developing countries 
[1].  In 2012, the number of deaths associated with cancer in Ireland was 8544. Of 
this number 30% were neoplasms of the gastrointestinal tract (e.g. colon cancer), 
excluding the stomach, 21% were trachea, bronchus and lung cancers, 17% were 
genitourinary and 8% were breast neoplasms [2]. In the last decade or so our 
knowledge of the molecular origins and implications of cancer has grown 
significantly and this has successfully translated into improved treatment options and 
patient outcome[3]. 
Early detection of cancer in any form can reduce the need for extensive treatment. 
Typically, once located, a solid tumour is surgically removed and, if it determined 
that it has not spread to other part of the body, a patient may not have to undergo 
chemotherapy or radiation. In some cases, especially breast cancer, clinical 
experience suggests that adjuvant treatment with radiation and/or chemotherapy may 
additionally ensure that no undetected errant cancer cells have survived. However, if 
it found that the cancer has spread or is more locally advanced a more intense 
treatment approach is indicated with toxic chemotherapy being the mainstay of 
disease management.  
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On its own or in combination with radiation and or surgery, application of relatively 
non-specific cytotoxic chemotherapy drugs has been a mainstay in the treatment and 
management of advanced malignancies (where the disease is a major burden in the 
body and/or has spread) for several decades and this is discussed in more detail in 
section 1.2. However more recently, treatment agents have started to be more 
targeted to the molecular drivers of the cancer, making them more specific. As 
examples, the treatment of breast cancer and chronic myeloid leukaemia (CML) are 
good illustrations of success of this approach of so-called “molecularly targeted 
therapy”. Overall survival of CML, in the chronic phase has improved from 15% 
pre-introduction of imatinib (a tyrosine kinase inhibitor) to as high as 87% since the 
introduction of the targeted therapy [4]. Molecular aberrations, such as over 
expression of the HER2 growth factor receptor and expression of the BCR/ABL 
transgene, have been successfully targeted with agents such as trastuzumab and 
gefitinib respectively. Breast cancer has become a particular focus for treatment 
individualisation and application of targeted therapeutics with notable success in 
increased survival, complemented by increased early detection and disease 
management. From initial studies carried out using trastuzumab in combination with 
first-line chemotherapy, data showed an increase in survival from 20.3 months with 
chemotherapy alone to 25.1 months with chemotherapy combined with trastuzumab 
[5]. 
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1.1.2 Breast Cancer 
 
According the World Health Organisation (WHO), breast cancer accounts for 16% 
of all cancers that affect women globally. Nationally, the Irish Cancer Society 
estimates that 1 in 10 Irish women will develop breast cancer at some stage in their 
life  and it accounted for 29% (excluding non- melanoma skin cancer) of the number 
of cancer diagnoses in Ireland between 1995 and 2007 in women [6]. The disease is 
most commonly diagnosed in women over the age of 50 but can affect women of any 
age. Pathological classification of this cancer, undertaken to provide predictive 
diagnostic information,  is based on a number of aspects such as, tumour size, 
tumour progression, nodal spread and receptor status e.g. estrogen receptor (ER), 
progesterone status (PR) and human epidermal growth factor 2 (HER2). 
Classification of these clinical parameters will generally dictate the course of 
treatment to be recommended to the patient. Breast cancer is often detected by self-
examination or routine mammographic screening. Tumour classification/staging can 
be completed using a number of methods. One such method is the TNM 
classification system. The tumour stage is assessed based on three criteria; tumour 
size (T), whether nearby lymph nodes are involved (N) and the presence or absence 
of metastatic tumours at other sites (M) [7]. Later stage breast cancers are often 
associated with a reduced chance of survival and the type of treatment offered may 
change. In early stage disease treatment will often be multimodal involving surgery 
followed by radiation, endocrine therapy (for hormone-positive malignancies) and/or 
adjuvant chemotherapy (aimed at eradicating any small undetected tumour deposits 
in the body. Chemotherapy, often simply called “chemo” involves treatment with 
cytotoxic drugs designed to bring about cell cycle arrest and/or apoptotic tumour cell 
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death [8] However, the application of these agents is limited by their toxicity to 
normal cells and the development of drug resistance. The toxicity to normal cells can 
result in adverse effects such as hair loss [9], extreme fatigue [10], depression of the 
immune system  and vomiting [11]. Hence there is need for more personalised 
medicine allowing treatment and dosage to be tailored to a particular patient’s 
tumour type, thus improving response to treatment and limiting patient exposure to 
unnecessary drugs.  
As breast cancer treatment has evolved over the last decades, it was recognised that 
there were many inconsistencies in the outcome of breast cancer patients when 
pathological classification alone was employed for prediction and prognosis.  Hence 
a lot of research effort has gone into improved molecular subclassification of tumour 
type to give better prognostic information for the patient and their clinician, with 
more recent research being used to predict the most efficacious treatments for 
specific molecular subtypes of cancer [12]. For example, using microarray analysis 
and hierarchal clustering analysis of over 100 patient tumour samples, Sorlie et 
al.,[13]  evaluated the different subtypes occurring in breast cancer patients. The 
microarray analysis consisted of examination of the expression of 534 genes.  
(Figure 1.1) 
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Figure 1.1: Hierarchial clustering of subtypes of breast cancer from Sorlie et al 2003. The tumour 
samples were analysed using microarray analysis which consisted of 534 genes. The microarray 
analysis identified four major cancer subtypes, which have their own individual characteristics and 
expected prognosis and the normal breast like tissue. The four cancer subtypes identified were 
luminal subtype A (blue), luminal subtype B (turquoise), ERBB2+ (pink) and basal subtype (red).  
 
Their analysis indicated that there were four major subtypes within the tumour 
sample population which they termed luminal type A, luminal type B, ERBB2 
(HER2) positive and basal. Each of the subtypes has their own individual 
characteristics that give general indications as to patient prognosis and what 
treatment type will often be most effective. Luminal type A and luminal type B are 
both considered to be ER positive, with subtype A found to be low grade with 
subtype B tending to be more high grade. As both subtypes express ER, they are 
treated with hormone inhibitor therapies (endocrine therapies)  such as tamoxifen or 
aromatase inhibitors (usually in post-menopausal women), with subtype B requiring 
additional chemotherapy [14]. The basal subtype is also referred to as triple negative 
as it does not overexpress HER2, ER or PR receptors. This sub group of cancer has 
been associated with poor prognosis [15, 16]. While many patients have been shown 
to respond to chemotherapy treatment, the use of newer targeted therapies in the 
treatment of this form of breast cancer has been very limited due to the lack of 
specific targets [17, 18]. 
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The last subtype ERBB2/HER2-overexpressing has been shown to be one of the 
most suitable for targeted therapies, and this is discussed in detail below.  
 
1.1.3 Role of HER2 in Breast Cancer 
 
Aberrations in the epidermal growth factor (EGFR) family of proteins have been 
identified as being important in breast cancer. One particular member of this growth 
factor receptor family, HER2/ ERBB2, has been found to be particularly important in 
breast cancer biology, in a subset of patients [19]. Although research is now trying to 
tease out the role and relevance of the three remaining members of this receptor 
group, EGFR, HER3 and HER4. The EGFR family are tyrosine kinase receptors, a 
class of transmembrane receptors that can bind and phosphorylate with other 
receptors within the family to activate a kinase-signalling pathway within the cell.  
Activation of the functional component of these receptors requires that the Src 
Homology 2(SH2) domain of the receptors must undergo phosphorylation. The SH2 
regions are conserved domains first identified within the Src oncoprotein [20]. The 
ability to enzymatically phosphorylate target substrates results from dimerisation and 
auto-phosphorylation of the C terminal tyrosine residue, induced by ligand binding 
to the extracellular domain of the receptor. 
Signal transduction within the cells therefore requires receptor dimerisation [21]. 
While homodimerisation can take place, a number of combinations of functional 
heterodimers have been identified since the first dimerisation was suggested [22, 23].  
The combination of receptors in the homo/heterodimer(s) will dictate which 
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signalling pathway is activated, with some dimers having inherent signalling activity 
and others requiring ligand binding for activation [24].  
However, these receptors do have some limitations. The kinase domain of HER3 is 
inactive and as a result the protein can only signal through hetrodimerisation partners 
[25]. HER2 has no known ligands and therefore acts as a signal transducer by 
hetrodimerising with EGFR, HER3 and HER4 [26].  
HER2-positive breast cancer, in which the HER2 receptor is overexpressed, 
generally through amplification of the HER2 gene, is found in approximately 20-
30% of human breast cancers [27] and has been associated with poorer prognosis 
and outcome [19, 28].  This alteration has been associated with the increase of 
tumour invasiveness by the down-regulation of α-4 integrin via the p38MAPK 
pathway[29]. It is this poor responsiveness, the aggressive nature of HER2+ breast 
cancers and the relatively high incidence of the target that has made this growth 
factor receptor a good therapeutic target. In addition, HER2-overexpressing breast 
tumours tend to become dependent on this aberration, a process which has been 
termed “oncogene addiction” hence inhibition also represents an effective 
treatment[30]. 
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1.1.4 Cancer Biomarkers  
 
The use of biomarkers has become increasingly important in the diagnosis and 
treatment of many malignancies including breast cancer. A biomarker has been 
described as a cellular, biochemical or molecular alteration that can be measured in a 
biological medium, e.g. blood or tissue. These alterations can be evaluated as an 
indicator of pharmacological response to therapy or a pathogenic process [31, 32]. 
Biomarkers can be classified as prognostic, predictive or diagnostic. Prognostic 
markers can be used to evaluate how a disease will progress in a patient regardless of 
their treatment. Predictive markers can be used to determine the effects that a 
treatment will have on a patient’s disease and diagnostic markers can be used to 
investigate the presence of a disease.   
 
1.1.4.1 Biomarkers in breast cancer 
 
 In the diagnosis of breast cancer, the evaluation of the molecular markers PR, ER 
and HER2 are routinely used in order to determine the most suitable treatment 
regime [33]. There are currently only two FDA-approved methods to determine that 
HER2 overexpression is present, immuno-histochemical analysis (IHC) and 
fluorescence in-situ hybridisation (FISH) [34].  
Recent developments in the field which utilise molecular-based assays to classify the 
different subtypes of cancer are moving away from the anatomical/pathological 
classification of the malignancy and have been focussed on giving more predictive 
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and prognostic information, thereby promising to allow physicians identify the most 
suitable treatment options available. Many of the assays that will be described below 
have both prognostic and predictive applications although it will likely be several 
years before their full utility is characterised and their use becomes the international 
standard of care. 
 The Breast BioClassifier or PAM50 is an RT-PCR assay which utilises analysis of 
the expression of 50 genes and 5 control genes to determine which subset of breast 
cancer the patient samples belong to [35, 36]. In the prognostic setting this assay 
evaluates the risk of recurrence or the likelihood of relapse following 5 years in 
patients based on the expression of these genes [36-38]. In the predictive setting, this 
assay has been utilised in the RxPonder trial to determine the most suitable course of 
treatment for ER positive, node positive patients, whether it be chemotherapy or 
hormone therapy [37].  
The oncotype DX assay which examines the expression of a 21 gene signature is 
used in the prognostic setting to evaluate the likelihood of disease recurrence in 
women with estrogen receptor (ER) positive only breast cancer [39]. In the 
TAILORx clinical trial, which was devised by the National Cancer Institute (NCI), 
the oncotype DX gene signature was used to predict if adjuvant chemotherapy 
treatment should be indicated in ER-positive, node negative breast cancer patients. 
[40]. The test uses recurrence scores to predict which patient will likely need 
additional chemotherapy added to their hormonal treatment. This recurrence score is 
calculate by normalising the expression of the 21 genes to the expression of the 5 
reference genes that are also screened for in the assay [41]. The resultant recurrence 
score is then segregated into 3 groups which dictates treatment option, scores lower 
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than 16 (hormonal treatment alone), scores 16 to 25(randomised arm) and scores 
greater than 26 (hormonal treatment in combination with chemotherapy) [41]. 
MammaPrint is a 70 gene expression-based assay that is manufactured by Agendia 
BV. This microarray based assay which uses fresh mRNA from patient resections 
has been utilised to determine the risk of metastasis from a breast cancer tumour. 
This assay is being utilised in the MINDACT clinical trial which aims to predict  the 
appropriate therapy option for patients suffering from lymph node negative, ER 
positive or negative breast cancer [42]. Using the MammaPrint assay in combination 
with standard clinicopathologic prognostic factors (tumour grade, ER status and 
HER2 status), patients are assigned high or low risk status.  Patients with a high risk 
status as determined by the MammaPrint assay and clinicopathological factors are 
treated with chemotherapy, patients with a low risk status from both assessments are 
not treated and are monitored and patients that show a difference between the two 
tests are given a randomised treatment.  In patients that are ER+ that present with a 
high risk from both the MammaPrint and the clinicopathologic prognostic factors, 
hormonal therapy (tamoxifen) is prescribed in combination with chemotherapeutic 
agents. In patients that present as low risk, while no chemotherapy is given they do 
undergo a course of hormonal therapy. This is the same for patients that are enrolled 
in the randomised arm [43]. 
The three assays that have been described above all use gene expression signatures 
to evaluate how a disease is expected to develop (prognosis) and also have been used 
to predict what patients would benefit from treatment with chemotherapeutic agents. 
However, none of these assays has the capability to determine if the patient will 
respond to the treatment that they will receive. In the case of HER2 positive patients 
who receive HER2 targeted therapies such as the monoclonal antibody trastuzumab 
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or the tyrosine kinase inhibitor lapatinib, it is estimated that as many as 50% of 
patients will develop resistance to the therapy within 12-36 months [27]. The cost of 
these therapies as well as the undue burden that they can cause to patients has 
resulted in regulatory agencies such as the FDA promoting the development of 
companion diagnostics that can be used by clinicians to determine whether or not 
patients are responding to treatment.  
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1.2 Cancer Treatment 
1.2.1 Conventional treatment 
 
Conventional treatment of cancer can include combinations of surgery, radiation 
and/or chemotherapy, depending on a large number of variables including patient 
age, anatomical location and molecular and pathological characteristics of the 
tumour. 
Surgery has proven to be one of the most successful methods for tumour eradication 
when the tumour is localised. and can be used in combination with chemotherapy, 
radiation and targeted drug therapies [44]. Radiation treatment uses ionising 
radiation to target and treat solid tumours, many of which have been detected at an 
early stage. By targeting the nuclear DNA of the cancer cell and disrupting it, 
radiotherapy is thought to work primarily by interrupting the cell cycle process and 
thereby killing the cancer cell [45].  
 
1.2.2 Cancer chemotherapy 
 
Chemotherapy is the use of cytotoxic chemical agents that have the ability to damage 
cancer cells, where successful this action disrupts growth of the cancer cell and can 
result in cessation of cell growth and/or (preferably) tumour cell death [46]. As a 
neo-adjuvant treatment, chemotherapy can be used, much like radiation to shrink 
tumours prior to surgery. As an adjuvant therapy it can be used to eliminate any 
cancer cells that may have spread from the primary tumour site and hence target 
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metastasis that might otherwise occur at a later date [47]. As with other cancer 
treatments, chemotherapy is also used in combination with radiation and it is not 
uncommon for a patient to be on regimens containing multiple agents. [48].  
Chemotherapy has been proven to be a useful therapeutic tool in the treatment of 
metastatic cancers. As radiation tends to damage surrounding tissue, it is generally 
employed only in localised disease, while chemotherapy can disseminate throughout 
the bloodstream to multiple potential sites in the body. Chemotherapy can be 
administered by oral dosage or, more usually, intravenously for delivery throughout 
the bloodstream [46].  
The cytotoxic actions of chemotherapy drugs are not specific to cancer cells, healthy 
cells can also be affected as a result of this, and hence, many patients suffer adverse 
effects. Fatigue is the most commonly reported side effect associated with 
chemotherapy treatment. Alopecia (hair loss), nausea, vomiting, diarrhoea, low 
blood cell counts, cardiotoxicity, fertility and sterility issues and neurotoxicity are 
also common side effects. In addition to these, patients undergoing chemotherapy 
can become immunosuppressed leaving them susceptible to opportunistic infections. 
This effect is due to chemotherapeutic agents causing damage to the bone marrow, 
which is responsible for the production of many of the immune cells that the body 
needs to fight infection, such as T-cell, B-cells, and dendritic cells [44].  
Chemotherapy drugs are classified depending on what stage of DNA synthesis they 
are capable of interfering with.  
Alkylating agents, such as cyclophosphamide, are used in the treatment of some 
breast cancers. These drugs add an alkyl group which damages cellular DNA. 
Platinum agents, e.g. cisplatin, damage DNA with the addition of a platinum adduct. 
15 
 
These cytotoxic agents are used in the treatment of many malignancies, including 
lung and ovarian cancer.  
Antimetabolites are responsible for the inhibition of pyrimidine and purine 
metabolites production which are required for DNA and RNA synthesis (a vital 
component of cell growth and division) [44]. Methotrexate and 5-fluorouracil are 
two agents that fall into the antimetabolite category. They are employed in many 
forms of cancer, for example, in  CMF (cyclophosphamide, mexotrexate, 5 
fluorouracil) combination therapy which has been used successfully in the treatment 
of node positive breast cancer [48].  
Anthracyclines or anti-tumour antibiotics such as doxorubicin or epirubicin are again 
used in several forms of cancer including breast cancer. These agents generally 
function by an intercalation interaction with DNA [49].  
Antimitotic agents, for example taxanes such as paclitaxel, target spindle formation 
in mitosis, thereby having a major impact on tumour cell growth.  Paclitaxel is used 
in many malignancies including lung, ovarian and breast cancer treatment [44].   
 
1.2.3 Targeted therapies 
 
 The use of targeted therapies has come to the forefront of oncology in the past 
decade. Monoclonal antibodies and tyrosine kinase inhibitors are currently being 
used for the treatment of a number of receptor and pathway alteration-driven forms 
of cancer. The Philadelphia chromosome (BCR-ABL) has proven to be extremely 
vulnerable to targeting with specific TKIs [50]. The introduction of imatinib into the 
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portfolio of drugs employed for the treatment of chronic myeloid leukaemia has been 
extremely successful, with one study indicating that, since its introduction, imatinib 
has improved the 8 year survival rate to 87% from a 20% pre-imatinib rate [4]. 
Following the success of imatinib, additional targeted therapies have also been 
developed for the treatment of CML, such as sunitinib and dasatinib. The epidermal 
growth factor receptor (EGFR) is another commonly expressed cell surface protein 
on cancer cells that has also been successfully targeted using TKI. Overexpression of 
this receptor has been found commonly in lung cancer and, as a result, gefitinib, an 
EGFR inhibitor, has been used in the treatment of EGFR-overexpressing lung and 
breast cancer [51, 52].  
 
1.2.3.1 Targeted therapies for HER2 positive breast cancer 
 
Since the identification of frequent overexpression of HER2 (especially in breast 
cancer) in the 1980s, HER2 receptor-based inhibitor strategies have proven to be a 
poster child for the applicability and clinical of molecularly targeted therapies. The 
monoclonal antibody trastuzumab was developed by Genentech and has been used 
extensively in HER2+ metastatic breast cancer patients, both as a mono-therapy and 
in combination with chemotherapeutic agents. In addition to monoclonal antibodies, 
tyrosine kinase inhibitors have also been developed that bind specifically to the 
HER2 kinase domain.  Lapatinib, along with second generation agents, such as 
afatinib and neratinib have been used in a large number of clinical trials. Figure 1.2 
illustrates the different binding domains of the epidermal growth factor family that 
are targeted by the molecularly targeted therapies discussed in this section.  
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Figure 1.2: Schematic representing the binding site of the target therapies trastuzumab, 
lapatinib, afatinib and neratinib.  
 
1.2.3.1.1  Trastuzumab 
 
Trastuzumab was the first inhibitor developed to target HER2. The recombinant 
humanised monoclonal antibody was generated by Genentech and works by 
preventing activation of downstream pathways such as RAS-MAPK and PI3K-AKT-
mTOR by the antibody binding to the extracellular membrane of the domain of the 
HER2 receptor. By inhibiting these downstream pathways, susceptible cancer cells 
are unable to proliferate [5]. A large number of clinical trials have demonstrated that 
the drug is a clinically active and tolerated therapy in metastatic HER2-
overexpressing breast cancer patients who have undergone extensive prior treatment 
[53]. Administered intravenously, patients are typically given a loading dose of 
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4mg/kg followed by a weekly infusion of 2mg/kg until the patient has progressed or 
responded to the therapy [54]. Cardiac toxicity is one of the main adverse effects 
attributed to trastuzumab. [55]. With the cost of treatment per patient estimated to be 
approximately €24,000 per year, the risk of cardiac toxicity and the incidence of 
intrinsic and acquired resistance, it has become increasingly important to clinicians 
to be able to determine which patients will benefit most significantly from this drug.  
A number of clinical trials have been undertaken to evaluate the synergistic effects 
of combining trastuzumab with other treatments. Kaufman et al., [56] evaluated that 
the combination of trastuzumab with anastrozole, an aromatase inhibitor.; When 
compared with anastrozole alone in HER2 positive, hormone positive metastatic 
breast cancer patients there was an increase in the activity of the combination 
treatment. Piccart-Gebhat et al., [57] and Romond et al., [58] have also provided 
results that indicate that combining trastuzumab with adjuvant chemotherapy has 
reduced the risk of relapse and death quite substantially. 
While trastuzumab has been shown to be extremely effective in the treatment of 
metastatic breast cancer, clinical experience, especially in advanced disease, has 
found that some patients don’t respond to treatment and a large number of patients 
develop resistance to the monoclonal antibody treatment [59]. In an attempt to 
overcome the development of this resistance, TDM1, a trastuzumab-maytansine 1 
conjugate has been developed and evaluated pre clinically and is now successfully in 
a number of clinical trials  [60-62]. In combining the cytotoxic drug maytansine with 
the HER2 specific antibody trastuzumab, TDM1 ensures that the toxin is delivered 
directly to tumour cells [63]. 
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1.2.3.1.2 Lapatinib 
 
Lapatinib, a dual kinase inhibitor developed by GlaxoSmithKline, targets both HER2 
and EGFR receptors[64]. By inhibiting the tyrosine kinase domains of the receptors, 
lapatinib prevents activation of important pro-cancer pathways such as Erk/MAPK 
(extracellular-signal-regulated kinase/mitogen-activated protein kinase) and PI3K 
(Phosphatidylinositol 3-kinases) which have vital roles in cell proliferation and 
survival [64, 65]. Lapatinib is currently approved for the second line treatment of 
metastatic breast cancer when used in combination with the chemotherapeutic agent 
capecitabine, a pro-drug that is enzymatically converted to 5-fluorouracil in the 
tumour [66]. Due to their complementary mechanisms of action, a number of studies 
have been undertaken to evaluate the synergistic effects of combining trastuzumab 
with lapatinib for the treatment of HER2 positive metastatic breast cancer [63, 67-
69]. As a result of these studies, this treatment regime has been approved for patients 
suffering from HER2 positive, HR negative metastatic breast cancer by the European 
Medicines Agency (EMA) [70]. It has also been approved in combination with the 
aromatase inhibitor, letrozole, in HER2 positive, hormone positive metastatic breast 
cancer patients, with the combination increasing progression free survival as well as 
clinical benefit rate [71]. 
There have been some studies to evaluate the potential use of lapatinib in non-breast 
malignancies such as HER2 positive gastric cancer [72]. These studies were based 
upon results that indicate the response of this subtype of gastric cancer to 
trastuzumab [73, 74] .  
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The typical dosage of lapatinib is 1250mg taken daily, orally. The TKI is usually 
taken for 21 days at a time with the next 7 days off. It is also recommended that the 
agent be taken one hour before or after food [75]. Adverse effects associated with 
lapatinib treatment include, cardio-toxicity, however, the risk is thought to be lesser 
than that associated with trastuzumab treatment. Additional adverse effects include 
diarrhoea, hepatic and skin toxicity [64].  
 
1.2.3.1.3 Afatinib 
 
Afatinib is also a tyrosine kinase dual inhibitor of HER2 and EGFR[76]. This agent, 
developed by Boehringer Ingelheim, has been shown to irreversibly inhibit the 
HER2 and EGFR receptors[77]. The drug has been shown to be more potent than 
lapatinib and, as a result, a dose of 50mg per day has been identified as being 
effective in comparison to the 1250mg twice daily that is required for lapatinib [78, 
79]. Clinical trial data has indicated that afatinib may have activity in metastatic 
breast cancer patients that have developed resistance to trastuzumab[80] Due to 
inhibition of the EGFR receptor, the inhibitor has been proven to be effective in the 
treatment of non-small cell lung cancer and lung adenocarcinomas and a number of 
phase 2 and 3 clinical trials have been undertaken studying these malignancies. The 
results of these trials have indicated that in patients who have developed resistance to 
a number of first line treatments such as gefitinib and erlotinib, treatment with 
afatinib may be beneficial [81, 82].  Bouche, O et al., [83]have also suggested that 
there may be some evidence to support the use of the agent in the treatment of 
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colorectal cancer [83]. As with lapatinib there are some notable adverse reactions 
with the use of afatinib, in particular diarrhoea, rash and fatigue [84].  
 
1.2.3.1.4 Neratinib 
 
Neratinib (HKI-272), a dual kinase inhibitor, developed by Pfizer, targets both HER2 
and EGFR [85]. By irreversibly binding to the HER2 and EGFR receptors, this TKI 
reduces auto-phosphorylation within the cell which in turn prevents the activation of 
downstream pathways [86, 87]. Phase 1 clinical trials within patients with solid 
tumours indicated that the most suitable dose of neratinib was between 240 and 
320mg per day. Doses greater than this resulted in dose-related toxicities, most 
predominately diarrhoea [88]. Initial phase 1 trials also indicated that treatment of 
patients with neratinib that had been pre-treated with trastuzumab, anthracyclines or 
taxanes showed therapeutic potential and warranted further studies [87]. Due to dose 
related adverse effects that has been associated with the drug, the number of phase 2 
trials have been limited in metastatic breast cancer [89-91]. As with afatinib, due to 
its ability to target EGFR, neratinib has also been investigated in the treatment of 
NSCLC [92]. Phase 1 [87] and phase 2 [88] trials have been limited and have shown 
disappointing results, with little to no response rate evident in the study. 
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1.3 Resistance to targeted therapies 
 
Resistance to targeted therapies has been the Achilles heel of the successful 
application of these emerging agents. The resistance can be as a result of pre-existing 
mutations/ alterations in the drug target (intrinsic) or induced following drug 
treatment (acquired) [93].   
Acquired resistance, i.e. resistance evident in patients who were initially responsive 
and have been treated typically a year to 18 months, has become a major issue for 
clinicians treating patients with targeted therapies, in particular trastuzumab and 
lapatinib. While the mechanisms by which this resistance occurs have not yet been 
fully characterised, a large number of studies have provided potential hypotheses. 
Liu et al., [94] have evaluated the activation of AXL, a member of the receptor 
tyrosine kinase subfamily, in BT474 cell lines with acquired resistance. The cell line 
was exposed to lapatinib over an extended period of time in order to induce the 
acquired resistance phenotype. Using AXL gene targeting siRNA, AXL expression 
was decreased in the BT474 lapatinib-resistant cell line, restoring sensitivity to the 
targeted therapy. While this initial data provides strong supporting evidence to 
examine the expression of AXL in patients, as of yet there has been no clinical 
evaluation of this finding. Xia et al., [95] investigated the role of estrogen receptor 
signalling and its involvement in the development of acquired resistance. Similar to 
Liu et al., the BT474 parental cell lines were cultured continuously for an extended 
period of time in the presence of lapatinib in order to establish an acquired resistance 
model. Transfection with siRNA targeting the estrogen receptor indicated that 
estrogen signalling was increased following treatment with lapatinib in the BT474 
lapatinib sensitive cell line. In the resistant cell line it was identified that cell survival 
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was no longer being driven by the HER2 pathway but a co-dependence of the HER2 
and ER pathways combined. This finding was confirmed using tumour biopsies from 
patients undergoing lapatinib treatment. It was hypothesised that acquired resistance 
could be avoided by inhibiting both the HER2 and ER pathways simultaneously 
during treatment.  In addition, Eichhorn et al., [96] established that mutation in the 
PI3K pathway leads to resistance to lapatinib in vitro. The mutations identified, loss 
of function of PTEN or activating mutation in PIK3CA, drove the resistance to 
lapatinib. However the resistance phenotype was reversed following treatment with a 
PI3K inhibitor developed by Novartis known as BEZ235 [97].  
Through the evaluation of all of these studies it has become clear that there are a 
number of different mechanisms that can be responsible for the induction of acquired 
resistance in patients undergoing treatment with targeted therapies. Further studies 
will have to be completed in order to determine what pathways are involved and 
what methods can be used in order to overcome them.  
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1.4 Aims of project 
Combining a number of bioinformatics, in vitro and in vivo techniques the aims of 
this project were to:  
- Identify differentially expressed genes which might act as possible indicators 
of response to HER2 drug treatment using analysis of a microarray data set 
derived from a panel of cell lines treated with lapatinib 
- Validate the relevance of these genes of interest in a more diverse panel of 
breast cancer cell lines with varying HER2 expression and in response to a 
broader range of therapeutics 
- Evaluate the relevance of these genes in a model of acquired lapatinib 
resistance  
- Assess whether the alterations in specific genes identified in the cell line 
models transpose to an in vivo cell line-derived tumour xenograft 
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2.  Materials and Methods 
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2.1. Cell Culture and reagents 
2.1.1. Cell Culture Solutions 
 
The following solutions were prepared as needed. Phosphate buffered saline (PBS) 
was prepared by dissolving 1 tablet (Oxoid, Basingstoke, Hampshire, England) in 
100mL of ultra-high purity (UHP) water and autoclaved. Sodium acetate buffer was 
prepared by dissolving sodium acetate (Sigma, St. Louis, MO, USA) to a 
concentration of 0.1M with 0.1% (v/v) triton-X-100 and then pH to 5.5. Phosphate 
substrate was prepared dissolving p-nitrophenol phosphate to a concentration of 
10mM in the previously described 0.1M sodium acetate. 1N NaOH was prepared by 
dissolving 40g/L of NaOH (Sigma, St. Louis, MO, USA) in UHP water. EDTA was 
prepared by dissolving 1% w/v EDTA (Sigma) in UHP and was then autoclaved. 1X 
trypsin was prepared by combining 50mL of 10X trypsin (Gibco by Life 
technologies, Grand Island, NY 14072, USA) and 10mL of 1% EDTA solution to 
440mL of sterile PBS.  
2.1.2. Cell Culture Equipment 
 
The following equipment was used throughout the course of this research. 30mL 
sterile universal containers (Ramboldi Ltd, Limassol, Cyprus), 96-well plates 
(Corning, Costar, Sigma Aldrich, St.Louis, MO), T25cm
2
 and T75cm
2
 vented flasks 
(Corning, Costar, Sigma Aldrich, St. Louis, MO) and cryovials (Greiner Bio-One 
GmbH, Frickenhausen, Germany) were used in cell culture. 
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2.1.3. Cells culture and aseptic techniques 
 
All cell culture work was carried out in a class II laminar airflow cabinet, Holten 
LaminAir Maxisafe. All experiments involving cytotoxic compounds were 
conducted in a cytoguard laminar airflow cabinet. Before and after use the laminar 
airflow cabinet was cleaned with 70% v/v industrial methylated spirits (IMS). Any 
items brought into the cabinet were also swabbed with 70% IMS. Only one cell line 
was used in the laminar airflow cabinet at a time and upon completion of work with 
any given cell line, the laminar airflow cabinet was allowed to clear for at least 15 
minutes before further use. This was to eliminate any possibility of cross-
contamination between cell lines. The cabinets were cleaned weekly with industrial 
disinfectants (Virkon, Antech International, P0550) and operation validated by 
annual inspection by a certified contractor.  
 
2.1.4. Monitoring of sterility of cell culture solutions 
 
Sterility testing was performed on all cell culture media and related culturing 
solutions. Samples of prepared basal media were incubated at 37
°
C for a period of 
seven days. This ensured that no bacterial or fungal contamination was present in the 
media. 
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2.1.5. Sub-culturing of cell lines 
 
The waste cell culture medium was removed from the tissue culture flask to a sterile 
bottle. The flask was rinsed with 1mL of 1X trypsin solution to ensure the removal 
of any residual media. 2mL of 1x tryspin was then added to the flask and incubated 
at 37
°
C for the required period of time until all cells were detached from the inside 
surface of the culture flask. The trypsin was deactivated with an equal volume of 
complete media. The cell suspension was removed from the flask and placed in a 
sterile universal container and centrifuged at 200g for 5 minutes. The supernatant 
was then discarded from the universal and the pellet was suspended in complete 
medium. A cell count was performed using a haemocytometer. An aliquot of cells 
was then used to re-seed a flask at the required density with fresh media. All cell 
lines used in the course of this research are described in table 2.1.  
 
2.1.5.1. Sub-culturing of Human Mammary Epithelial Cells (HMEC) 
 
As cultured cells derived from normal mammary epithelium, the culturing of the 
HMEC (Human mammary epithelial cells) (CC-2551, Lonza) was different to that of 
the immortalised cell lines used within this project. The preparation of the media was 
completed 5-7 days prior to thawing of cells. The singlequots kit (CC-4136, Lonza) 
which contained cytokines, growth factors and supplements were added to the 
MEBM (Mammary epithelial basal media, CC-3151, Lonza) and the media 
underwent sterility checks as outlined in section 2.1.4.  
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30 minutes prior to addition of cells, 1mL/5cm
2 
of media was added to a T25cm
2
 
vented flask and returned to the incubator. Cells were seeded at a recommended 
density of 2500 cells/cm
2
. The flask was gently rocked to ensure dispersion of the 
cells. The media was changed the day after thawing and every other day thereafter.  
To sub-culture these cells, the Lonza ReagentPack (CC-5034, Lonza) was 
recommended for use. Waste media was removed from the flask and HEPES- 
buffered saline was first used to wash the cells. Following this, trypsin/EDTA 
solution was added to the flask and the cells were returned to the incubator in order 
to allow the cells to detach from the flask. Trypsin neutralizing solution was used to 
stop the trypsin action and to wash all detached cells from the flask. Harvested cells 
were centrifuged at 220g for 5 minutes to pellet them. Once again the cells were re-
suspended at a density of 2500 cells/cm
2
. Cells were re-suspended in T75cm
2
 vented 
flasks. According to the manufacturer, these cells are capable of 18 doubling and 
have a doubling time of approximately 18 hours.   
 
  
2.1.6. Cryopreservation of cells 
 
Cells for cryopreservation were harvested in the log phase of growth. Cell pellets 
were resuspended in a suitable volume of FCS (PAA, GE Healthcase BioScience 
Corp, New Jersey, USA). An equal volume of a 10-20% DMSO/FCS solution was 
added drop-wise to the cell suspension. A total volume of 1mL of this suspension 
was then placed in a cryovial. These vials were then placed in the vapour phase of a 
liquid nitrogen container, which was equivalent to a temperature of -80
°
C. 
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After a period of three hours, vials were removed from the vapour phase and 
transferred to the liquid phase for storage (-196
°
C). 
 
2.1.7. Thawing of cryopreserved cells 
 
A volume of 5mL of fresh warmed growth media was added to a sterile universal. 
The cryopreserved cells were removed from the liquid nitrogen tank and thawed 
rapidly at 37
°
C. The cells were removed from the vials and transferred to the 
aliquoted media. The resulting cell suspension was centrifuged at 200g for 5 
minutes. The supernatant was removed and the pellet resuspended in fresh culture 
medium. Thawed cells were then added to a T25cm
2
 tissue culture flask with a 
suitable volume of fresh growth media. 
 
2.1.8. Mycoplasma testing  
 
Cell lines were tested for possible mycoplasma contamination quarterly in house by 
Mr Michael Henry according to the SOP 007-01 using the in-direct test. 
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Table 2.1: Description of breast cancer cell lines, characteristics and basal 
media components 
Cell Line Characteristics Basal Media Source 
BT474 HER2-overexpressing, 
ER positive  
Dulbecco’s Modified 
Eagles medium (DMEM) 
supplemented with 10% 
fetal bovine serum, 2% 
L-Glutamine and 1% 
Sodium Pyruvate 
NICB 
through the 
ATCC 
SKBR3 HER2-overexpressing, 
ER negative 
RPMI 1640 medium 
supplemented with 10% 
fetal bovine serum 
NICB 
EFM 192a HER2-overexpressing 
ER positive 
RPMI 1640 medium 
supplemented with 10% 
fetal bovine serum 
NICB 
HCC1954 HER2-overexpressing, 
ER negative 
RPMI 1640 medium 
supplemented with 10% 
fetal bovine serum 
NICB 
MDAMB453 HER2-overexpressing, 
ER negative 
RPMI 1640 medium 
supplemented with 10% 
fetal bovine serum 
NICB 
MDAMB231 Triple negative, 
ER negative 
RPMI 1640 medium 
supplemented with 10% 
fetal bovine serum 
NICB 
HMEC-
Mammary 
Epithelial 
Cells 
Normal breast tissue MEGM BulletKit (CC-
3150) containing MEBM 
(CC3151) and the 
SingleQuots (CC4136) 
Lonza 
Bioresearch, 
Basel, 
Switzerland 
SKBR3-L HER2-overexpressing 
acquired lapatinib 
resistance 
RPMI 1640 medium 
supplemented with 10% 
fetal bovine serum 
NICB, 
generated by 
Fiona 
O’Neill as 
part of this 
thesis 
 
All cell lines were cultured at 37°C in a 5% CO2\95% humidified air incubator. 
 
The chemical compounds listed in Table 2.2 were prepared as stock solutions in 
dimethyl sulfoxide (Sigma Aldrich, St Louis, MO, USA) with the exception of 
trastuzumab and epirubicin which were provided already in solution and not in 
powder form as the other were. 
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Table 2.2: Source and stock concentrations of chemotherapy drugs and 
inhibitors in this project 
 
Drug Name Source Stock Concentration 
Lapatinib Sequoia Chemicals 
Pangbourne, 
RG8 7AP, 
United Kingdom 
10mM 
Neratinib Sequoia Chemicals 10mM 
Afatinib Sequoia Chemicals 10mM 
5’DFUR Sigma 10nM 
Gefitinib Sequoia Chemicals 10mM 
Dasatinib Sequoia Chemicals 10mM 
Trastuzumab Roche, Basel, Switzerland 21mg/ml 
Epirubicin Pfizer Inc. 235 East 42nd 
Street, New York, NY 10017 
21mg/mL 
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2.2. Proliferation Assay 
 
Proliferation was measured using an acid phosphatase assay [1]. This colorimetric 
asssy uses p-nitrophenyl phosphate to determine the percentage of live cells 
following treatment with a therapy. This percentage is expressed as the IC50 which is 
the inhibitory concentration in which 50% of the biological activity of the cell lines 
is inhibited. 1x10
3
 cells/well were seeded in 96-well plates with the exception of the 
BT474 cells which were seeded at 5x10
3
 cells/well. Plates were incubated overnight 
at 37°C followed by the addition of drug at appropriate concentrations and incubated 
for a further 5 days until wells were 80% to 90% confluent. All media was removed 
and the wells were washed twice with PBS (Sigma). 10mM paranitrophenol 
phosphate substrate (Sigma-Aldrich) in 0.1M sodium acetate buffer with 0.1% 
Triton X (Sigma) pH 5.5 was added to each well and incubated at 37°C to 1 hour. 
50µL of 1 M NaOH was added and the absorbance was read at 405 nm with a 620nm 
reference wavelength using the Synergy HT plate reader (BioTek, Winooski, 
Vermont, USA). 
 
2.3. Establishment of Lapatinib-Resistant Cell Lines 
 
The lapatinib-sensitive, HER2+ cell line, SKBR3 was chosen to be conditioned in 
lapatinib. A 96 well plate dose response proliferation assay was completed in order 
to determine the IC70 concentration for conditioning This toxicological value was 
employed as it was felt to be more appropriate for developing resistant lines,  
consistent with Sheikh et al., [2] who had also been developing   a lapatinib resistant 
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cell line (of pancreatic origin).  Duplicate flasks of the cell line were grown until 65-
70% confluent at which time they were treated with 250nM lapatinib. The cells were 
treated with the lapatinib twice a week for 6 months. After two months the dose of 
lapatinib was increased to 300nM and again to 350nM two months later. 
Proliferation assays were performed at regular intervals in order monitor the 
alteration in response to the drug. Cells were considered to be resistant when an IC50 
value of 1µM or greater was achieved.  
 
2.4. Genomic DNA Isolation 
 
Using the Promega Wizard SV genomic DNA purification system, genomic DNA 
was isolated for parental and lapatinib-resistant variants of the SKBR3 breast cancer 
cell line. Briefly, a cell suspension containing 2x10
6
 cells was spun down and re-
suspended in 150µL of cell lysis buffer. This sample lysate was then transferred to a 
Wizard SV mini-column. The column was centrifuged for 1 minute at 13,000g. The 
eluent was removed. 650µL of wash solution containing 95% of ethanol was added 
to the column and once again was centrifuged for 1 minute at 13,000g. This step was 
repeated a further 3 times. The eluent was discarded following each spin. To elute 
the DNA, 250µL of nuclease free water containing 2µL of RNase, which removes 
any co-purified RNA, was added to each column and allowed to incubate for 2 
minutes at room temperature. The column was then centrifuged for 1 minute at 
13,000g. The isolated genomic DNA was stored in labelled tubes at -20°C until it 
was required for DNA fingerprinting analysis. The DNA was quantified using the 
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Nanodrop (ND-1000 spectrophotometer, Thermo Scientific) and a DNA purity with 
an OD 260/280 ratio of 1.8 was required for the DNA fingerprinting.  
 
2.5. DNA fingerprinting of the SKBR3 parental and acquired resistance cell 
lines 
 
The DNA fingerprinting of the parental and resistant variants of the SKBR3 cell line 
was carried out by the lab of Dr. Michael Crowley in the University of Alabama at 
Birmingham. The method used looked at STR profiling of 9 polymorphic regions.  
Briefly, the lab used the ABI Identifiler® Kit (Life Technologies) to map the DNA 
fingerprint of the cell lines. The markers that were present in this kit include those as 
used by the ATCC which included Amelogenin, CSF1PO, D135317 and TH01. 
Using gene amplification technologies, the genomic DNA was mapped. The mapped 
genomic DNA was then analysed using Gene-mapper software, and the genomic 
fingerprint was compared to that provided by the ATCC.  
 
2.6. RNA Extraction 
 
RNA extraction was achieved using the Qiagen RNeasy mini Kit (Qiagen). Briefly, 
cells were grown until confluent in a T75cm
2
 cell culture flask. Media was removed 
and cells were trypsinised, centrifuged at 8000 x g and a pellet formed. All media 
was removed from the pellet as it can interfere with the lysis buffer. One volume of 
lysis buffer per number of pelleted cells was added to the cells, in this case 600µL, 
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and mixed gently. Cells were passed gently through a 19 gauge needle to induce 
lysis. One volume of 70% ethanol (600µL) was then added to the cells and 700µL of 
the cell suspension was added to the column and were centrifuged for 15 seconds at 
8000g. This step was repeated with the remainder of the sample. Flow through was 
discarded following each spin. Following this 350µL of the RW1 buffer provided 
was then added to the column and was spun for 15 seconds at 8000g. The Qiagen 
DNase incubation mix was prepared. 70µL of RDD buffer and 10 µL of the DNase 1 
stock were mixed together per sample with additional volume prepared for pipetting 
error. The incubation mix was placed directly on the column membrane and was left 
for 15 minutes at room temperature. 350µL of the RW1 buffer was added to the 
column and it was centrifuged for 15 seconds at 8000g. 500µL of RPE buffer was 
added to the column and it was further centrifuged for 15 seconds at 8000g. This step 
was repeated and the column centrifuged for 2 minutes at 8000g. To dry, the column 
was then added to a new collection tube and centrifuged at full speed for 1 minute. 
The column was transferred to a 1.5mL collection tube. 40µL of nuclease free water 
was added and it was centrifuged for 1 minute at 8000 x g. This was repeated once 
more. The extracted RNA was quantified using a Nanodrop (ND-1000 
spectrophotometer, Thermo Scientific). The RNA was stored in labelled tubes at -
80°C until analysed.  
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2.7. Homogenisation of animal tissue 
 
To extract RNA from mouse tumour tissue, a homogenisation step was required 
prior to the addition of one volume of 70% ethanol in the extraction method above. 
Two methods of tissue homogenisation were optimised for the animal tissue. 
 
 
2.7.1. Disruption and homogenisation using a rotor-stator homogeniser 
 
30mg of tissue was placed in 2mL non-stick nuclease-free tubes which contained 1 
5mm diameter stainless steel bead.  600µL of lysis buffer from the Qiagen RNeasy 
kit containing 1% β-mercaptoethanol was added to the tube. Samples were placed in 
the Qiagen tissuelyser, which was then operated at 20-30 Hz until the tissue was 
fully disrupted. The steel bead was removed from the tube and disposed of and the 
sample was centrifuged at full speed for 3 minutes. The supernatant was removed 
and retained at -80°C until the RNA extraction could be completed.   
 
2.7.2. Disruption and homogenisation using a pestle and mortar and 
QiaShredder 
 
30mg of tissue was placed in a pestle and mortar, to which a small volume of liquid 
nitrogen was added. The sample was crushed until a fine powder formed. Once all 
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the tissue was broken down, the liquid nitrogen was allowed to evaporate without 
allowing the tissue to thaw. The tissue in its powder form was then scraped into a 
2mL non-stick nuclease-free tube containing 600µL of lysis buffer from the Qiagen 
RNeasy kit containing 1% β-mercaptoethanol. The powder was dissolved in the 
buffer. The suspension was then centrifuged at full speed for 3 minutes. The 
supernatant was removed and retained at -80°C until the RNA extraction could be 
completed.  
 
 
2.8. Reverse Transcription (RT) Reaction 
 
To synthesise cDNA, the extracted RNA was diluted to a concentration of 2µg. A 
high capacity cDNA reverse transcription master mix (Applied Biosystems) was 
prepared containing 2µL of 10X RT Buffer, 0.8µl of 25X dNTP, 2 µL of 10X  RT 
primers, 1 µL of Multiscribe Reverse transcriptase, 1 µL RNase inhibitor and 3.2 µL 
nuclease free water per reaction. 10 µL of the master mix was added to 10 µL of the 
2 µg RNA solution. The solution was pipetted gently to mix and briefly centrifuged 
to remove any bubbles.  The tubes were labelled and were placed in the G storm 
thermo cycler (Model GS1, Somerton Biotechnology Centre, Somerset, UK). The 
thermo cycler conditions were 25°C for 10 minutes, 37°C for 120 minutes and 85°C 
for 5 minutes. The resulting cDNA was stored at -20°C in labelled tubes.  
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2.9. Taqman Real Time PCR 
 
Taqman real time PCR was used for the mRNA quantification in this study. Real-
time RT PCR monitors the progress of the reaction as it occurs and only requires a 
few nanograms of target RNA in order for the amplification reaction to take place. 
The reactions are characterised by the point during the cycle when the amplification 
of a target is first detected. This detection occurs when the quencher dye that is 
found in the 3’ end of the probe is separated from the fluorescent dye which is found 
in the 5’ end of the probe due to cleaving of the probe with the target. The higher the 
copy number of the target, the sooner a fluorescent signal will be observed. The 
value at which this increase is seen is known as the threshold cycle (Ct). It is defined 
as the fractional cycle number at which the fluorescence passes the fixed 
threshold[3].  
2.9.1. Taqman Array Fast 96-well plate 
 
RNA was extracted and cDNA synthesised as per section 2.3 and 2.4. Taqman Real 
Time PCR analysis was performed using Taqman Array Fast 96-well plate (Applied 
Biosystems), which was pre-prepared containing assays for our 28 targets and 4 
endogenous controls. The experiment was prepared by diluting the cDNA to a 
concentration of 40ng/well. A total cDNA volume of 5µL is required per well. 
5µL/well of Taqman fast universal PCR master mix (2x), NO AmpErase UNG 
(Applied Biosystems) was combined with the diluted cDNA and 10µL of the 
solution was added to each of the wells on the Taqman plate. Plates were vortexed to 
remove any bubbles and ensure that the solutions were mixed. The thermocycler 
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conditions were as follows: hold at 95°C for 20 seconds, followed by melt at 95°C 
for 3 seconds and anneal/extend at 60°C for 30 seconds for 40 cycles on a 7900 fast 
real-time PCR instrument (Applied Biosystems).  
  
2.9.2. Individual Taqman Gene expression assays 
 
Additional Taqman RT PCR reactions were performed using individual gene 
expression assays.  
The assay was prepared by diluting the cDNA to a concentration of 80ng/well 
(20ng/µL) in dH2O. A total cDNA volume of 4µL is required per well. For each 
assay a master mix was prepared containing 1µL of the taqman assay, 10µL of 
Taqman fast universal PCR master mix (2x), NO AmpErase UNG (Applied 
Biosystems) and 5µL of dH2O was required for each well. 16µL of the assay and 
master mix solution was added to each well and 4µL of the 80ng/well cDNA 
solution in dH2O. Plates were vortexed to remove any bubbles and ensure that the 
solutions were mixed. The thermocycler conditions were as follows: hold at 95°C for 
20 seconds, followed by melt at 95°C for 3 seconds and anneal/extend at 60°C for 30 
seconds for 40 cycles on a 7900 fast real-time PCR instrument (Applied 
Biosystems).  
.  
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Table 2.3 Individual Taqman Gene expression assays 
Gene Target Species detected Assay ID 
ALDH3A2 Human Hs00166066_m1 
CCND1 Human, Murine Hs00277039_m1 
CDKN1B Human Hs00153277_m1 
ERBB3 Human Hs00951444_m1 
FOXO3a Human Hs04195365_s1 
FOXO3a Human, Murine Hs00818121_m1 
FOXO3a Murine Mm00490673_m1 
GAPDH Human Hs99999905_m1 
GAPDH Murine Mm99999915_g1 
NR3C1 Human, Murine Hs00230818_m1 
NR3C1 Human Hs00230813_m1 
PIK3C3 Human, Murine Hs00176908_m1 
RB1CC1 Human, Murine Hs01089010_m1 
RB1CC1 Human Hs00207547_m1 
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2.9.3. Relative gene expression analysis using the Comparative CT method 
 
Relative expression values were calculated using the comparative threshold cycle 
(Ct) method [3]. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was selected 
as the endogenous control for all experiments. The cycle threshold (Ct) indicates the 
cycle number by which the amount of amplified target reaches a fixed threshold. The 
Ct data for GAPDH was used to create ΔCt values [ΔCt = Ct (target gene)-Ct 
(GAPDH)]. ΔΔCt values were calculated by subtracting ΔCt of the calibrator 
(untreated controls) from the ΔCt value of each drug-treated sample. Relative 
quantification (RQ) values were calculated using the equation:  
2
-ΔΔCt
 
 Genes with a fold change ± 2 in the drug-treated BT474 and SKBR3 cell lines were 
deemed to be differentially expressed. 
Standard deviations (SD) were calculated on the mean of the ΔΔCt value, which was 
based on triplicate replicate measurements of the relative expression of each gene. 
Error bars on each graph represent the SD of each estimate. This mean ΔΔCt value 
was then used in the calculation of the RQ value using the equation above. This 
method for calculating the error bars was used in lieu of using the RQmax and RQmin 
values, which are which is sometimes employed in related analysis.    
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2.10. Protein Extraction 
 
Whole cell lysis buffer was prepared by combining 7M urea (Sigma), 4% w/v 
CHAPS (Sigma), 1% Triton X (Sigma) and 1x PICS (Protease Inhibitor Cocktail) 
(Roche Diagnostics, Mannheim, Germany) in UHP water. This lysis buffer was 
aliquotted into 1mL eppendorfs and stored at -20°C. In order to extract the protein 
from the cells, the cells are first trypsinised and pelleted. Once a pellet had been 
formed following centrifugation, 100µL of the lysis buffer was added to the cell 
pellet and was pipetted gently. The cell suspension and lysis mixture was left on ice 
for approximately 1 hour, with the eppendorf being vortexed every 20 minutes. 
Following an hour on ice, the cell suspension was centrifuged at 3000 x g at 4°C for 
15 minutes. The supernatant was removed and stored in labelled tubes at -20°C. 
  
2.11. Protein Quantification 
 
Protein concentrations were quantified using a Bradford Assay.  Bovine Serum 
Albumin standards were prepared from a stock concentration of 2mg/mL, with 
concentrations per well from 0.312µg to 10µg prepared. To ensure that the sample 
concentrations were within the standard curve, one sample was chosen and diluted 
down by various factors. These dilution factors were then examined to make sure 
that they were within the standard curve.  If dilutions were required, all samples were 
diluted. All samples and standards were left on ice. To each plate, 5µL of either 
standards or sample were added to each well. To this, 245µL of Bradford reagent 
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was added to each well. The plate was then left in the dark to develop and the plates, 
once developed, were read at 595nm on the BioTek Plate reader.  
 
 
2.12. Immunoblotting 
 
Protein (30µg) was electrophoretically resolved on 7.5% (Lonza, 59501) denaturing 
polyacrylamine gels. The resolved proteins were then transferred to nitrocellulose 
membranes (Invitrogen, IB3010-01) using the iBlot transfer system (Invitrogen, 
IB1001). Protein transfer was visually confirmed using Ponceau S staining (Sigma, 
P7170). Membranes were blocked with 2.5% skimmed milk powder in PBS and 
incubated overnight at 4°C with primary antibodies. Antibody dilutions and sources 
can be found in Table 2.4. Proteins were visualised using horseradish peroxidase-
conjugated anti-mouse or anti-rabbit antibodies (Sigma – see Table 2.4). and ECL 
Prime reagent (GE Healthcare, RPN 2232). Membranes were washed with 0.1% 
PBS-tween 3 times for 10 minutes each, both prior to and following incubation with 
secondary antibodies. Following the final washing, the membranes were exposed to 
ECL Prime reagent (GE Healthcare, RPN 2232) in the dark room and the membrane 
was exposed to autoradiographic film (Kodak,) for various times (from 10 seconds to 
30 minutes depending on the signal). The exposed autoradiographic film was 
developed for 3 minutes in developer (Kodak, LX-24). They were then washed in 
water and transferred to fixative (Kodak FX-40) for 5 minutes. The film was then 
washed with water and allowed to dry at room temperature.  
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Table 2.4 List of primary antibodies. 
 
Protein 
of 
interest 
Primary 
Antibody 
Primary 
Antibody 
Dilution 
Source Secondary 
Antibody 
Source Secondary 
Antibody 
Dilution 
CCND1 #2922s 1/1000 Cell 
Signalling 
Technology 
(CST) 
Rabbit Sigma 
Aldrich 
1/10,000 
ERBB3 #4754s 1/1000 CST Rabbit Sigma 
Aldrich 
1/10,000 
FOXO3a #2497s 1/1000 CST Rabbit Sigma 
Aldrich 
1/10,000 
NR3C1 #7437s 1/1000 CST Rabbit Sigma 
Aldrich 
1/10,000 
RB1CC1 17250-1-
AP 
1/1500 ProteinTech Rabbit Sigma 
Aldrich 
1/10,000 
β-actin  1/10,000 Sigma Mouse Sigma 1/10,000 
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2.13. Development of cell line-derived tumours in vivo (xenografts) 
 
2.13.1. Mice 
 
28-35 day old CB17/lcr-Prkdc
scid
/Crl mice were used under the guidelines of the 
Irish Department of Health and procedures approved by the research ethics 
committee of Dublin City University, Dublin 9. CB17/lcr-Prkdc
scid
/Crl mice were 
purchased from Charles River (Charles River International Inc., Wilmington, MA). 
The immunodeficiency of these animals is as a result of the inhibition to produce B 
and T lymphocytes. This deficiency provides the mice with a wide tolerance to 
implanted foreign tissues and tumours, which makes them an ideal model for 
research. 
 
2.13.2. Cell line suspension preparation 
 
BT474 cells were grown until 70% confluent in T75cm
2
 vented flasks. A cell count 
was completed and the cells were re-suspended at a density of 5 x 10
6
 per 100µL in 
serum free Dulbeccos modified Eagles Medium (DMEM). To this cell- and serum- 
free media suspension was added a 1:1 volume of matrigel (BD, Franklin Lakes, NJ, 
USA 07417). Cell and matrigel suspension was stored on ice until needed. 
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2.13.3. Estrogen implantation and tumour development 
 
BT474 cells are estrogen dependent. In order to support the growth of the cells in 
vivo, 72mg estrogen pellets (Innovative technology, Sarasota, FL, USA) were 
implanted in the shoulder region of the mice. 200µL of the cell lines and matrigel 
suspension was subcutaneously injected into the flank of the mice. Mice were 
monitored daily and once tumours were observed they were measured using a digital 
calliper. The equation used to evaluate the tumour volume was; 
 
H(height of tumour) x W(width of tumour) x D (depth of tumour)/2 =                              
volume of tumour (mm
3
) 
 
2.13.4. Tumour graft implantation 
 
Once tumours had developed following the injection of the cell line into the 
subcutaneous layer of the skin, they were removed and placed into serum free media. 
24 hours prior to implantation with the tumours, mice were implanted with 72mg 
estrogen pellets. The tumour was cut into approximately 2 x 2 x 2mm
3 
sections and 
dipped in matrigel before they were inserted subcutaneously in a small incision in 
the flank of mice. The incision was sealed using a wound clip, which was removed 
10 days post-surgery.  
2.13.5. Vehicle and Drug preparation 
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The vehicle used to administer the drug suspension to the mice was prepared by 
dissolving 0.5% hydroxyl-propyl-methyl-cellulose (Sigma-Aldrich, St Louis, MO, 
USA) and 0.1% Tween 80 (Sigma-Aldrich, St Louis, MO, USA) in UHP water.  
Lapatinib ditosylate (Sequoia Chemicals) was administered at a dose of 200mg/kg. 
100µL of drug was given to each mouse by oral gavage.  
Animals were monitored daily during the treatment with either the vehicle or 
200mg/kg lapatinib. They were weighed prior to the treatment and visually observed 
post treatment to ensure that there were no complications. 
 
2.13.6. Drug Quantification in Plasma samples using LC-MS 
 
Lapatinib was quantified according to [4] and the analysis was carried out by Dr. 
Sandra Roche, NICB, DCU. 
 
2.13.6.1. Liquid-liquid extraction procedure 
 
100L of 500ng/mL internal standard was added, to 10 µL of plasma. Dasatinib 
500ng/mL was used as the internal standard for lapatinib. Also 200L of 1M 
ammonium formate pH 3.5 buffer and 1.6mL of extraction solvent tBME/ACN (3:1) 
w/v was added to the plasma. The extraction tubes were vortexed and mixed on a 
blood tube mixer for 15mins. The samples were centrifuged at 3200g for 5 minutes; 
the organic layer was removed with a glass pasteur pipette and 1.1mL of solvent was 
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transferred to conical bottomed glass LC autosampler vials. The vials were 
evaporated to dryness using a Genevac EZ-2 evaporator at ambient temperature, 
without light. The samples were reconstituted in 40L of acetonitrile with 20L 
injected automatically by the autosampler 
 
2.13.6.2. Preparation of standard curve 
 
10 µL of plasma was added to an extraction tube, with the addition of 100L of 
500ng/mL internal standard and 100L of analyte varying in concentration from 
1ng/mL to 1000ng/mL. Samples were extracted as outlined in section 2.13.6.1. Each 
concentration point was extracted in triplicate. Samples were analysed by LC-
MS/MS at intervals during the sample run time.  
 
2.13.6.3. System standard preparation 
 
A 10mL solution of lapatinib 100ng/mL and 100ng/mL dasatinib was prepared in 
acetonitrile and divided into 200L aliquots. Aliquots were stored at -20°C. A 
system standard was analysed before each run to verify the instrument was operating 
as normal. During the analysis of a batch of samples, system standards and mobile 
phase blanks were run at intervals to identify any potential instrumentation errors.  
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2.13.6.4. Chromatographic and mass spectrometric conditions 
 
Chromatographic separation was achieved using a Hyperclone BDS C18 column 
(150mm×2.0mm i.d., 3μm particle size) with a SecurityGuard C18 guard column 
(4mm×3.0mm i.d.) both from Phenomenex, UK. An optimised mixture of 
acetonitrile and 10mM ammonium formate pH 4 (54:46, v/v) was used as mobile 
phase, at a flow rate of 0.2mL/min. The column temperature was maintained at 20
0
C 
and the temperature of the autosampler was maintained 4
0
C. The complete 
chromatographic run time of each sample was 10min, which separated dasatinib and 
lapatinib from each other with retention times 2.3 and 5.1 minutes respectively. 
Peaks were quantified using Agilent Masshunter Software. 
The mass spectrometer was operated using an ESI source in the positive ion 
detection mode. The ionisation temperature was 350
0
C, gas flow rate was 11L/min 
and nebulizer pressure was 50psi. Nitrogen was used as the ionisation source gas and 
ultrapure nitrogen, the collision cell gas. 
Analysis was performed using MRM (multiple reaction monitoring) mode with the 
following transitions: m/z 581→m/z 365 for lapatinib, and m/z 488→m/z (231 and 
401) for dasatinib, with a dwell time of 200ms.   
Quantification was based on the integrated peak area as determined by the 
Masshunter Quantification Analysis software which quantitates the peak areas of the 
MRM transitions of each analyte. 
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3. Gene expression changes in response 
to lapatinib 
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3.1 Introduction 
 
Cancers originating from cells of the breast are among the most common female 
malignancies [1].  Breast cancer is a very heterogeneous malignancy and there has 
been extensive research conducted aimed at better subcategorising breast cancer into 
subtypes of the disease to better understand the implications of this heterogeneity in 
treatment response and survival [2]. Over-expression of HER2, defines one such 
subtype that has been identified [3]. Due to the downstream effects of activation of 
the HER2 signalling pathway, HER2 over-expression is associated with more 
aggressive, often treatment resistant disease with patients often presenting with the 
malignancy at a lower median age than the general breast cancer population. [4, 5]. 
Multimodality therapy (surgery and/or drug treatment with radiation therapy) is the 
mainstay of general treatment. However, treatment options have moved towards a 
more targeted approach. Current targeted therapies available for this breast cancer 
subtype include the monoclonal antibody trastuzumab and the dual tyrosine kinase 
inhibitor lapatinib. The adverse effects associated with these types of therapies are 
generally less severe than those of traditional chemotherapies as they target cancer 
cells more specifically [6].  
Tyrosine kinases are a group of enzymes that play a critical role in the signalling 
cascades of the cell. The function of these enzymes is typically coupled to, and 
moderated by ligand binding (receptor) components, and receptor-coupled tyrosine 
kinases are involved in the phosphorylation of tyrosine receptors in targeted proteins. 
Many important receptor-coupled tyrosine kinases are located in the cell membrane 
and proteins are activated by the binding of ligands to their extracellular domain. 
HER2 and EGFR (epidermal growth factor receptor) are two such examples of 
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growth factor receptors which can homodimerise or heterodimerise with other 
members of the human epidermal growth factor receptor family, which, in turn, 
activates their tyrosine kinase moiety. The activated tyrosine kinases have critical 
roles in cell signalling processes such as cell proliferation and growth [7, 8]. 
Tyrosine kinase inhibitors (TKIs) prevent the activation of these tyrosine kinases 
thus inhibiting the activation of the pathways that would promote tumour cell growth 
and proliferation.  
Despite the wide application of HER2 testing in breast cancer to stratify patients for 
HER2 targeting treatment, a significant proportion of HER2-positive patients do not 
respond to HER2-targeted therapy [9]. In recent studies performed using lapatinib as 
a monotherapy, in combination with capecitabine and also with trastuzumab, clinical 
benefit response rates were found to range from 12.4% with lapatinib alone, 22% in 
combination with capecitabine and 24.7% for the combination of lapatinib with 
trastuzumab [10-12]. When one factors in the enormous financial cost of such 
medicines, there is huge need to develop methods to identify patients who will 
specifically benefit from treatment. We have therefore sought to use cellular models 
to examine and identify the gene expression changes which might be characteristic 
of response to treatment with lapatinib. The longer term hope being that if such gene 
expression changes were characteristic of human tumour response to lapatinib, they 
could form the basis of a diagnostic capable of very rapidly identifying patients who 
are responding to treatment from those who are not. 
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3.2 Materials and Methods 
 
In summary, microarray data on a panel of responsive and non-response cell lines in 
response to lapatinib completed by GSK was analysed using the Co-inertia Analysis 
(CIA) technique as described in detail in section 3.3.1-4. All bioinformatic analysis 
was completed by Dr. Stephen Madden. 
The sensitivity of the BT474, SKBR3, EFM192a, HCC1954, MDAMB453 and 
MDAMB231 cell lines to lapatinib was determined by measuring IC50 values using 
proliferation assays as described in section 2.2. Taqman RT-PCR was used to 
examine the expression of a panel of 19 genes and 9 transcription factors identified 
as potentially being altered in cells responding to lapatinib in a panel of cell lines 
(Table 3.4). These cell lines were cultured until 70% confluent at which point they 
underwent treatment with 1µM lapatinib for 12 hours. These optimal treatment 
conditions were determined based on the bioinformatics analysis undertaken (section 
3.6). Following this treatment, RNA was extracted from the cells using the Qiagen 
RNeasy extraction kit (section 2.2). As described in sections 2.8 and 2.9 the 
extracted RNA underwent reverse transcription followed by Taqman RT-PCR to 
evaluate the gene expression changes in the cells following treatment with the drug. 
Using the comparative cycle threshold method, the relative expression of these genes 
was examined.  
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3.3 Results 
 
3.3.1 GSK microarray data set 
 
Microarray data provided by GlaxoSmithKline (GSK) formed the back bone for this 
study. Completed and published by Hedge et al. [13], the microarray analysis 
consisted of gene expression data from 4 cell lines; BT474, SKBR3, T47D and 
MDAMB468, which were treated with varying concentrations of lapatinib at 
different time points. The analysis was conducted using the Affymetrix human 
genome HG U133A arrays containing more than 22,000 probe sets. RNA was 
extracted from four independent biological replicates for each cell line condition. An 
array for each of the following conditions was completed on each of the four cell 
lines; 0.1% DMSO-treated cells at 0, 2, 6, 12 and 24 hours (5 arrays), 0.1µM 
lapatinib-treated cells at 2, 6, 12 and 24 hours (4 arrays) and 1µM lapatinib treated 
cells at 2, 6 and 12 hours (3 arrays). When completed in each of the four independent 
replicates, there were a total of 48 arrays per cell line. When completing the 
bioinformatics analysis of this data set, the data associated with T47D and 
MDAMB468 cell lines were not taken into consideration. The hypothesis of the 
experiment was to initially identify genes that were differentially regulated in 
response to lapatinib. As T47D and MDAMB468 cell lines do not overexpress the 
HER2 receptor and as such are not responsive to the drug, the gene expression 
analysis from these cell lines would not contribute to evaluating differentially 
expressed genes in response to the HER2 targeted therapy lapatinib. Figure 3.1 
illustrates the unsupervised CIA that was undertaken on the microarray expression 
data for the MDAMB468 and T47D cell lines. This analysis indicated that there was 
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no clear clustering of the replicate samples when the samples were labelled 
according to the treatment they received. Figure 3.2 and figure 3.3 illustrate the 
clustering that was evident in the BT474 and SKBR3 cell line data when the data for 
these cell lines was labelled in the same fashion. While this analysis indicated that 
there were no consistent gene expression changes in the MDAMB468 and T47D cell 
lines in response to lapatinib and as such the data from these cell lines would not be 
useful to identify genes indicative of response to the drug, it did highlight 15 gene 
targets that were found to be differently expressed in all four cell lines. These genes 
were disregarded from all further analysis as they would not have informed the 
objective of the analysis which was to evaluate genes differently expressed in 
responsive cell lines.  
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Figure 3.1: Plot of the correlation of axes 1 (horizontal) and 3 (vertical) of the unsupervised 
CIA for (A) MDAMB468 and (B) T47D cell line data. A gene/TFBS (transcription factor 
binding site)  frequency table produced with a position specific scoring matrix (PSSM) 
threshold of 0.8 was used. (I) shows the projection of the cell line samples. There is no clear 
split in the 0.1% DMSO-treated samples (red), the 0.1µM-lapatinib treated samples (blue) or 
the 1µM lapatinib treated samples (green) in either cell  line. (II) Shows the projection of the 
TFBS motifs. The position of the individual TFBS in (II) had a direct relationship with the 
genes in the same position in (I). The TFBS in (II) was predicted to regulate the expression 
of the genes situated at the same position in (I). 
 
 
 
II 
I 
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3.3.2 Co-Inertia analysis of BT474 and SKBR3 cell lines 
 
There are a number of data mining and bioinformatics techniques that have the 
capability to identify differentially expressed genes from microarray data, such as 
canonical correlation analysis or canonical correspondence analysis. While these 
techniques could have been used, CIA (Co-inertia analysis) was applied in this 
study, as this emerging technique has previously been shown to be capable of 
correlating gene expression data with databases containing target predictions such as 
miRNA or transcription factor binding sites [14, 15]. This ability to correlate TFBS 
with predicted gene targets was used to guide the selection of genes for validation 
using Taqman RT PCR. Without this guidance from the TFBS, the gene expression 
data could have been evaluated using gene lists generated by between group analysis 
(BGA), examining the fold changes of the genes from the microarray data or 
clustering trends [16, 17].   
CIA is a multi-variant data analysis technique that allows for the identification of 
trends in gene expression across multiple datasets of the same samples. CIA is 
flexible and is a suitable approach for unifying data to identify patterns and trends 
from data that contain the same sample. CIA analysis provides simple representation 
of the data and is robust and efficient in its application to large datasets [18, 19].  
The use of the CIA multi-variant technique in this study was the first time this 
method was applied to breast cancer data. This analysis was used as a data 
exploration technique on the microarray data set and allowed incorporation of time 
series data at low and high drug concentrations from lapatinib-sensitive HER2-
positive cell lines. This analysis, described in detail in sections 3.3.3 and 3.3.4, 
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yielded a list of 512 genes differentially regulated in response to the lapatinib 
treatment in the BT474 and SKBR3 cell lines. The six comparisons described in 
table 3.1, which incorporated all data from the two lapatinib responsive cell lines at 
all of the time points following treatment (2 hours, 6 hours, 12 hours and 24 hours) 
and treatment conditions (0.1% DMSO, 0.1 µM and 1 µM lapatinib), were utilised in 
the generation of the list of differentially regulated genes.  The description of these 
comparisons was suggested by the initial unsupervised analysis. The 512 genes were 
found to be differentially expressed across all six comparisons and the direction of 
their changes was also consistent across all of the comparisons. This list of genes 
whose expression was altered can be found in appendix 4. In addition to this, the 
analysis suggested the optimal treatment conditions for the molecular validation 
study that was completed using qRT-PCR. This conditions were chosen based on the 
separation of data points observed in figure 3.2 and 3.3. These conditions were a 12 
hour treatment of 1µM lapatinib.  
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Table 3.1: The six comparisons of the gene expression data which were 
determined by the CIA (Group 1 vs Group 2) 
 
Comparison 
Number 
Cell Line Group 1 Group 1 
Microarray 
Number 
Group 2 Group 2 
Microarray 
Number 
1 BT474 6hr & 12hr 
1µM 
lapatinib 
8 all 
remaining 
samples 
40 
2 BT474 6hr & 12hr 
1µM 
lapatinib 
8 6hr & 12hr 
0.1% 
DMSO 
8 
3 SKBR3 6hr &12 hr 
0.1 and 
1µM 
lapatinib 
16 all 
remaining 
samples 
32 
4 SKBR3 6hr &12 hr 
0.1 and 
1µM 
lapatinib 
16 remaining 
samples 
less 24hr 
0.1µM 
lapatinib 
28 
5 SKBR3 12hr 0.1 
and 1µM 
lapatinib 
8 all 
remaining 
samples 
32 
6 SKBR3 12hr 0.1 
and 1µM 
lapatinib 
8 remaining 
samples 
less 24hr 
0.1µM 
lapatinib 
28 
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Furthermore, to identifying significantly differentially expressed genes, this CIA 
multivariate statistical technique was used to link transcription factor binding site 
target predictions and gene expression data in order to identify transcription factors 
(TFs) associated with the cellular response to lapatinib [15, 20]. CIA allowed us to 
identify commonality between the expression of the genes and the TFs that are 
predicted to target these genes. It also provided a ranked list of TFs predicted to be 
associated with the cellular response to lapatinib.  
To complete the CIA analysis, the microarray expression data underwent two 
methods of analysis. Un-supervised analysis, which assumes that there is no prior 
knowledge of the sample data, allowed for the clustering of groups of similar 
samples e.g. the same treatment concentration or time exposed to drug. This form of 
analysis is not driven by any hypothesis, it is used to evaluate the clustering of 
samples that behave similarly. Supervised analysis evaluated the number of 
differentially expressed genes in response to the drug treatment. Supervised analysis 
requires a hypothesis to be in place to apply to the data. The hypothesis that genes 
would be differentially expressed following exposure to a targeted therapy for a 
period of time formed the basis of our supervised analysis. Thus the unsupervised 
step allowed for data exploration and the identification of interesting trends or splits 
in the data as a result of the lapatinib treatment and trends in the predicted TFBS 
(transcription factor binding sites) frequency tables. The supervised analysis allowed 
us to identify which TFs were specifically associated with the response to lapatinib 
and ranked them in order of importance. This ranked list aided in the selection of the 
genes that were chosen for validation using Taqman RT-PCR, as the majority of the 
genes selected were predicted to be regulated by one of the eight ranked TFs (table 
3.4). 
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3.3.3 Unsupervised Co-Inertia Analysis identified clear and consistent gene 
expression changes in the BT474 and SKBR3 cell lines 
 
 
In analysing the data from the responsive cell lines (BT474 and SKBR3), CIA was 
employed to simultaneously analyse mRNA expression levels arising from the arrays 
with the detail on transcription factor binding sites (TFBS) in the promoters of the 
genes in the data. Unsupervised CIA was applied to the data from the 48 microarrays 
for each of the BT474 and SKBR3 cell lines and the associated gene/TFBS 
frequency tables and was used to identify underlying trends in the data in each of the 
cell lines. The TFBS tables were generated from information known about 1236 
known TFBS from three publications[21-23] and predicted TFBSs for ~17,000 
genes. The ultimate aim of this analytical approach was to identify the transcription 
factors (TF) responsible for the gene expression change trends in the data which 
would therefore also identify the differentially regulated genes these TFs were 
predicted to target. The results of the unsupervised CIA of the BT474 and SKBR3 
cell lines are shown in figures 3.2 and 3.3 respectively. CIA was used to combine 
two linked datasets (two sets of measurements on the same objects) and perform two 
simultaneous non-symmetric correspondence analyses (NSC) and identify the axes 
that are maximally co-variant [19, 20]. The use of an ordination method such as NSC 
allowed us to summarise the data in a low dimensional space. In this case, the two 
linked datasets were normalised gene expression data from the lapatinib-treated cell 
lines and TFBS information for the same genes. 
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3.3.3.1 Unsupervised co-inertia analysis of the BT474 cell line identifies a 
separation of 6- and 12-hour 1µm lapatinib-treated samples from those 
treated for 24 hours  
 
Axes one and three of the CIA for BT474 are plotted in figure 3.2. This allowed us 
to evaluate the response in the BT474 cell line to the 1µM lapatinib treatment at 
various time points. Axes one and three were chosen as they represent the dominant 
split within the data. The samples are represented as different colours based on 
treatment. The samples at 6 hours and 12 hours post treatment with 1µM lapatinib 
(green) clearly separate from those treated with 0.1% DMSO (red) with 0.1µM 
lapatinib (blue) and those 2 hours post treatment with 1µM lapatinib (green). With 
the exception of the 2 hour 0.1µM treatment, all 1µM treated samples form a clear 
separation from all of the other samples. However, no difference was observed in the 
data from the 0.1µM lapatinib-treated cells and 0.1% DMSO-treated cells. This 
suggested a dosage-dependant response in that a data separation only occurred 
between the data from control samples and the high dose lapatinib samples, with the 
exception of one outlier on the far right of the plot. The lack of sample separation at 
2 hours post treatment with 1µM lapatinib suggested that the gene expression effects 
of the drug were not yet apparent at this time point. These observations guided our 
choice of comparisons for both the supervised CIA and the differential gene 
expression analysis which are summarised in Table 3.1.  
 
 
72 
 
 
Figure 3.2 Plot of the correlation of axes 1 (horizontal) and 3 (vertical) of the unsupervised 
CIA for BT474 cell line data. A gene/TFBS frequency table produced with a position 
specific scoring matrix (PSSM) threshold of 0.8 was used. (A) shows the projection of the 
cell line samples. The 0.1% DMSO-treated samples (red), the 0.1µM-lapatinib treated 
samples (blue) are split from the 1µM lapatinib treated samples (green), the exception being 
the four 1µM lapatinib treated samples at 2 hours post treatment. (B) Shows the projection 
of the TFBS motifs.  The position of the individual TFBS in (B) had a direct relationship 
with the genes in the same position in (A). The TFBS in (B) was predicted to regulate the 
expression of the genes situated at the same position in (A). 
  
A 
B 
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Figure 3.2B shows the TF motifs associated with the genes separating the data. The 
most extreme motifs along each axis are labelled and named. Those motifs furthest 
from the origin in the same orientation as the split of interest shown in figure 3.2A 
are most associated with that split. V.AHRARNT.02 was the motif most associated 
with the separation of 1µM lapatinib-treated cells from the other samples and 
therefore was the motif most associated with the response to lapatinib. This was the 
motif for the agonist-activated heterodimer AHR/ARNT (Aryl hydrocarbon 
receptor/Arnt (hypoxia inducible factor 1 beta)) which directly associates with the 
estrogen receptors ER-alpha and ER-beta in ER-positive breast cancer, although its 
function in HER2-positive breast cancers is not well characterised[24]. 
These results indicated that the BT474 gene expression response was dose-
dependent. 
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3.3.3.2 Unsupervised co-inertia analysis of the SKBR3 cell line identifies a 
separation of 6- and 12-hour 0.1µM and 1µm lapatinib treatment 
samples from the 24-hour 0.1 µM lapatinib treatment samples. 
 
Figure 3.3A shows axes one and two of the CIA for the SKBR3 cells. The samples 
are labelled as before based on treatment. There was a clear split between the 0.1µM 
(blue) and 1µM (green) lapatinib-treated cells at 6 and 12 hours post treatment from 
the 0.1% DMSO treated cells (red), with the exception of one outlier. As with the 
BT474 cell line, there was no separation at 2 hours post treatment with 0.1µM and 
1µM lapatinib suggesting that the effects of the drug are not yet apparent at this time 
point in both cell lines. However, in this cell line the split occurred at both the 0.1µM 
and 1µM lapatinib dosages. Again, as with the BT474 data, these analyses were used 
to guide our comparisons for the supervised CIA and the gene expression analysis 
(Table 3.1).  
The TF motifs associated with this split in the data are in the same orientation 
relative to the origin as the genes separating the data in Figure 3.3B. These include 
the VDR/RXR heterodimer (V.VDR_RXR.06, vitamin D receptor/retinoid X 
receptor). The expression of the VDR/RXR heterodimer has been previously 
associated with numerous cancers, including breast cancer. It has been suggested that 
its expression of this heterodimer may indicate a patient population that may 
response better to adjuvant therapy[25]. 
These results indicated that the SKBR3 gene expression response was also a time-
dependent response.  
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Figure 3.3: Plot of the correlation of axes 1 (horizontal) and 2 (vertical) of the unsupervised 
CIA for SKBR3 cell line data. A gene/TFBS frequency table produced with a PSSM 
(position specific spacing matrix) threshold of 0.8 was used. The PSSM gives the log-odds 
score for finding a particular motifs in a target sequence. (A) shows the projection of 
the cell line samples. The 0.1% DMSO-treated samples (red), are split from the 0.1µM 
lapatinib-treated samples (blue) and the 1µM lapatinib-treated samples (green), the 
exception being the eight 0.1µM lapatinib and 1µM lapatinib-treated samples at 2 hours post 
treatment. (B) Shows the projection of the TFBS motifs. . The position of the individual 
TFBS in (B) had a direct relationship with the genes in the same position in (A). The TFBS 
in (B) was predicted to regulate the expression of the genes situated at the same position in 
(A). 
 
B 
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3.3.4 Supervised CIA identifies 8 putative transcription factors associated 
with the response to lapatinib 
 
In order to systematically identify the TFBSs specifically associated with the 
response to lapatinib in the two responsive cell lines, we performed a supervised 
analysis of the data, combining CIA and Between Group Analysis (BGA). BGA co-
ordinates the expression data from sets of grouped microarray samples described in 
table 3.1 [17]. CIA was performed twice in the BT474 dataset and four times in the 
SKBR3 dataset to perform all comparisons described in table 3.1. The description of 
these comparisons was provided by the most distinct separation of the data in the 
unsupervised analysis (sections 3.3.4 and 3.3.5). This resulted in six ranked lists of 
TFBS associated with a response to lapatinib treatment. The 8 transcription factor 
motifs (representing 8 individual transcription factors) which were consistently 
ranked highly across the six comparisons are displayed in Table 3.2.  From these 
motifs we can infer the transcription factors which are most important in driving the 
response to lapatinib in these cell lines. 
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Table 3.2: The ranked list of TFs associated with the response of BT474 and 
SKBR3 to lapatinib. 
TF Motif ID Description 
RAR V.RAR_RXR.02 Retinoic acid receptor 
RXR V.RAR_RXR.02 Retinoid X receptor 
ARNT V.AHRARNT.02 hypoxia inducible factor 1 beta 
AHR V.AHRARNT.02 Aryl hydrocarbon receptor 
ZNF143 V.STAF.02 Zinc finger protein 143 
PAX9 V.PAX9.01 Paired box gene 9 
OLF1 V.OLF1.01 Olfactory neuron-specific factor 
PAX3 V.PAX3.01 Paired box gene 3 
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3.4 Selection of breast cancer cell line panel 
 
The analysis of the microarrays outlined in the previous sections was undertaken in 
SKBR3 and BT474 breast cancer cell lines. Both of these cell lines are HER2 
overexpressing and have been previously shown to be responsive to lapatinib[3]. 
Proliferation assays were performed on these cell lines to determine their sensitivity 
to lapatinib. In order to examine if this sensitivity corresponds to the magnitude of 
the differential gene expression, a further four cell lines known to have different 
levels of lapatinib sensitivity were also analysed using the methods outlined in 
section 2.2 (Table 3.3). The additional cell lines chosen were the lapatinib-sensitive 
HER2over-expressing EFM192A and HCC1954, the lapatinib-insensitive HER2 
over-expressing MDAMB453 and the lapatinib-insensitive triple negative 
MDAMB231. A triple negative cell line is one that does not expression the 
oestrogen receptor (ER), progesterone receptor (PR) nor overexpress HER2. For our 
purposes we defined an insensitive cell line as one demonstrating a drug IC50 greater 
than 1µM [3]. 
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Table 3.3: Lapatinib IC50 values for the panel of breast cancer cell lines employed in 
this programme n=3 (biological replicates). 
 Cell Line Name IC50 ± SD (µM) 
Lapatinib-Sensitive Cell Lines BT474 0.036 ± 0.015 
 SKBR3 0.080 ± 0.017 
 EFM 192A 0.193 ± 0.067 
 HCC1954 0.416 ± 0.180 
Lapatinib-Insensitive Cell Line MDAMB453 6.08 ± 0.83 
Triple Negative Cell Line MDAMB231 7.46 ± 0.10 
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3.5 Determination of appropriate endogenous control genes 
 
An endogenous gene control was required for this analysis as it was necessary for the 
calculation of the relative expression of the genes in response to lapatinib [26]. For a 
particular gene to be useful as endogenous control it should be expressed at a 
constant level across different sample types and should not be affected by 
experimental treatments[27, 28].The Ct values of each of the evaluated genes were 
normalised to the Ct value of the endogenous control to provide the ∆Ct value of that 
gene.  
Four endogenous control genes (GAPDH, GUSB, 18S and HPRT1) were examined 
for their suitability and were quantitated using Taqman RT-PCR. These endogenous 
controls are commonly employed in the literature [28, 29].  In order to evaluate 
which would be most suitable in the comparative threshold analysis, the Ct values of 
the four candidate genes in the BT474 and SKBR3 cells lines (untreated and treated 
with 1µM lapatinib in triplicate) were examined to evaluate the variability of the 
expression of the putative control genes. The standard deviations (SD) of the 
triplicate untreated and treated Ct values of both cell lines at both conditions were 
calculated (Figure 3.3). The SDs resulting from these analyses were as follows; 18s 
= 1.14, GAPDH = 0.92, GUSB = 0.77 and HRPT = 1.23. The SD for 18s and HRPT 
were deemed to be too high so they were eliminated as endogenous control 
candidates. In choosing between GAPDH and GUSB, with the SD values being quite 
similar, GAPDH was chosen over GUSB for use as an endogenous control in further 
studies as it demonstrated a higher level of expression with Ct values of ~18, while 
the GUSB had Ct levels ~26. GAPDH is also a very well established control in the 
literature [30, 31].
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Figure 3.4: Determination of endogenous controls in SKBR3 and BT474 cell lines. Triplicate (untreated and treated with 1µM lapatinib for 12 hours) Ct 
values were evaluated and the standard deviation values were calculated. Utilising a combination of both of these values GAPDH was determined to be the 
most suitable endogenous control.
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3.6 Expression of eight transcription factors in response to lapatinib 
 
Taqman RT-PCR analysis was performed to validate the transcription factor 
expression in lapatinib-treated BT474 and SKBR3 breast cancer cell lines. Treatment 
with 1µM lapatinib for 12 hours was chosen as the optimal condition for treating the 
cells based on the separations seen in CIA analysis (Figures 3.2 and 3.3). In addition, 
1µM of lapatinib is a clinically relevant concentration [32]. These two cell lines are 
highly sensitive to lapatinib with IC50 values of 0.036µM ± 0.015µM and 0.080µM ± 
0.017µM respectively (table 3-1) [3]. Four additional cell lines were also chosen 
based on their sensitivity to lapatinib (EFM192A, HCC1954, MDAMB453 and 
MDAMB231). Their IC50 values are shown in Table 3.3. 
The expression levels of eight TFs described in table 3.2 were assessed. Six of the 
eight transcription factors were found to be expressed following 1µM 12hr lapatinib 
treatment relative to untreated controls (Figure 3.5). Ct values for these TFs were all 
determined to have values between 27 and 29. Although these TFs were not 
identified as significantly differentially expressed in the microarray analysis, they 
were clearly dysregulated in these cell lines, as predicted by CIA. Two of the 
predicted transcription factors (PAX3 and OLF1) were not expressed (data not 
shown). While the expression of the TFs did not follow an obvious pattern, there 
were some distinct trends. For example, all of the TFs were up-regulated following 
treatment in the most lapatinib-sensitive cell line (BT474) and nearly all were down-
regulated following lapatinib treatment in the most lapatinib-insensitive cell line 
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(MDAMB453). In addition, ARNT was up-regulated following lapatinib treatment 
in all lines, apart from MDAMB231, the triple negative cell line. 
It should be noted that even the smallest changes in the expression of any of the TFs 
could have had some major effects. This would be due to the key role that these TFs 
play in a large number of pathways so as such large changes in the expression of 
these genes would not be expected. 
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Figure 3.5:  The expression of transcription factors (TFs) was evaluated in the six cell line panel following 1µM lapatinib for 12 hours and are ordered left to 
right in order of importance from the ranked list generated from the CIA (table 3.2). Although theses TFs were not identified as significantly differentially 
expressed in the microarray analysis, they are clearly dysregulated in these cell lines as predicted by the CIA  The cell lines are represented in order of 
lapatinib sensitivity, with BT474 being the most sensitive and MDAMB231 being the triple negative insensitive cell line. The analysis was completed in 
triplicate the error bars represent the standard deviation of the mean ∆∆Ct value.  
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3.7 Expression of differentially expressed genes in response to lapatinib 
From the panel of 512 genes of interest arising from the original CIA analysis, a 
subset of 19 genes was selected for more detailed validatory analysis. The genes 
were selected on the basis of the following criteria; a large alteration in expression 
following treatment , the expression of the gene was predicted to be regulated by one 
or more of the ranked TFs or the gene was known to play an important role in some 
aspect of cancer biology. (Table 3.4). As with the TFs, the 19 genes (CCND1, 
ERBB3, FOXO3a, NR3C1, RB1CC1, ALDH3A2, CDKN1B, PIK3C3, AKT1, BID, 
E2F3, eIF4E, FKBP4, MAPK9, PARP2, PSMD13, SLC29A1, TFPT and CBFA2T2)  
were first analysed for expression in BT474 and SKBR3 cells that had been treated 
with 1µM lapatinib for 12 hours using untreated cells as a control (Figure 3.5). Table 
3.4 summarises the basic characteristics of these genes of interest. The analysis was 
first completed in these two cell lines as they were the cell lines used by Hedge et 
al., [13] in the microarray analysis. Eight of the 19 genes (CCND1, ERBB3, 
FOXO3a, NR3C1, RB1CC1, ALDH3A2, CDKN1B and PIK3C3) were found to be 
differentially expressed with an RQ value of ≥ ±2 in both the BT474 and SKBR3 
cell lines. The remaining 11 genes (AKT1, BID, E2F3, eIF4E, FKBP4, MAPK9, 
PARP2, PSMD13, SLC29A1, TFPT and CBFA2T2), were also found to be 
differentially expressed, however, the alterations in gene expression level did not 
occur in both of the cell lines and hence we did not conduct any further analysis of 
them . 
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Table 3.4 : List of genes chosen for Taqman RT PCR validation. 
Gene Symbol Gene Name Key 
Known Gene Function Specific TF that gene is 
predicted to be a target of  
CCND1 Cyclin D1 
1,3
+ 
regulates the cell-cycle during 
G(1)/S transition [33] 
AHR/ARNT, 
PAX9,RAR/RXR 
ERBB3 
v-erb-b2 erythroblastic leukemia 
viral oncogene homolog 3 
2,3
+ 
Binds and is activated by 
neuregulins [34] 
 
OLF-1 
FOXO3a Forkhead box protein O3 
1,3
+ 
Downstream target of 
PIK3/AKT pathway which are 
associated with cellular 
differentiation, metabolism, 
tumorgenesis [35] RAR/RXR 
NR3C1 
nuclear receptor sub family 3 group 
C member 1 
2,3
+ 
Regulated transcription of the 
NR3C1[36] 
 
AHR/ARNT, PAX3 
RB1CC1 RB1 inducible coiled coil protein 1 
3
+ 
Inhibition of G1-S progression 
[37] 
ZNF143 
ALDH3A2 
aldehyde dehydrogenase 3 family 
2
+ role in the detoxification of  
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member 2a aldehydes generated by 
alcohol metabolism and lipid 
peroxidation [38] 
CDKN1B cyclin dependent kindase inhibitor 1B 
2
+ 
Regulation of cell cycle 
progression [39]   
PIK3C3 phosphoinositide 3 kinase class 3 
2
+ 
mediates formation of 
phosphatidylinositol 3-
phosphate [40]  
AKT1 
v-akt murine thymoma viral oncogene 
homolog 1 
3 
Tumour angiogenesis[41]  
RAR/RXR 
BID BH3 interacting domain 
2 
important component of death 
receptor-mediated caspase 
activation [42]  
E2F3 E2F transcription factor 3 
1,3 
control the cell cycle-dependent 
expression of genes that are 
essential for cellular 
proliferation [43] 
AHR/ARNT, OLF-1, PAX9, 
ZNF143 
eIF4E 
eukaryotic translation initiation factor 
4e 
3 
role in cancer initiation and 
progression [44] 
PAX3, RAR/RXR 
FKBP4 Fk506 binding protein 4 
2,3 
regulates progesterone activity  
[45] 
ZNF143 
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MAPK9 mitogne-activated protein kinase 9 
2 
cell proliferation, 
differentiation, migration, 
transformation and programmed 
cell death [46] 
 
PARP2 poly (ADP-ribose) polymerase 2 
2 
DNA-break sensing and 
signaling[47]  
PSMD13 
proteasome 26S subunit non-ATPase 
13 
2 
processing of class I MHC 
peptides[48] 
 
SLC29A1 solute carrier family 29 member 1 
2 
mediates the cellular uptake of 
nucleosides from the 
surrounding medium [49]  
TFPT TCF3 (E2A) fusion partner 
2,3 
promotes cell differentiation 
[50] 
ZNF143 
CBFA2T2 
core-binding factor, runt domain, alpha 
subunit 2; translocated to, 2 
2 
promoting leukemogenesis [51] 
 
 
1
 denotes a highly differentially regulated gene (±2 fold across all 6 supervised CIA comparisons)   
2
 denotes a gene that has been previously shown to be 
associated with cancer or was a known drug target, 
3
 denotes a gene was predicted to be targeted by one or more of the transcription factors. Those in bold 
were found to be consistently dysregulated in response to lapatinib in all 6 of the cell lines. + denotes that the gene was found to be differentially expressed in 
BT474 and SKBR3 cell lines but not in the additional four cell lines also tested.
89 
 
 
For further validation, expression levels of CCND1, ERBB3, FOXO3, NR3C1, 
RB1CC1, ALDH3A2, CDKN1B and PIK3C3 genes were measured in two additional 
lapatinib-sensitive cell lines; EFM192A and HCC1954. These genes were chosen for 
further validation as they exhibited RQ values that were greater than 2 in both the 
BT474 and SKBR3 cell lines. Both of these cell lines are HER2-overexpressing and 
have varying sensitivities to lapatinib, with IC50 values of 0.193µM ± 0.067µM and 
0.417µM ± 0.18µM, respectively (Table 3.3). Two lapatinib-insensitive cell lines 
were also analysed, MDAMB453 and MDAMB231.  
In the lapatinib-sensitive cell lines (BT474, SKBR3, EFM192A and HCC1954), five 
of the eight genes (RB1CC1, FOXO3a, NR3C1, ERBB3 and CCND1) analysed 
showed differential expression post lapatinib treatment and are highlighted in bold in 
table 3.4. The relative expression of three genes that did not follow this trend 
(PIK3C3, ALDH3A2 and CDKN1B) is shown in figure 3.7. It should be noted 
however, that this expression trend was evident in the BT474 and SKBR3 cell lines 
but not in the other four cell lines. Thus these genes would not be considered as 
robust indicators of response to the lapatinib. 
Figure 3.6 shows the expression of RB1CC1, FOXO3A, NR3C1, ERBB3 & CCND1 
in the four lapatinib-sensitive cell lines and clearly demonstrates a correlation 
between the degree of sensitivity of the cell line to lapatinib and the magnitude of 
gene expression change. BT474 was the most lapatinib-sensitive cell line and has the 
highest expression values for the four up-regulated genes. As the cell lines become 
less sensitive to lapatinib, the magnitude of gene expression decreased. In contrast, 
in the lapatinib-insensitive cell lines, MDAMB453 and MDAMB231, the differential 
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expression of these genes was seen to be down regulated following lapatinib 
exposure. 
In the case of CCND1, the differential gene expression pattern followed a largely 
proportional response across the various cell lines. In the lapatinib-sensitive cell lines 
expression of this gene was found to be strongly down-regulated following the 12hr 
treatment. The magnitude of this down-regulation was reduced as the cells became 
more lapatinib-insensitive (Figure 3.6).  
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Figure 3.6: The differential expression of five genes was examined following 1µM lapatinib treatment for 12 hours in a panel of six breast cancer cell lines 
with varying degrees of lapatinib sensitivity. It was established that   the degree of dysregulation of the genes in each of the cell lines was proportional to the 
response to lapatinib.  The cell lines are represented in order of sensitivity to lapatinib, with BT474 being the most sensitive and MDAMB231 being the least. 
The analysis was completed in triplicate the error bars represent the standard deviation of the mean ∆∆Ct value. 
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Figure 3.7:  The differential expression of three genes was examined following 1µM 
lapatinib treatment for 12 hours in a panel of six breast cancer cell lines with varying 
degrees of lapatinib sensitivity. There were some differences in the expression pattern of 
these three genes when compared with the five genes examined in figure 3.6, in particular in 
the HCC1954 cell lines, The cell lines are represented in order of sensitivity to lapatinib, 
with BT474 being the most sensitive and MDAMB231 being the least. The analysis was 
completed in triplicate, the error bars represent the standard deviation of the mean ∆∆Ct 
value.  
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3.8 Comparison of pre-seeded TaqMan plates vs individual TaqMan assays. 
 
For the initial validation of the bioinformatic predictions from the CIA (Section 3.7) 
custom pre-seeded Taqman RT-PCR plates were used for the analysis. These custom 
pre-seeded Taqman RT-PCR plates are manufactured with the selected genes assays 
lyophilised to the wells of the 96 well plates. All cell lines were examined in 
biological triplicate using these plates. In using these custom pre-seeded plates, it 
was possible to validate the expression of a larger number of genes using a small 
concentration of target material. When further analysis on a sub-set of eight genes 
was required, individual gene assays were utilised. These individual assays were 
employed as they were more versatile and cost effective for the smaller number of 
gene targets. The cell lines were examined in both biological and technical triplicate 
using the individual assays. These individual assays were prepared by the addition of 
the Taqman universal master mix with the individual assay and the sample cDNA. 
For the pre-seeded plates the  Taqman universal master mix in combination with the 
cDNA for the sample was added to each well as the assay was already present in the 
well.  
In figure 3.8 the fold changes calculated from the custom pre-seeded Taqman plates 
and the individual assays have been compared. The trend that was exhibited in the 
initial analysis with the pre-seeded plates remained evident in the analysis completed 
with the individual assays. However, in the BT474 cell lines, there was a large 
increase in the magnitude of expression of RB1CC1, FOXO3a and PIK3C3 using the 
individual assays.  
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No published data could be found which could explain the difference that was 
observed. It is possible that there was some evaporation of the assays which were 
lyophilised on to the pre-seeded plates. There was no difference in the Ct values for 
the endogenous controls between the pre-seeded plates and the individual assays 
with all of them showing values between 21 and 22. However, there was some 
variation in the Ct values of the target genes which account for the changes in 
magnitude of gene expression.  For all further gene expression analysis, the 
individual assays were utilised as they were more suitable for the smaller number of 
genes being validated. 
 
 
 
 
 
 
 
 
 
95 
 
 
 
Figure 3.8: Differential gene expression of significant genes using both preseeded custom Taqman plates and individual gene assays. Analysis was completed 
on all six cell lines and the cells lines were treated with 1µM lapatinib for 12 hours. The preseeded custom taqman plates were used for the initial validation 
of the 27 targets and the individual gene assays were used for all other analysis completed following the selection of the gene targets. The main difference 
between the two is exhibited, particularly, in the BT474 cell lines which showed higher fold change values for all of the gene targets using the individual 
assays.  The analysis was completed in triplicate the error bars represent the standard deviation of the  mean ∆∆Ct value.
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3.9 Evaluation of the lapatinib gene expression profile in a sub-panel of 
lapatinib-treated breast cancer cell lines over time 
 
In order to establish if the altered expression of the genes that had been shown in 
figure 3.6 and figure 3.7 was stable over a period of time, lapatinib-induced gene 
expression changes over different durations of time were quantitated. Three cell lines 
were chosen for this study; BT474 and SKBR3, the most lapatinib-sensitive cell 
lines and MDAMB453, the HER2-overexpressing lapatinib-insensitive model. The 
cells were treated for 6hrs, 24hrs and 36hrs with 1µM lapatinib. The 12hr treated 
cells were also re-analysed using the individual Taqman RT-PCR assays. The 
expression of the five genes (RB1CC1, FOXO3a, NR3C1, ERBB3 and CCND1) in 
the lapatinib-treated cell lines were compared with those of the untreated cell lines, 
see figure 3.9.  
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Figure 3.9: Analysis of (A) RB1CC1,(B)  FOXO3a, (C )NR3C1, (D) ERBB3 and ( E )  
CCND1 in BT474, SKBR3, and MDAMB453 over 4 different time points. Cell lines were 
treated with 1µM lapatinib for 6, 12, 24 and 36 hours. This analysis was undertaken to 
determine how robust the differential expression of the genes were over a time course. The 
analysis indicated that the expression of the genes remained consistent to a time point of 36 
hours. The analysis was completed in triplicate, the error bars represent the standard 
deviation of the mean ∆∆Ct value. 
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In figure 3.9, the alteration in the relative expression of each gene has been graphed 
independently showing the three cell lines that were tested over the 36 hour time 
period. The expression of RB1CC1 (figure 3.9 A) in the lapatinib-insensitive cell line 
MDAMB453 was found to be unchanged over the 36 hour time period. In 
comparison, the lapatinib-sensitive cell lines BT474 and SKBR3 demonstrated 
considerable up-regulation of RB1CC1 in response to the lapatinib treatment over the 
36 hours.  
FOXO3a (figure 3.9 B) expression in the MDAMB453 cell line was found to be 
down-regulated in response to lapatinib. The lapatinib-sensitive BT474 cells showed 
a slight decrease in FOXO3a expression following the 12 hour treatment but the 
expression remained consistently up-regulated. As with the expression of RB1CC1, 
in the SKBR3 cells, the expression of FOXO3a increased after the 12 hour time 
point, and at 36 hours the expression was higher in the SKBR3 cell lines than it was 
in the BT474 cells.  
NR3C1 (figure 3.9 C) expression slightly increased in the MDAMB453 cell line 
from 6 to 12 hours, after which its expression became down regulated in the 
remaining time points. The expression in the lapatinib-sensitive cell lines showed a 
slight increase after 12 hours in the SKBR3 and a higher level of expression in the 
BT474, with a decrease at 36 hours.  
The expression of ERBB3 (figure 3.9 D) in the MDAMB453 cell lines was shown to 
be predominately down regulated. In the SKBR3 and BT474 cell lines, The 
expression of the gene, showed a constant up-regulation across all the time points. 
The last of the genes, CCND1 (figure 3.9 E), was shown to be unchanged in 
response to the lapatinib treatment over the time course. The response was 
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considered unchanged as it had a fold change less than two. As was found in the 
initial analysis of these genes, there was a down-regulation in the expression of this 
gene in the lapatinib-sensitive cell lines. The trend remained consistant over the time 
points.  
A comparison of the data from all of the different time points indicated that the 
expression of the genes was reasonably constant over the 36 hours of examination 
and that difference in the expression levels between the lapatinib-insensitive cell 
lines MDAMB453 and the lapatinib-sensitive BT474 and SKBR3 remained 
recognisable.  All RQ values can be found in appendix 2. 
As shown in section 3.7 it was determined that while the genes PIK3C3, ALDH3A2 
and CDKN1B, were interesting in response to lapatinib in BT474 and SKBR3 cell 
lines, they did not follow the same trend of proportional response to lapatinib that the 
remaining five genes did when the panel of cell lines was expanded. The relative 
expression changes of these genes over the 36 hour time period did follow similar 
patterns to those observed in the other five genes (Figure 3.10 A-C). In PIK3C3, 
there was a continued up-regulation in the lapatinib sensitive cell lines and a down-
regulation in the MDAMB453 cell line. This trend was evident also in relation to the 
expression profile for the ALDH3A2. In the expression profile for CDKN1B, the gap 
between the expression of the gene in the lapatinib-sensitive and insensitive cell lines 
was most evident. The expression of the gene in the MDAMB453 cell line remained 
stable over the 36 hours. In the BT474 and SKBR3 cell lines, the expression was 
stable over the four time points and has at a similar level to each other.  
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Figure 3.10 A-C: Analysis of (A) PIK3C3, (B) ALDH3A2 and (C) CDKN1B in BT474, 
SKBR3, and MDAMB453 over 4 different time points. Cell lines were treated with 1µM 
lapatinib for 6, 12, 24 and 36 hours. This analysis was undertaken to determine how robust 
the differential expression of the genes were over a time course. The analysis indicated that 
the expression of the genes remained consistent to a time point of 36 hours. The analysis was 
completed in triplicate, the error bars represent the standard deviation of the mean ∆∆Ct 
value. 
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3.10 Evaluation of differential gene expression changes in normal breast tissue 
cells in comparison to the panel of breast cancer cell lines. 
 
If the findings of this study were to be applied to a real cancer treatment scenario to 
evaluate the gene expression changes in response to drug treatment, samples would 
be required for both pre and post treatment. To translate this method to the clinic 
would therefore require biopsy samples to be taken pre and post treatment from the 
tumour site. The tumour material that would be taken during these biopsies would 
not necessarily be pure tumour. As a result of this, it was necessary to establish if 
normal breast tissue would have an impact on the gene expression pattern that had 
been identified.  
To investigate this, human mammary epithelial cells (HMEC) isolated from donor 
normal breast tissue were purchased and cultured as described in section 2.1.5.1. 
RNA was extracted from the cells pre and post 12 hour lapatinib treatment (1µM). 
Cells were treated with the lapatinib so as to evaluate if it was possible to identify the 
gene expression pattern pre and post lapatinib treatment.   
Figure 3.11 shows that when the gene expression changes were examined in the 
HMEC cells pre and post 1µM lapatinib treatment for 12 hours, there was no 
evidence of lapatinib-induced differential expression of the genes in these cells. This 
result indicated that the normal breast cells did not express the pattern observed in 
the cancer cell lines in response to lapatinib, indicating that the gene expression 
changes are specific to tumour tissue. It also indicated that inclusion of normal tissue 
in the examination of tumour biopsies could have an impact on the gene expression 
analysis as contamination of the tumour tissue with normal tissue could reduce the 
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signal of the gene in the analysis. Such interference could lead to an inaccurate result 
of no change in gene expression.   
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Figure 3.11: In order to establish if there would be any interference in the gene expression 
pattern from normal breast tissue in the event that biopsy samples were taken, the expression 
of the genes was examined following 1µM lapatinib treatment for 12 hours in human 
mammary epithelial cells (HMEC). The analysis indicated that there was no distinct pattern 
evident in the gene expression in the normal breast cells following the lapatinib treatment. 
However as some of the genes did indicate a fold change greater than 2, it is possible that the 
inclusion of normal tissue in the examination of tumour biopsies may reduce the gene signal 
from the tumour material leading to an inaccurate result. The analysis was completed in 
triplicate the error bars represent the standard deviation of the mean ∆∆Ct value.   
 
 
 
 
 
 
-3
-2
-1
0
1
2
3
4
RB1CC1 FOXO3a NR3C1 ERBB3 CCND1 PIK3C3 ALDH3A2 CDKN1B
Fo
ld
 C
h
an
ge
 (
R
Q
) 
107 
 
Table 3.5 represents the gene expression changes between untreated and treated 
HMEC cells with untreated and treated breast cancer cell lines. To determine the 
relative expression of the genes, in the untreated comparison, the RNA expression 
values from the untreated HMEC cells were used as the calibrator sample. In the 
treated comparison, the lapatinib-treated HMEC cells were used as the calibrator 
sample. These comparisons, breast cancer cell lines versus HMEC cells pre and post 
lapatinib treatment, were used to evaluate the tumour specificity of the findings and 
evaluate if the gene expression pattern could potentially be identified using a 
heterogeneous biopsy material from a patient which could likely contain both normal 
breast and tumour tissue. 
Table 3.5 and figure 3.12 A +B shows the differences in the expression of the genes 
between the HMEC cells and the sub-panel of breast cancer cell lines. The gene 
changes were examined both pre and post 1µM lapatinib treatment. The relative gene 
expression change for a number of the genes was quite high in the untreated 
comparison. The expression of ERBB3 was exceptionally high, with RQ values of 
>200 in comparison to the expression of RB1CC1, which has RQ values between 
two and eight across the three cell lines. The expression of NR3C1 was greater in the 
MDAMB453 cell line compared to the BT474 and SKBR3, which indicated that 
there are differences in the expression of the genes in the different cell lines.  With 
the exception of ERBB3, MDAMB453 showed a higher relative expression of the 
genes in the untreated comparison. In the expression of ERBB3 the MDAMB453 cell 
lines had a lower level of relative expression than the BT474 and SKBR3 when 
related to the expression in the HMEC cells.  It should be noted that the Ct values for 
the endogenous control for the HMEC cells both untreated and treated were shown 
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to be stable with values ~ 17-18 which is comparable to those seen in the breast 
cancer cell lines.  
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Table 3.5: Relative gene expression comparisons between HMEC cells and the sub-
panel of HER2 over-expressing breast cancer cell lines.  
 
 
 
 
 
 
 
  HMEC untreated vs Cancer 
untreated RQ values 
  HMEC Treated vs Cancer 
Treated RQ values 
  BT474 SKBR3 MDAMB453  BT474 SKBR3 MDAMB453 
RB1CC1 2.0 2.1 8.9  19.2 7.8 13.7 
FOXO3a 4.4 1.1 14.9  20.6 2.5 3.9 
NR3C1 -1.0 1.8 199.7  6.8 5.7 30.9 
ERBB3 276.3 247.8 178.9  823.9 456.2 1193.9 
CCND1 18.9 10.2 57.4  5.6 1.9 44.3 
PIK3C3 9.1 1.8 37.7  24.7 5.1 23.7 
ALDH3A2 8.9 5.0 92.7  11.2 3.4 22.9 
CDKN1B 29.6 9.9 84.0  104.5 43.2 124.6 
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Figure 3.12:   To determine if there was any distinct pattern emerging from the comparison 
of the HMEC cells and three of the breast cancer cell lines, gene expression analysis was 
completed both before (A) and after (B) 1µM 12 hour lapatinib treatment. While expression 
changes were clearly evident, there were no distinct patterns that could be used to evaluate 
response to lapatinib using the different cell types. This analysis indicated that the optimal 
method to evaluate the gene expression changes in response lapatinib treatment would be pre 
and post treatment tumour samples. The analysis was completed in triplicate the error bars 
represent the standard deviation of the mean ∆∆Ct value.   
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Following treatment with lapatinib, the RQ values for the genes in the MDAMB453 
cell line were seen to be reduced compared to RQ values exhibited in the untreated 
cell line data with the exception of the values for RB1CC1, ERBB3 and CDKN1B. 
The ERBB3 response also differed following treatment with lapatinib in the BT474 
and SKBR3 cell lines. There was a large increase in the RQ values, with values 
ranging from 200-276 to 456-1193. The largest rise in the expression value is in the 
MDAMB453 cell line. In the SKBR3 cell line there was a sharp increase in 
expression from ERBB3 to 823 following treatment. Biologically, these large RQ 
values make sense. HMEC cells have been shown not to overexpress HER2 [52] and 
the co-expression of HER2 and ERBB3 is frequently observed [53] which would 
indicate that the HMEC cells would not over-express ERBB3 either.   Studies have 
indicated that there is an increase in the expression of ERBB3 in breast cancer 
following lapatinib treatment [54]. This observation would support the large relative 
expression (RQ) value for ERBB3 that was seen following lapatinib treatment in the 
breast cancer cell lines in comparison to HMEC cells. 
 Unlike the data shown in figures 3.6 and 3.7, while there were changes evident, 
there was no distinct pattern emerging from the data that could be used to evaluate a 
response to lapatinib using the different cell types. These results indicate that the 
optimal method to evaluate the gene expression changes in response to lapatinib 
treatment would require pre and post treatment tumour samples.   
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3.11 Discussion 
 
CIA, a multi-variant bioinformatics technique was used to identify a number of 
genes and TFs associated with the cellular response to lapatinib. In applying these 
methods there was no requirement for the filtering of gene expression data or the 
generation of gene lists or clusters that can be necessary in other bioinformatics 
methods such as gene ontology. This technique utilised transcription factor binding 
site information in combination with the genes that these TFs putatively regulate. 
This was the first time that this technique had been applied to a breast cancer dataset 
in response to targeted treatments. The technique has also been employed to other 
linked data sets, for example, to link geographic locations and species composition in 
ecology [20]. Jeffery et al.,[15] provided examples of how the CIA technique can be 
utilised in determining transcriptional pathways associated with differences between 
benign and metastatic samples in prostate cancer. Using this technique we identified 
a panel of 512 gene targets of interest which was reduced to 19 genes and 8 TFs that 
were associated with lapatinib response in BT474 and SKBR3 cell lines. The 19 
genes and 8 transcription factors were selected for more detailed qPCR analyses 
based on varying combinations of the following criteria; (i) the magnitude of 
response to lapatinib, (ii) whether the selected genes were predicted targets of the 8 
TFs, (iii) the involvement of the gene in important oncogenic processes (determined 
from functional annotation using the literature mining analysis software Pathway 
Studio Enterprise (Ariadne Genomics). Genes were manually selected on the basis of 
meeting two or more of these criteria. This panel included both known and novel 
markers of lapatinib response and represents a cohort of markers for predicting both 
the response and the cellular sensitivity to lapatinib. The gene expression pattern was 
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evaluated in a panel of breast cancer cell lines that had varying sensitivities to 
lapatinib but also differing HER2 over-expression status. There have been a number 
of recent publications that have found a correlation between pTEN/AKT/PI3K 
pathway activation and the response of the patient to either trastuzumab or lapatinib. 
The consensus is that patient with low pTEN expression would suggest trastuzumab 
resistance but sensitivity to lapatinib [55-57]. These studies have provided a valuable 
insight into intrinsic resistance in the HER2 target models. The changes in PTEN 
and AKT expression have been well characterised and published by a large number 
of preclinical and clinical studies. However, there have been limited studies 
completed on molecular gene targets that are expressed in response to lapatinib or 
other targeted therapies.  
 From the panel of 19 genes that were molecularly validated, five were found to be 
differentially regulated in a lapatinib sensitive manner with changes in the 
expression of these genes correlated directly with the lapatinib sensitivity of the cell 
line being examined (figure 3.6). These five genes included known lapatinib 
response genes such as FOXO3A and CCND1, as well as novel genes such as, 
RB1CC1 and NR3C1. In addition to these five genes, PIK3C3, ALDH3A2 and 
CDKN1B  were also found to be differentially expressed in response to lapatinib in 
BT474 and SKBR3 cell lines, however, they did not provide as compelling a 
response in the remaining four cell lines (EFM192a, HCC1954, MDAMB453 and 
MDAMB231) and so were not further investigated.  
Putative candidate regulators (TFs) of this lapatinib response were also identified, 
none of which have been previously studied in lapatinib-treated cells. It is important 
to note that none of these TFs were associated with the lapatinib response through 
conventional microarray differential expression and their prioritisation here was only 
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achieved via the novel use of the CIA method in this breast cancer dataset. CIA was 
not restricted to a specific gene list but rather used the entire microarray data as 
input. CIA is therefore not limited to arbitrary cut-offs which may exclude important 
TFs of interest.   
The expression of 6 TFs, AHR, ARNT, RXR, RAR, PAX9 and ZNF143 were found to 
be altered across all the cell lines in response to lapatinib treatment. These TFs are 
putative regulators of the cellular response to lapatinib and are predicted to target a 
number of the significantly differentially regulated genes. The expression of these 
TFs does not follow a set pattern but do follow some distinct trends as mentioned 
above in section 3.6. All of these TFs have been previously demonstrated to play 
important roles in cancer, although their function in HER2-positive breast cancer is 
unclear. The AHR/ARNT heterodimer has been implicated as having importance in 
ER positive breast cancer and has been shown to directly associate with estrogen 
receptors ER-alpha and ER-beta[24, 58, 59].  Retinoids targeting the RXR/RAR 
heterodimer have marked effects on cellular processes such as proliferation and 
apoptosis and this has been shown both in vivo and in vitro in breast cancer models 
[60]. The RARA receptor has also been recently identified as being co-amplified with 
HER2 in some breast cancers [61]. While being known oncogenes, PAX9 and 
ZNF143 have not been extensively studied in breast cancer [62, 63]. The remaining 
two TFs that were identified through the CIA were OLF-1 and PAX3. Although the 
TFs were present in the microarray probes and were identified as being involved in 
the regulation of a number of the genes, it was not possible to validate them using 
Taqman RT PCR. It was possible that the signal emitted from the expression of the 
TF was not strong enough to be detected using the Taqman probes.  
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Utilising transcription factor genes or indeed the TFs themselves as potential 
biomarkers could prove to be very difficult in practice.  A small change in the 
expression of a transcription factor can have a much larger an effect on the 
expression of a gene that it regulates. Also, as this study has indicated, it can be 
difficult to measure these changes using microarray or Taqman RTPCR methods. In 
addition, TF genes are not suitable as potential drug targets as, even if other practical 
hurdles were overcome, a single transcription factor can be responsible for the 
regulation of a number of different genes, inhibiting its expression could have an 
impact on a number of different pathways and cell functions.  
In the case of five of the genes identified FOXO3A, CDKN1B, CCND1, RB1CC1 
and NR3C1, in the panel of six cell lines their expression correlated broadly with 
sensitivity of each cell line to lapatinib. Four of the genes; FOXO3A, CDKN1B, 
RB1CC1 and NR3C1 were found to be up-regulated in response to lapatinib. The 
results indicate that the more sensitive that the cell line is to lapatinib, as determined 
using proliferation assays, the greater the magnitude of up-regulation of the four 
genes. In contrast to the findings with the sensitive cell models, these genes were 
found to be downregulated in the remaining two lapatinib-insensitive cell lines 
(MDAMB453 and MDAMB231). In the case of CCND1, the expression of CCND1 
became less down-regulated as the level of lapatinib sensitivity decreased.  
All five of the genes have been previously demonstrated to have importance in 
cancer. Increased RB1 inducible coiled-coil 1 (RB1CC1) expression has been shown 
to be associated with improved long term survival of breast cancer patients and has 
been found to have a role in the inhibition of G1/S progression and proliferation in 
breast cancer cell lines [37, 64]. Genetic variations to a non-coding BclI restriction 
fragment length polymorphism in NR3C1, a glucocorticoid receptor, have been 
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associated with poor response to treatment in multiple myeloma samples [65]. Up-
regulation of ERBB3 (HER3) has been connected with invasive breast carcinomas 
and also drug resistance in some HER2 over-expressing cancers [66, 67]. FOXO3A 
and CCND1 have been demonstrated to be important in both breast cancer and the 
lapatinib response [13, 68]. FOXO3A and CCND1 were both shown by [13] to be 
differently expressed following treatment with lapatinib. This group reported up-
regulation of FOXO3A in both BT474 and SKBR3 and also a down-regulation of 
CCND1 in the same cell lines following lapatinib treatment. These results are 
consistent with the results obtained by our study. It should be noted that CDKN1B 
was also differentially expressed in response to lapatinib in our study although its 
dysregulation did not correlate with lapatinib sensitivity. The authors identified that 
these three genes all played roles in the regulation of the AKT pathway, both 
positive and negative. They noted that the down regulation of CCND1 and that the 
up-regulation of CDKN1B in response to lapatinib could be as a result of a 
FOXO3A-dependent mechanism, which promotes lapatinib-induced apoptosis. 
However, they did not examine the expression of these genes in other lapatinib 
sensitive cell lines nor did they observe that the expression of these genes correlated 
with the sensitivity of the cell lines to lapatinib. They also observed additional 
changes in response to genes associated with a number of cellular processes such as 
glycolysis and cell cycle regulation. 
Of the five lapatinib responsive genes, lapatinib associated alterations in FOXO3A 
and CCND1 have been previously described in lapatinib-treated BT474 and SKBR3 
cell lines by the group that generated the original microarray dataset [13]. However, 
the inclusion of the additional 4 cell lines allowed us to examine expression of the 
five differentially expressed genes in the context of cell lines with varying 
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sensitivities to lapatinib. The up-regulation of RB1CC1 and NR3C1 in response to 
lapatinib has not been previously observed, while only limited work has been 
performed on ERBB3, FOXO3A and CCND1 in this setting [69, 70].  
In evaluating the expression of these genes over a period of 36 hours we sought to 
establish if the relative expression changes in our genes of interest were stable over 
this period. There was an increase in the expression of RB1CC1, NR3C1, FOXO3a 
and ERBB3 over the additional time points in the lapatinib-sensitive BT474 and 
SKBR3 cell lines. For CCND1, the relative expression of the gene remained down 
regulated in the lapatinib sensitive cell lines. All of the genes remain unchanged in 
the MDAMB453 lapatinib in-sensitive cell line. Examination of the gene expression 
changes at a number of different time points indicated that these changes are steady 
for more than 24 hours. This finding could have an impact on the translation of this 
work to patient samples. Pre and post treatment samples would be required to 
complete the analysis and these results indicated that the post treatment sample could 
be taken a number of days following treatment. 
We also sought to examine any alterations in our gene expression profile in normal 
breast cells in comparison to the breast cancer cell lines, BT474, SKBR3 and 
MDAMB453. Evaluation of the lapatinib gene expression profile response in the 
HMEC cells provided evidence that the profile exhibited was not seen in normal, 
non-HER2 over-expressing cells. This indicated that in order to evaluate the 
response, analysis would have to be run on relatively pure cancer cell samples. This 
finding was further strengthened by the data looking at the relative expression of the 
genes between the HMEC cells and a sub panel of breast cancer cell lines. While 
there were changes evident in both the untreated and the lapatinib-treated cells 
compared to the HMEC cells, only the lapatinib-responsive cells demonstrated 
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distinct gene expression patterns that could be used to determine response to the 
therapy. These result also indicated that there would be implications in the presence 
of normal tissue in tumour samples that would be analysed. Too much normal tissue 
with the tumour tissue could confound the results generated from the gene 
expression analysis. It should be noted, however, that this analysis has some 
impactful limitations. In order for cancer cell lines to continue to proliferate 
indefinitely, cell cycle pathways involved in replicative senescence and apoptosis are 
disturbed which results in the cells continuing to divide and multiple. This results in 
an immortal cell line that can continue to proliferate indefinitely [71]. The HMEC 
cells, as a primary cell source, would not have undergone any of these changes and, 
as such, can only be cultured for an finite period of time [72] (as indicated which by 
the limited doubling times recommended by the supplier, in this case 18 doublings). 
It is therefore important to note that the pathways associated with replicative 
senescence in both of the cell lines and the HMEC cells would be extremely 
different, which could have an impact on the expression of genes that are associated 
with cell cycle progression, proliferation and cell death. These distinct differences 
between the two cell types would explain some of the large differential expression 
changes that were observed in this analysis.     
In using the CIA method, a number of genes and TFs associated with the cellular 
response to lapatinib were identified. This was the first time that this technique has 
been applied to a dataset derived from drug-treated breast cancer cells. CIA allowed 
for the integration of two data sets, the transcription factors binding sites and the 
gene expression data. Using this method it was possible to identify TF that were 
involved in the regulation of a number of the genes without them being differentially 
expressed on the microarray. The methods utilised in this study represent a novel 
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route to identify putative response biomarkers or targets for therapeutic intervention 
to increase treatment efficacy. The Taqman RT PCR methods that were applied to 
this study were fast and specific and provided relative expression of the genes. 
Although initial validation of the 19 genes and 8 TFs were completed using custom 
pre-seeded Taqman 96 well plate, all further examination of target genes was 
completed using individual assays. These preseeded plates, while advantageous for 
the initial validation, did not have the flexibility that the individual assays provided. 
Another advantage of the Taqman RT-PCR method was the small amount of sample 
material that was necessary. The maximum concentration of RNA necessary to 
complete this type of analysis is as low as 2µg.  Although the maximum 
concentration of RNA (2µg) was used for this analysis, which resulted in the cDNA 
generated needing considerable dilution, analysis of the dilutions  employed suggests 
that it would be possible to perform the RT PCR with as little as 20ng of RNA.  In 
needing only a small amount of sample material it would allow for additional 
analysis to be completed and/or allow for further gene expression analysis to be 
completed.  
While all of this work has been undertaken in cell lines, in order for this to move 
forward and potentially be tested in the clinic, a number of challenges first need to be 
overcome. Firstly, as all of the gene expression changes have been identified by 
relating transcription of specific genes before and after treatment hence, multiple 
samples over a relatively short duration of time from the same patients would be 
needed. For this to progress further, it will also be necessary to determine how many 
days after treatment had started that the second biopsy should be taken to provide the 
most suitable tumour sample, i.e. the time at which relative changes are clearest.  
Our cell line data does suggest though that this is likely to be a reasonably large 
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window of several days, particularly when some of the pharmacokinetic differences 
in drug delivery between cell models and real human tumours, and the differences in 
human tumour growth rates are considered.  The Taqman method itself, although it 
does not require a large amount of material to be analysed, would require a trained 
person to process the samples correctly without incorporating any genomic DNA 
contamination which can have an impact on the analysis.  
This initial study has delivered extensive preclinical data that can be further 
investigated. The five genes identified have the potential to represent a strong panel 
of biomarkers of response to lapatinib and potentially additional targeted therapies 
used for the treatment of HER2 positive breast cancer. 
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4. Gene expression changes in response 
to a panel of targeted therapies 
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4.1 Introduction 
 
While chemotherapeutic drugs, such as anthracyclines, are still routinely used in 
breast cancer treatment, in recent years a more molecularly-informed approach has 
been taken with the introduction of targeted therapies. Tyrosine kinase receptors 
have proven to be successful targets for inhibition. Lapatinib was one of the first 
HER2-targetting tyrosine kinase inhibitors (TKI) to be used in the clinic. It is 
approved in combination with capecitabine for the treatment of metastatic breast 
cancer that is no longer responding to trastuzumab [1]. Trastuzumab is a humanised 
monoclonal antibody that binds to the extracellular membrane of the HER2 receptor, 
preventing activation of the receptor and interrupting the cell cycle progression [2] .  
More recently the small molecule TKI therapeutic arsenal has seen the addition of 
newer agents such as, afatinib and neratinib.  
Afatinib is an irreversible EGFR/HER2 inhibitor developed by Boehringer 
Ingelheim [3] currently being clinically evaluated in non-small cell lung 
cancer(NSCLC). The aniline-quinazoline structure of the inhibitor has the potential 
to irreversibly bind to the EGFR and HER2 receptors, which in turn prevents 
activation of the kinase domain [3-5].  
Similar to afatinib, neratinib is also an irreversible inhibitor of the EGFR and HER2 
receptors. Developed by Wyeth, this small molecule drug also inhibits the HER4 
receptor [6]. Neratinib interferes with phosphorylation by binding to the cytoplasmic 
domain of the receptors resulting in the inhibition of downstream phosphorylation of 
substrates. This inhibition in turn has an effect on the cells ability to proliferate and 
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can ensure that the cell arrests at the correct cell cycle transition to ensure cell death 
occurs [7, 8].   
TKIs have also been employed, with some specific successes, in the treatment of 
other forms of cancer by targeting different tyrosine kinase receptors. Gefitinib, an 
EGFR inhibitor, has been used in the treatment of lung cancer patients with EGFR 
mutations or overexpression [9]. Dasatinib, a BCR/ABL inhibitor, has been used in 
the treatment of chromic myeloid leukaemia in patients that are not responding to 
imatinib [10]. 
In order to assess if the panel of lapatinib response gene expression changes 
identified in chapter 3 were exclusive to the agent alone, were also associated with 
other HER2 targeting therapies or were non-specific, we examined the gene 
expression changes associated with a number of drug treatments. To characterise the 
breath and specificity of the response we employed three groups of agents, 1) a panel 
of HER2-targeted therapies, which included, afatinib, neratinib, trastuzumab and, the 
clinically-relevant combination of lapatinib in combination with capecitabine [11, 
12];. 2) non-HER2 TKI therapeutics, gefitinib and dasatinib, and 3) the apoptosis-
inducing cytotoxic anthracycline, epirubicin. All agents were employed at 
therapeutically relevant concentrations. 
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4.2 Materials and Methods 
 
Similar to the initial lapatinib experiments (Section 3.7), BT474, SKBR3 and 
MDAMB453 breast cancer cell lines were exposed to clinically relevant doses of 
tyrosine kinase inhibitors neratinib (150nM for 12 hours), afatinib (150nM for 12 
hours), dasatinib (1µM for 12 hours) and gefitinib (1µM for 12hours), monoclonal 
antibody trastuzumab, (150nM for 12 hours) and the combination of lapatinib and 
capecitabine (1µM and 20µM for 12 hours). In addition to this, the response to an 
anthracycline chemotherapeutic was evaluated using epirubicin (25nM for 12 hours).  
RNA was extracted and the differential expression of targeted genes was determined, 
using Taqman RT-PCR, and compared to the relative gene changes in response to 
lapatinib alone.   
In the analysis of this data the trend of the relative differential expression changes in 
response to the drugs when compared with lapatinib in the three cell lines were 
examined to establish if the response of the cells to these additional targeted 
therapies resulted in alterations in the expression of the same genes.  
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Results 
4.3 Comparison of gene expression changes between lapatinib and other TKIs 
 
Following the identification of the panel of response genes from section 3.7 evident 
after 12 hours of 1µM lapatinib treatment, the gene expression responses associated 
with additional TKI drugs were examined to establish if these gene changes are 
unique to a lapatinib response or more broadly characteristic of other drug responses.  
4.3.1 Neratinib 
Neratinib, an irreversible tyrosine kinase inhibitor that targets HER2, HER4 and 
EGFR [13], is more potent than lapatinib (Table 4.1). BT474 (HER2+, lapatinib-
sensitive), SKBR3 (HER2+, lapatinib-sensitive) and MDAMB453 (HER2+, 
lapatinib-insensitive) cell lines were treated with a relevant dose of neratinib for 12 
hours. In this case the dose chosen for the treatment was 150nM. This dose was 
based on knowledge of the  Cmax (peak plasma concentration) of the drug [14].   
 
Table 4.1: IC50 values for BT474, SKBR3 and MDAMB453 for lapatinib and 
neratinib. n=3 
Cell Lines Lapatinib IC50 (µM± SD) Neratinib IC50 (µM± SD) 
BT474 0.036 ± 0.015 0.0019 ± 0.0005 
SKBR3 0.08 ± 0.02 0.0023 ± 0.0001 
MDAMB453 6.08 ± 0.83 0.820 ± 0.140 
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The differential expression of the five genes characteristic of the lapatinib response, 
RB1CC1, FOXO3a, NR3C1, ERBB3 and CCND1 (section 3.7), was examined 
following treatment with 150nM neratinib and compared to expression changes in 
response to lapatinib.  This data is presented in figure (A) and demonstrated that the 
gene expression pattern was similar in response to both drug treatments. 
As had been previously seen with the lapatinib findings, in the expression 
comparison for RB1CC1, the magnitude of differential up-regulation seen in the 
BT474 and SKBR3 cell lines was not present in the MDAMB453. While the gene 
was distinctly up-regulated in the lapatinib sensitive cell lines, the relative expression 
(RQ) of the gene in the MDAMB453 cell line was less than 2 and as such was 
considered unchanged in response to the neratinib treatment.  The other genes, 
FOXO3, NR3C1, ERBB3 were also found to be differentially up-regulated in 
response to neratinib, similar to the response that was observed when the cells were 
treated with lapatinib in the BT474 and SKBR3 cell lines. It should be noted that the 
magnitudinal changes in the relative response to neratinib were higher than the 
changes exhibited in response to lapatinib. This increase in the gene response to 
neratinib treatment may be as a result of the irreversible inhibitory action of neratinib 
as opposed to the reversible inhibition provided by lapatinib treatment. It should be 
noted that the Ct values for the endogenous control GAPDH following treatment 
with both lapatinib and neratinib were equivalent in all the cell lines. This indicated 
that although different doses of drug were used, there was no difference in the 
expression in the control gene. For CCND1, the lapatinib-sensitive cell lines 
responded with a downregulation of expression of this gene in a similar fashion in 
response to neratinib as they did in response to lapatinib as did the lapatinib 
insensitive MDAMB453.  
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In relation to the relative gene expression changes in the remaining three genes, 
PIK3C3, ALDH32 and CDKN1B, shown in (figure 4.1B), while the genes were up-
regulated in the lapatinib-sensitive cell lines BT474 and SKBR3 in response to 
neratinib, which follows the trend seen in response to lapatinib, they were found to 
be unchanged in the lapatinib-insensitive cell line MDAMB453 in response to 
neratinib.  All RQ and standard deviation values can be found in appendix 2.  
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Figure 4.1(A&B) Mean relative differential gene expression changes in BT474, SKBR3 and 
MDAMB453 cell lines in response to lapatinib (1µM for 12 hours) and neratinib (150nM for 
12 hours) treatment. Similar to lapatinib, neratinib is a HER2 targeted TKI that irreversibly 
inhibits HER2 signalling. The gene expression changes in response to lapatinib were 
conserved when examined in response to the neratinib treatment with some increase in the 
magnitude of the fold change in response to neratinib. This result indicated that the gene 
expression pattern that had been identified was not specific to lapatinib response but may 
also be an indicator of additional HER2 TKI response. The analysis was completed in 
triplicate, the error bars represent the standard deviation of the mean ∆∆Ct value.  
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4.3.2 Afatinib 
Afatinib, an irreversible tyrosine inhibitor, which inhibits EGFR, HER2 and HER4 
[15] is more potent than lapatinib (Table 4.2.) BT474, SKBR3 and MDAMB453 cell 
lines were treated with afatinib for 12 hours. In this case the dose chosen for the 
treatment was 150nM. 
  
Table 4.2: IC50 values for BT474, SKBR3 and MDAMB453 for lapatinib and 
afatinib. 
Cell Lines Lapatinib IC50 (µM± 
SD) 
Afatinib IC50 (µM± SD) 
BT474 0.036 ± 0.015 0.0032 ± 0.008  
SKBR3 0.08 ± 0.02 0.0075 ± 0.005 
MDAMB453 6.08 ± 0.83 1.59 ± 0.18 
 
 
As illustrated in figure 4.2 A, it should be first noted that the genes that were found 
to be up-regulated in response to lapatinib were also found to be up-regulated in 
response to afatinib. Interestingly, the magnitude of expression of these 4 up-
regulated genes in response to afatinib was far greater than the magnitude of 
expression of the genes in response to lapatinib in the BT474 cell lines, the most 
sensitive of the HER2-overexpressing cell lines. Afatinib was slightly less potent 
than neratinib in our cell lines models (tables 4.1 and 4.2) with IC50 values differing 
in all cell lines, e.g. for BT474 IC50 value for afatinib was 0.0032µM ± 0.0001 and 
for neratinib was 0.0019µM ± 0.0005. In spite of this observation, the gene 
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expression changes in response to afatinib had a higher magnitude of expression than 
in response to neratinib. It should also be noted, as with the neratinib treatment, the 
Ct value of the endogenous control gene GAPDH for the afatinib treatment was 
equivalent to that of the lapatinib and the neratinib treatment.  
RB1CC1 expression in response to afatinib was shown to be similar to that following 
the neratinib treatment (Figure 4.1A and 4.2A). The lapatinib-sensitive cell lines 
BT474 and SKBR3 showed an increase in the magnitude of expression of the gene 
in response to neratinib, while the relative expression of the gene in the 
MDAMB453 cell line was less than 2 which was considered unchanged in response 
to the drug. (Figure 4.2 A)  The expression of the FOXO3a gene in BT474 cell lines 
was shown to be highly differentially up-regulated in response to afatinib. The 
MDAMB453 cell line demonstrated down-regulation of this gene in response to 
afatinib treatment and, although the SKBR3 cell line exhibited up-regulation of the 
FOXO3a gene, the magnitude of the expression change was lower than that shown in 
response to lapatinib.  
NR3C1 and ERBB3 relative gene expression changes displayed similar expression 
patterns for all three cell lines in response to afatinib. There was a high level of up-
regulation in the BT474 cell line, slightly lower level of expression in the SKBR3 
and, while the genes were not shown to be down regulated in response to the drug in 
the MDAMB453 cells, there was no up-regulation shown either. The expression 
pattern for CCND1 displayed in response to afatinib Figure 4.2 A) was very similar 
to that seen in response to neratinib (Figure 4.1A). The lapatinib-sensitive cell lines 
responded in a similar profile as they did in response to lapatinib. Interestingly in the 
lapatinib-insensitive cell line MDAMB 453, the gene became up-regulated in 
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response to afatinib. All RQ and standard deviation values can be found in appendix 
2. 
For the remaining three genes, (figure 4.2 B) PIK3C3, ALDH3A2 and CDKN1B, it 
was once again evident that the expression profile showed a higher magnitude of 
expression in the BT474 cell line in response to afatinib than lapatinib. For PIK3C3, 
there was very little difference in the level of expression between the SKBR3 and 
MDAMB453 cell lines. For ALDH3A2 and CDKN1B, the trend shown in response to 
lapatinib in the three cell lines was similar to that shown in response to afatinib.  
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Figure 4.2(A&B) Mean relative differential gene expression changes in BT474, SKBR3 and 
MDAMB453 cell lines in response to lapatinib (1µM for 12 hours) and afatinib (150nM for 
12 hours) treatment Similar to neratinib, afatinib is a HER2 targeted TKI, that irreversibly 
inhibits HER2 signalling. The gene expression changes in response to lapatinib were 
conserved when examined in response to the afatinib treatment with some increase in the 
magnitude of the fold change in response to afatinib. This result indicated that the gene 
expression pattern that had been identified was not specific to lapatinib response but may 
also be an indicator of additional HER2 TKI response. The analysis was completed in 
triplicate, the error bars represent the standard deviation of the mean ∆∆Ct value.  
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4.3.3 Differential expression of genes in response to lapatinib, neratinib and 
afatinib examined at 36 hours 
 
To examine if the gene expression changes found at the 12 hour time point were 
specific to that duration of drug exposure or were more temporally robust, the cell 
lines were treated with the three HER2 TKIs for a period of 36 hours. As before, the 
differential gene expression changes were assessed using Taqman RT-PCR. The 
differential expression changes were compared to the 12 hour treatment gene 
changes.  
For RB1CC1, FOXO3a, NR3C1 and ERBB3 in the lapatinib- and afatinib-treated 
cells there was an increase in the magnitude of up-regulation in the BT474 and 
SKBR3 cell lines 36 hours post treatment, while in the MDAMB453 cell line the 
expression of the genes remained unchanged or slightly more down-regulated in 
response to the treatments (Figure 4.3 A-E). In the neratinib-treated cell lines, the 
same trend was evident in the BT474 and SKBR3 cell results, with a large increase 
in gene expression post treatment, albeit the extent of this increase varied somewhat 
over the time course of the experiment. As with the other treatments, in the 
MDAMB453 cells the gene expression levels remained unchanged or down-
regulated 36 hour post treatment. 
Expression of the CCND1 gene in the lapatinib-treated BT474 and the SKBR3 cell 
lines continued to be down-regulated or showed no change in expression 36 hour 
post treatment.  In the MDAMB453 cells the gene expression remained unchanged 
in response to the 36 hour drug treatment. RQ values that were less than 2 were 
considered unchanged. For the afatinib and neratinib-treated BT474 and SKBR3 cell 
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lines the gene expression changes remained down regulated 36 hour post treatment 
of the drugs. As was the case with the other four genes, the expression pattern 
remained largely unchanged between treated and untreated cells (either drug) in the 
MDAMB453 cells. All RQ and standard deviation values can be found in appendix 
2. 
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Figure 4.3 (A-E): Differential gene expression changes in the 5 genes of interest following 
12 and 36 hour treatment with 1µM lapatinib, 150nM afatinib and 150nM neratinib. The 
figures show that the following 36 hours treatment the trend that was exhibited following the 
initial 12 hour treatment remained and thus indicates that the genes are robustly changed 
following longer drug treatments. This result supports the analysis that was completed in 
chapter 3 which indicated that the differential gene expression was robust following a 36 
hour treatment with 1µM lapatinib treatment. The analysis was completed in triplicate, the 
error bars represent the standard deviation of the mean ∆∆Ct value.  
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4.3.4 Western Blot analysis of proteins after 36 hours of drug treatment 
 
The corresponding proteins of the five main genes of interest were assessed through 
immunoblotting (section 2.12). This was undertaken in order to evaluate if the genes 
of interest are expressed at the protein level following 36 hour treatment with 
lapatinib, afatinib and neratinib.  
Lysates were processed following a 36 hour treatment with 1µM lapatinib, 150nM 
afatinib and 150nM neratinib. β-actin acted as endogenous and loading control for 
the analysis. Figure 4.4 illustrates the expression of the proteins following the drug 
treatments.  
CCND1 protein expression exhibited some changes in the BT474 and SKBR3 cell 
lines; however, there was no distinct trend or pattern visible. NR3C1 demonstrated a 
limited expression in the cell lines, in particular the MDAMB453 cell line which 
displayed no expression following treatment with the panel of targeted therapies. 
FOXO3a protein was detectable across the cell lines and in the different treatment 
samples; however, it was not possible to discern any specific trends in expression of 
the protein between samples. RB1CC1 protein levels were detectable; however, the 
expression change that was seen at the mRNA level was not evident at the protein 
level. Finally, HER3 was detectable in all of the samples across the cell line panel, 
however, once again it was not possible to identify specific trends between samples.  
The protein changes that were exhibited in response to the 36 hour treatment with 
lapatinib, afatinib and neratinib did not appear to correlate in any way with the gene 
expression changes that were previous described in figure 4.3 A-E, indicating that 
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the changes at the gene transcription levels did not correspond to changes at the 
translational level of the protein products of the gene. 
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Figure 4.4: Western blot analysis of corresponding proteins to the genes of interest. These 
Western blots represent a single replicate for each cell line (BT474, SKBR3 and 
MDAMB453) and drug treatment (36 hour treatments).  Lane one of each cell lines 
represents the control (untreated) samples. Lane two represents the 36 hour 1µM lapatinib 
treatment. Lane three represents the 36 hour 150nM afatinib treatment and lane four 
represents the 36 hour 150nM neratinib treatment. This analysis indicated that the expression 
of the corresponding proteins of the genes of interest did not correlate in response to the 
drug treatments in the same manner in which the genes did. This result indicated that 
examining the protein expression of the gene genes of interest would not provide relevant 
drug response information.  
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4.3.5 Gene expression changes in response to treatment with lapatinib in 
combination with capecitabine 
 
Currently the US FDA licence lapatinib to be used in combination with the cytotoxic 
chemotherapeutic agent, capecitabine, in the second line treatment of metastatic 
breast cancer [1]. Capecitabine is a pro-drug and is converted in humans (but not in 
vitro) to 5-fluorouracil in the tumour, which, in turn, inhibits DNA synthesis and 
slows the growth of the tumour cells [16]. Prior to conversion to 5-fluorouracil, the 
drug is converted into a number of precursors. The major precursor is 5'-deoxy-5-
fluorouridine (5’DFUR) and it was this active agent that the cells were treated with 
for 12 hours in combination with lapatinib (1µM). The dose of 5’DFUR that was 
used was 20µM. 
Figure 4.5A and 4.5B illustrated the gene expression profile of the three cell lines in 
response to lapatinib in combination with 5’DFUR (capecitabine active agent) in 
comparison to the cell lines treated with lapatinib alone. The addition of capecitabine 
in the treatment of the cell lines did not impact prominently the expression profile 
that was exhibited by lapatinib alone treatment.  
The main differences that were seen between the two treatments were an increase in 
the magnitude of expression of the four up-regulated genes (RB1CC1, NR3C1, 
ERBB3 and FOXO3a) in the BT474 cell lines with the lapatinib plus capecitabine 
treatment when compared with lapatinib alone. In addition to this, there was a slight 
reduction in the amount of increased expression of FOXO3a in the SKBR3 cell lines 
in response to the combination treatment. Figure 4.6B also indicated that the 
combination treatment resulted in an increase in the expression of PIK3C3, 
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ALDH3A2 and CDKN1B in the BT474 cell lines, while the amount of increased 
expression of the three genes in the SKBR3 cell line was slightly reduced in the 
combination treated cells.  
These results indicated that the inclusion of the capecitabine to the cell treatment did 
not particularly impact the gene expression response pattern which was evident with 
lapatinib alone. This observation has significant implications, as lapatinib has been 
shown to be modestly successful as a mono-therapy and is much more commonly 
used as part of the 2
nd
 line capecitabine combination treatment [17]. All RQ and 
standard deviation values can be found in appendix 2. 
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Figure 4.5(A&B):  Mean relative differential gene expression in BT474, SKBR3 and 
MDAMB453 cell lines in response to lapatinib (1µM for 12 hours) and lapatinib in 
combination with capecitabine. This analysis was undertaken to evaluate the effect 
capecitabine could have on the gene expression pattern. Lapatinib is licenced in combination 
with capecitabine as a second line treatment of metastatic breast cancer. The gene expression 
changes in response to lapatinib were conserved when examined in response to the lapatinib 
and capecitabine combination treatment. These results indicate that the inclusion of 
capecitabine in the treatment regime did not interfere with the gene expression pattern that 
has been seen in response lapatinib alone. The analysis was completed in triplicate, the error 
bars represent the standard deviation of the mean ∆∆Ct value.  
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4.3.6 Gene expression changes in response to trastuzumab 
 
Trastuzumab is a monoclonal antibody that targets the HER2 pathway. It was the 
first therapeutic developed for the treatment of HER2 over-expressing breast cancer. 
As with the other drug treatments that were carried out, a relevant dose of 
trastuzumab, 150nM was used to treat BT474, SKBR3 and MDAMB453 cell lines. 
This concentration represented the typical pharmacokinetic trough concentration 
(Cmin) that has been reported from patient trials [18] .  
Figure 4.6A and 4.6B illustrated the gene expression response following treatment 
with trastuzumab in comparison to the gene expression response following lapatinib 
treatment. The results indicated that treatment with trastuzumab generates the same 
gene expression changes in RB1CC1, FOXO3a, NR3C1 and ERBB3 as was evident 
with lapatinib treatment in all cell lines. The magnitude of expression in the cell lines 
between both treatments was also equivalent to that seen in response to lapatinib 
with the exception of the relative expression of the FOXO3a gene in the SKBR3 
cells which was found to be below 2 and as a result was considered unchanged in 
response to the treatment. In the case of CCND1, expression of the gene was found 
to be up-regulated following the trastuzumab treatment in the BT474 and 
MDAMD453 cell lines.  
These results indicated that the expression pattern that had been identified in 
response to lapatinib in chapter 3 is not specific to TKI treatment in the HER2 
setting but could also be used to provide response information for HER2 targeting 
monoclonal antibodies. All RQ and standard deviation values can be found in 
appendix 2. 
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Figure 4-6(A&B): Mean relative differential gene expression in BT474, SKBR3 and 
MDAMB453 cell lines in response to lapatinib (1µM for 12 hours) and trastuzumab (150nM 
for 12 hours). Trastuzumab is a monoclonal antibody that was one of the first targeted 
therapies produced for the inhibition of HER2 and is widely used. This analysis was 
undertaken to determine if the gene expression pattern that had been identified in response 
the HER2 targeting TKIs would also be evident in response to other forms of HER2 targeted 
therapies, such as monoclonal antibodies. The gene expression changes in response to 
lapatinib were conserved when examined in response to the trastuzumab treatment. This 
result indicated that the gene expression pattern identified can also be utilised to determine 
response to other forms of HER2 targeted therapies and not limited to TKIs The analysis 
was completed in triplicate, the error bars represent the standard deviation of the mean ∆∆Ct 
value.   
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4.3.7 Gene expression changes in response to dasatinib 
 
Dasatinib, a TKI that targets the BCR/ABL transgene product as well as Src kinase, 
but not HER2+ or EGFR, was used to examine if the gene changes that had been 
exhibited in response to lapatinib, neratinib and afatinib were also evident with other 
non-HER2-targeting tyrosine kinase inhibitors. Following a 12 hour treatment with 
1µM dasatinib, the expression pattern of the genes of interest was examined in 
BT474, SKBR3 and MDAMB453 cell lines. This dose was selected based on the 
IC50 values reported in the literature.  
The dasatinib gene expression pattern from the three cell lines was compared to that 
of the response to lapatinib.  Changes in RB1CC1, NR3C1 and CDKN1B relative 
expression levels showed a similar pattern in response to both lapatinib and dasatinib 
(Figure 4.7).  
However, in the case of FOXO3a, ERBB3, PIK3C3 and ALDH3A2, the gene 
expression changes exhibited following dasatinib treatment in the three cell lines 
were different to those exhibited in response to lapatinib (Figure 4.7). In BT474, the 
genes were seen to be up-regulated, while, in SKBR3 and MDAMB453 the genes 
were shown to be down-regulated. It should be noted that magnitude of the 
expression in the MDAMB453 in response to dasatinib treatment was greater than 
that seen in response to lapatinib. 
For CCND1, the profile exhibited in response to dasatinib was the opposite of the 
profile that was found in response to lapatinib. None of the CCND1 expression 
changes were of a magnitude that would be considered significant in the cell lines 
treated with dasatinib.  
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Examination of the gene expression changes of RB1CC1, ERBB3, NR3C1, FOXO3a 
and CCND1 in the panel of cell lines in response to dasatinib treatment indicated that 
the gene expression profile seen in response to lapatinib, afatinib and neratinib was 
not visible when the HER2 pathway was not being targeted. All RQ and standard 
deviation values can be found in appendix 2. 
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Figure 4.7(A&B): Mean relative differential gene expression in BT474, SKBR3 and 
MDAMB453 cell lines in response to lapatinib (1µM for 12 hours) and dasatinib (1µM for 
12 hours) treatments. The dasatinib treatment was undertaken to evaluate if the gene 
expression pattern evident in response to HER2 inhibition was visible in response to other 
TKI treatments. The gene expression changes in response to the lapatinib treatment were not 
conserved when examined in response to the dasatinib treatment indicating that the response 
was specific to HER2 TKI. The analysis was completed in triplicate, the error bars represent 
the standard deviation of the mean ∆∆Ct value. 
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4.3.8 Gene expression changes in response to gefitinib 
 
The HER2-targetting TKIs (lapatinib, afatinib and neratinib) that were employed in 
the previous work were all also EGFR inhibitors. In order to determine if the gene 
expression pattern that had been identified was associated with the disruption of the 
EGFR pathway, or specific to HER2 inhibition, cell lines were treated with 1 µM 
gefitinib. Gefitinib is a TKI that targets the EGFR receptor kinase and interrupts 
signalling through the EGFR pathway. The BT474 and SKBR3 cell lines express 
low levels of EGFR [19] and are sensitive to the drug [20]. However, the 
MDAMB453 cells do not express EGFR [19] and are insensitive to the drug [21]. 
The sensitivity of these cells to gefitinib is important as the gene expression pattern 
that we have identified is based on the responsiveness of the cells to lapatinib. When 
the differential expression of the cells following gefitinib treatment was compared to 
that of the lapatinib treatment, it was evident that even though the cells had a similar 
sensitivity to gefitinib as they did to lapatinib, the gene expression pattern was 
different. 
Gefitinib treatment at 1µM resulted in a completely different expression pattern 
within the cell lines following 12 hour treatment. With the exception of the RB1CC1 
expression in the BT474 and SKBR3 cells and the FOXO3a expression in the BT474 
cells, the relative expression of all of the remaining genes was either  down-regulated 
or there was no change post treatment. These results, combined with those following 
dasatinib treatment, indicated that unless the HER2 pathway of the cell line was 
being directly inhibited or targeted, the gene expression pattern that was seen in 
response to lapatinib was not evident.  
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Figure 4.8(A&B) Mean relative differential gene expression in BT474, SKBR3 and 
MDAMB453 cell lines in response to lapatinib (1µM for 12 hours) and gefitinib (1µM for 
12 hours) treatments. Gefitinib inhibits EGFR expression, which lapatinib, neratinib and 
afatinib also have been shown to inhibit, as well as HER2. This analysis was undertaken to 
evaluate if the gene expression pattern was evident when EGFR expression was targeted.  
The gene expression changes in response to lapatinib were not conserved when examined in 
response to the gefitinib treatment again indicating that the gene expression pattern was 
specific to HER2 inhibition. The analysis was completed in triplicate, the error bars 
represent the standard deviation of the mean ∆∆Ct value. 
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4.3.9 Gene expression changes in response to epirubicin 
 
Epirubicin is an anthracycline cytotoxic chemotherapeutic used in the management 
of many cancers, including breast and ovarian cancer [22], which has been shown to 
stimulate apoptosis in cancer cells through inhibition of the topoisomerase II 
enzyme[23].  
By examining the gene expression changes in response to this chemotherapeutic 
drug (Figure 4.9A and 4.9B), we were able to establish that once again the profile 
exhibited by the cells post treatment with the HER2 targeted agents was as a result of 
the specific inhibition of the HER2 pathway.  
As with the gefitinib treatment, the relative gene expression change exhibited after 
epirubicin treatment was completely different to that post lapatinib treatment. In all 
cases the genes of interest were found to be unchanged or differential down-
regulated in response to the epirubicin treatment.  
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Figure 4.9(A&B): Mean relative differential gene expression in BT474, SKBR3 and 
MDAMB453 cell lines in response to lapatinib (1µM for 12 hours) and epirubicin (25nM for 
12 hours) treatment. This analysis was used to further demonstrate that the gene expression 
pattern that was initially seen in response to lapatinib and further more with afatinib, 
neratinib and trastuzumab was only evident when the HER2 receptor was being targeted. 
The gene expression changes in response to lapatinib were not conserved when examined in 
response to the epirubicin treatment. The analysis was completed in triplicate, the error bars 
represent the standard deviation of the mean ∆∆Ct value. 
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4.4 Discussion 
 
In this study, we aimed to further examine the significance of our prior finding 
(section 3.7) of a characteristic five gene expression response pattern to lapatinib 
treatment.  To do this we characterised the impact of two other HER2-targetting 
TKIs, afatinib and neratinib, on these genes changes, and the durability of this 
response over different time points. In addition, we assessed the gene changes in 
response to two further approved treatments for HER2-positive breast cancer; 
trastuzumab, and lapatinib in combination with capecitabine.  Finally, to evaluate 
how HER2-centric the changes were, we interrogated gene expression changes in 
response to the EGFR inhibitor, gefitinib, the BCR/ABL and Src inhibitor, dasatinib, 
and the anthracycline agent epirubicin [24]. BT474, SKBR3 and MDAMB453 cell 
lines were treated with 150nM afatinib and neratinib for 12 hours and the gene 
expression analysed using RT-PCR. In line with the previously reported lapatinib 
treatment finding, in our panel of five genes (section 3.7), four RB1CC1, NR3C1, 
FOXO3A and ERBB3 were also up-regulated in response to other HER2 inhibitor 
treatments. The magnitude of the expression of these genes was correlated with the 
sensitivity of cells to the drug. CCND1 was shown to be down-regulated in response 
to the drug treatment, again consistent with the previously published lapatinib data.  
Even in patients who over-express targetable molecular changes in cancer, we cannot 
predict who will respond, hence there is an urgent clinical and 
pharmacoeconomically driven  need for an effective diagnostic assay for targeted 
therapies that would have the ability to determine if a patient is responding to the 
treatment during the early stages of the treatment regime. Currently over-expression 
of HER2 is the only available indicator for use of HER2 targeting drugs in patients. 
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However, not all patients that over express HER2 will respond to treatment with a 
HER2 targeting therapeutic. It has been estimated that as many as 50% of patients 
that overexpress HER2 do not respond to targeted therapies [25] either due to an 
innate/ de novo resistance or an acquired resistance to the treatment. There have been 
some limited studies evaluating expression of the cell proliferation marker, Ki67, 
following lapatinib treatment to evaluate if it could be employed as a predictive 
marker for treatment response [26]. Expression of this protein can be detected during 
the active phases of the cell cycle but is not evident during the rest phase G0 [27]. 
Decensi et al., [26] found that in patients with ER-negative tumours, Ki67 
expression was reduced by as much as 34% in comparison to the placebo arm of 
their study. In patients with ER-positive tumours, the expression of Ki67 was 
reduced by approximately 12%.  In measuring the level of expression of this protein, 
using IHC, it may be possible to determine if the cells are continuing to proliferate or 
if they are undergoing apoptosis, regardless of the treatment being employed [28]. In 
addition to the clinical drivers for early prediction of response, these agents are also 
extremely costly so hence there is a clear pharmacoeconomic imperative to know, as 
early on in a treatment regime, if a patient is responding and in so doing potentially 
save the responsible health service significant money. If the patient is not responding 
to a treatment, continuing on the regime could cause unnecessary toxicity without 
potential efficacy and at significant financial cost. The similarity of our findings 
among the HER2-targeting treatments of the panel of cell lines, with trastuzumab, 
and the combination treatment of lapatinib with capecitabine, further strengthens the 
hypothesis that this gene expression pattern is indicative of the HER2 pathway being 
inhibited. Both of these additional HER2-targeting treatments provided similar 
expression patterns at 12 hours post treatment. It should also be noted that despite 
159 
 
the addition of the chemotherapeutic agent capecitabine to the lapatinib treatment, 
the gene expression profile remained evident. 
To examine if the gene changes are stable over a longer period of time, the cell lines 
were treated for 36 hours with the 1µM lapatinib, 150nM afatinib and 150nM 
neratinib. The trends that were exhibited 12 hour post treatment were also seen 36 
hour post treatment. These results provide a strong indicator that expression changes 
in this panel of genes is a good and robust representation of responsiveness not only 
to lapatinib but also afatinib and neratinib. 
An examination of the expression of proteins corresponding to the genes of interest 
was also undertaken. In examining the corresponding proteins of the genes 
previously examined, we aimed to determine if these proteins would be altered 
following 36 hours treatment with lapatinib, afatinib and neratinib. If a treatment 
induced a corresponding protein expression response, this might indicate the 
possibility that the drug response could be monitored via protein-detecting assays, a 
generally cheaper and more straightforward analytical process. If protein alterations 
were detected and such proteins were part of the tumour secretome, it might 
additionally be possible to measure response using by quantification of the level of 
these proteins circulating from the tumour cell.  Following evaluation of the protein 
expression in response to the three targeted treatments, there was no correlation in 
the expression of the proteins and their corresponding genes. This lack of correlation 
is not uncommon, as other studies have established that correlation between the 
expression of proteins and their corresponding gene can be as low as 40% due to the 
large number of processes that must be undertaken between transcription and 
translation  [29, 30]. The lack of correlation could also be attributed to a possible 
transient nature of expression of these proteins and the inherent variations in protein 
160 
 
half-life and stability [31] . It is possible that for some of the genes that were being 
examined, the levels of the proteins which would have correlated with the expression 
of the corresponding gene may have been bettered examined at shorter time points 
such as 12 or 24 hours. These earlier time points may have allowed for a better 
representation of the changes in the protein levels in response to the treatment. The 
blots that were represented in section 4.3.4 may have been over saturated with 
protein expression following a 36 hour treatment of the cells with the different drug 
treatments. Additional time point analysis would be necessary to examine this. 
To evaluate if this gene panel was only responsive to HER2-targeted therapies, the 
panel of cell lines (BT474, SKBR3 and MDAMB453) were also treated with 1µM 
gefitinib. Gefitinib is a EGFR inhibitor that is used in the treatment of non-small cell 
lung cancer [32]. The panel of cell lines examined have a variable level of EGFR 
expression. MDAMB453 do not express any EGFR [19] with BT474 expressing low 
levels [33] and SKBR3 expressing intermediate levels [19]. BT474 and SKBR3 are 
both sensitive to gefitinib[34]. The trend that was observed in response to gefitinib 
did not correlate with that shown in response to the HER2-targeting TKIs, giving a 
strong indication that this gene expression trend is associated with response to HER2 
and not EGFR inhibition. Cells were also treated with 1µM dasatinib, a BCR/ABL 
and src inhibitor and 25nM epirubicin for 12 hours. Acting as control treatments, the 
observation that there was no similarities in the gene expression exhibited following 
these treatments, allows us to assume that it is the inhibition of the HER2 pathway 
that gives rise to this and not the induction of apoptosis using unspecific targeted or 
chemotherapeutic agents.  
Although all of the genes in this panel have been reported to have roles in breast 
cancer [24], there have been no reports of expression changes in NR3C1 and 
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RB1CC1 genes in response to afatinib, neratinib or gefitinib. FOXO3A expression 
changes have not been reported to change in response to neratinib or afatinib. 
However, there are a small number of publications that have indicated that gefitinib 
can target FOXO3A and thereby mediate cell cycle arrest and apoptosis in breast 
cancer [21, 35, 36]. ERBB3 has not been studied in the context of neratinib treatment 
and very limited information regarding the effects of afatinib on the expression of 
this gene is available [3].  
CCND1 expression changes have not been reported for cellular responses to 
neratinib or afatinib, however, there is some data in the literature demonstrating that 
treatment with gefitinib can result in down-regulation of CCND1 which supports our 
finding [37, 38]. 
In conclusion, by exposing the three breast cancer cell lines, BT474, SKBR3 and 
MDAMB453 to an array of targeted and chemotherapeutic agents, it has been 
determined that the gene expression profile, that had been observed in response to 
lapatinib, was also observed in response to other HER2 specific agents. This profile 
was not evident following the treatment of the cell lines with non-HER2 specific 
agents. Therefore, this profile has the potential to be used not only in determining 
response to lapatinib but also afatinib, neratinib and trastuzumab and most likely all 
HER2-targeting agents. The advantage to having one test that could be applied to the 
identification of treatment efficacy with a number of established and validated 
therapies is that the same diagnostic assay could be used globally where the 
treatment regime may differ due to the clinicians preferred course of therapy. As of 
yet there has been no validated or approved assay or biomarkers developed or 
identified. However, it should be noted that pharmaceutical companies and the FDA 
have realised the economic benefits of having such  assays and are looking for 
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evidence of such diagnostics as part of the regulatory registration submission for 
such agents [39].  
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5.1 Introduction 
Development of resistance to treatment with targeted therapeutic agents in tumours 
is a significant challenge in the efficacious use of such agents. For example, acquired 
resistance to lapatinib, i.e. breast cancer which initially responds to therapy but then 
recurs during ongoing treatment, has proved to be a hurdle that has yet to be 
overcome or, indeed, fully understood [1-3]. In many cases, patients who initially 
respond to targeted therapies such as lapatinib or trastuzumab combinations with 
chemotherapy will relapse within a year of commencing treatment [4-7].  
Development of a mechanistic understanding of the molecular causes of such 
resistance could clearly contribute to formulation of resistance circumvention 
strategies and generation of cell lines resistant to targeted agents, such as lapatinib, 
may provide simple models with which to explore and better understand resistance 
phenomena.  
 
5.2 Material and methods 
5.2.1 Materials 
The SKBR3 cell line was cultured as set out in section 2.1.4. 
The SKBR3-L cell line was developed as outlined in section 2.3. Briefly, SKBR3 
cells were treated with increasing doses of lapatinib over a period of six months and 
proliferation assays (section 2.2) were used periodically to evaluate the level of 
resistance that was being developed by the cell line. Once the cell line had reached 
an IC50 of >1µM, the cell line was considered to be resistant and the treatment was 
ceased. The parental cell line has an IC50 value of 0.08 µM  ± 0.017. IC50 values 
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were also determined for afatinib and neratinib in these cell lines. After such an 
extensive period in culture, DNA fingerprinting was undertaken, as described in 
section 2.4 and 2.5., to ensure that the cell line had not been contaminated and 
maintained a genotype consistent with the original SKBR3 parental line.  
5.2.2 Methods 
In order to examine the expression of the genes of interest identified from chapters 3 
and 4, in a lapatinib resistance setting, the lapatinib-resistant SKBR3 cells (termed 
SKBR3-L)  were treated with 1µM lapatinib, 150nM afatinib or 150nM neratinib. 
The differential gene expression of the five genes was determined using Taqman RT-
PCR, as described in sections 2.6, 2.8 and 2.9. The three remaining genes were not 
evaluated in this cell line study as they were not considered as distinct, robust 
indicators of response to the targeted therapies. The results were evaluated to 
determine if the acquired lapatinib resistance of the cell lines had an impact on the 
differential expression of the genes.  
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5.3 Results 
5.3.1 Evaluation of differential gene expression changes in SKBR3-L cell line.  
 
SKBR3 are a routinely used HER2 over-expressing lapatinib-sensitive cell line. 
They have proven successful for the development of acquired lapatinib resistance 
cell line models [8]. It was determined that their IC50 values were 0.08 ± 0.017µM 
for lapatinib, 0.0075 ± 0.005µM for afatinib and 0.0023 ± 0.0001 µM for neratinib 
(Table 5.2). Following six months of continuous treatment with increasing 
concentrations of lapatinib, starting with 250nM twice weekly for approximately 1 
month before being increased to 305nM, the resistance was tested using proliferation 
assays. Triplicate assays determined that the cell lines had an IC50 which was greater 
than 1µM. The IC50 values were determined to be >1µM for lapatinib, 0.130 ± 
0.045µM for afatinib and 0.083 ± 0.038µM for neratinib in the SKBR3-L cell line. 
For DNA fingerprinting analysis, the short tandem repeat (STR) profile of the 
SKBR3-L cells was compared to that provided by the American type culture 
collection (ATCC) for the SKBR3 parental cells to confirm that there were no 
differences in our resistant model of the cell line. Short tandem repeat profiles are 
used to compare specific loci on DNA from different samples. Amelogenin is a gene 
used for gender determination while the remaining eight are core STR loci that are 
used by the ATCC to discriminate human cell lines [9]. Gender is determined by 
detecting different sizes and locations of two gene products, AMEX and AMEY on 
the sex chromosome [10]. Table 5.1 details the STR profile of SKBR3 as published 
on the ATCC website and that of SKBR3-L profile that was generated following the 
fingerprinting analysis. 
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Table 5.1 STR profile for the SKBR3 parental cell line from the ATCC and the 
profile generated from the DNA fingerprinting carried out on the SKBR3-L cell 
line 
ATCC STR Profile for SKBR3 SKBR3-L STR Profile from DNA fingerprinting 
Amelogenin: X Amelogenin: X 
CSF1PO: 12 CSF1PO: 12 
D13S317: 11,12 D13S317: 11,12 
D16S539: 9 D16S539: 9 
D5S818: 9,12 D5S818: 9,12 
D7S820: 9,12 D7S820: 9 
THO1: 8,9 THO1: 8,9 
TPOX: 8,11 TPOX: 8,11 
vWA: 17 vWA: 17 
 
5.3.2 Eradication of mycoplasma contamination in SKBR3-L cell line using 
plasmocin. 
During routine mycoplasma testing that was performed quarterly on all cell lines 
used (section 2.1.8) it was found that the SKBR3-L cell line had become infected 
with mycoplasma. Due to the time and materials involved in the development of this 
resistant cell line, the decision was taken to treat the cell line in an attempt to 
eradicate the mycoplasma infection using Plasmocin (Invivogen, Toulouse, France) 
[11]. This treatment works by combining two bactericidal components. One 
component interferes with bacterial ribosome translation which has an impact on the 
protein synthesis machinery. The other component interferes with bacterial DNA 
replication. Both of these targets are found in mycoplasma and bacterial cells, 
however, they are not found in eukaryotic cells. This treatment generally has a high 
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success rate with one study indicating that it had a 65% success rate in the 
elimination of mycoplasma in the panel of cell lines used [11]. The anti-mycoplasma 
treatment was used as recommended for 2 weeks at 25µg/mL.  
Following completion of the recommended treatment, the cells were tested for the 
presence of mycoplasma 14, 21 and 28 days post Plasmocin treatment. Using both 
direct and indirect methods (Section 2.1.8.1 and 2.1.8.2) it was determined that the 
cells were mycoplasma free. At this point the cells were also re-tested to confirm that 
the cells remained resistant to lapatinib and it was found that they were.  
Table 5.2 details the response of the SKBR3-L cell line to lapatinib, afatinib and 
neratinib. The second column indicates that the acquired lapatinib resistance resulted 
in decreased sensitivity of the cell line to afatinib and neratinib.  
 
Table 5.2 IC50 values comparing SKBR3 and SKBR3-L for lapatinib, afatinib 
and neratinib. 
 SKBR3 (Lapatinib 
sensitive) 
SKBR3-L  (acquired lapatinib 
resistance) 
 IC50(µM±SD) IC50(µM ±SD) 
Lapatinib 0.08 ± 0.017 >1 
Afatinib 0.0075 ± 0.005 0.130 ± 0.045 
Neratinib 0.0023 ± 0.00008 0.083 ± 0.038 
N=3 
 
Figure 5.1 showed that the treatment with Plasmocin had an impact on the 
expression of the five genes in the untreated parental SKBR3 cell line. Following 
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treatment with the Plasmocin for 2 weeks at the recommended dose of 25µg/mL, it 
was shown that the expression of the genes was differentially down-regulated 
following the treatment. Examination of the Ct values for the endogenous control 
GAPDH indicated that the expression of this gene was equivalent across all 
treatments in the cell lines. 
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Figure 5.1: The mean fold changes in expression of the five gene expression pattern. This 
data was generated by comparing the gene expression values for plasmocin-treated SKBR3 
parental cells with the corresponding values from untreated SKBR3 parental cells The 
parental cell line was treated with the recommended treatment of Plasmocin of 25µg/mL for 
2 weeks. The plasmocin treatment resulted in differential downregulation of all of the genes 
in the SKBR3 parental cells, which indicated that the agent had an effect on the expression 
of these genes. The analysis was completed in triplicate, the error bars represent the standard 
deviation of the mean ∆∆Ct value. 
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5.3.3 Gene expression changes in SKBR3-L cell line in response to targeted 
therapies 
SKBR3-L cells were treated with 1µM lapatinib, 150nM afatinib and 150nM 
neratinib for 12 hours. These treatments were completed in order to determine if the 
acquired resistance of the cell line to lapatinib would have an impact on the 
expression pattern that had been previously described in chapter 3 and 4 in response 
to lapatinib, afatinib and neratinib. Taqman RT-PCR was completed. When 
comparing the expression of the genes in the SKBR3-L and the SKBR3-L cells 
treated with lapatinib, afatinib and neratinib, the relative expression was shown to be 
unchanged (as indicated by a fold change less than 2) in response to the treatment 
(Figure 5.2).  The ∆Ct values from the untreated parental SKBR3 cell line were used 
as the calibrator in the calculation of the RQ value (Figure 5.3).These results 
indicated that the changes established in chapters 3 and 4 were only present in 
sensitive cell lines and not those with acquired resistance to lapatinib. This 
strengthens the hypothesis that the pattern was indicative of the response in sensitive 
cell lines. Analysis of the gene expression pattern in further acquired resistant cell 
lines would need to be completed in order to evaluate if the gene changes are not just 
as a result of a cell lines specific response. 
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Figure 5.2: Gene expression changes from SKBR3-L cells treated with 12 hour treatments of 
1µM lapatinib, 150nM afatinib and 150nM neratinib respectively with all data normalised by 
division of the relevant untreated SKBR3-L gene expression values. All cells in this 
experiment had previously been treated with plasmocin. The results indicated that the 
acquired resistance of the SKBR3-L cells to lapatinib impacted the gene expression pattern 
that had been seen in the parental cell lines response to the same targeted treatments as seen 
in chapter 4. The analysis was completed in triplicate, the error bars represent the standard 
deviation of the mean ∆∆Ct value. 
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Plasmocin treatment of the SKBR3-L was necessary to attempt to eliminate a 
mycoplasma contamination on the cell lines. To establish if the Plasmocin treatment 
itself had an impact on the gene expression within the cell lines, Plasmocin treatment 
of the parental SKBR3 cell line was undertaken. The parental cells were treated with 
the same recommended dose of 25µg/mL for 2 weeks. Following treatment the cells 
were allowed to recover and RNA was extracted and Taqman RT-PCR was 
completed. The ∆Ct values of the Plasmocin treated SKBR3 parental cell lines were 
used as a calibrator in the calculation of the RQ values of the SKBR3-L cells 
following treatment with the panel of TKIs. (Figure 5.3) 
Chapters three and four illustrated that differing treatments resulted in variability in 
the magnitude of the differential expression of the genes in the same cell lines. In the 
SKBR3-L cell lines, this was not the case. The magnitude of the gene expression 
remained consistent regardless of the four conditions that were compared. The four 
conditions were the SKBR3-L cells alone, the SKBR3-L cell line following 12 hour 
1µM lapatinib, 150nM afatinib and 150nM neratinib. Irrespective of the calibrator 
sample that was used to calculate the RQ values, whether it was SKBR3 untreated or 
SKBR3 treated with Plasmocin, this trend remained.  
The change in the calibrator from SKBR3 control not treated with Plasmocin to 
SKBR3 control treated with Plasmocin did have an impact on the quantitation of the 
expression of the genes. In the analysis of the RQ values when the calibrator sample 
was the SKBR3 untreated cell lines, there was noteworthy down-regulation in the 
relative expression of NR3C1, ERBB3 and CCND1 genes in response to all of the 
conditions (Figure 5.3). RB1CC1 expression was shown to be slightly down-
regulated with RQ values of between two and three. FOXO3a expression was shown 
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to be unchanged in all of the cell treatments. When the calibrator was switched to 
utilise the SKBR3 plasmocin-treated gene expression results, the relative expression 
of the genes was unchanged. This was defined by a fold change less than 2 in 
response to the generation of acquired resistance to lapatinib or the treatment of the 
acquired resistant cell line with lapatinib, afatinib or neratinib (Figure 5.4).  
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Figure 5.3:  Relative gene expression changes in SKBR3-L cells (previously treated with 
Plasmocin) which were then further treated with 1µM lapatinib, 150nM afatinib and 150nM 
neratinib for 12 hours. The control sample was untreated SKBR3 parental cells.  The results 
indicated that the acquired resistance of the SKBR3-L cells resulted in a different expression 
pattern than that seen in the parental cell lines in response to the targeted treatments which 
are described in chapter 3. The analysis was completed in triplicate, the error bars represent 
the standard deviation of the mean ∆∆Ct value.  
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Figure 5.4: Relative gene expression changes in SKBR3-L cells (previously treated with 
Plasmocin) which were then further treated with 1µM lapatinib, 150nM afatinib and 150nM 
neratinib for 12 hours. The control sample was plasmocin-treated SKBR3 parental cells.  
The results indicated that the acquired resistance of the SKBR3-L cells resulted in a different 
expression pattern than that seen in the parental cell lines in response to the targeted 
treatments which are described in chapter 3. The results indicated that the acquired 
resistance of the SKBR3-L cells resulted in a different gene expression pattern than that seen 
in the parental cell lines in response to the targeted treatments. It also indicated that the 
plasmocin treatment has an impact on the gene expression pattern as it results in differences 
in the gene expression changes that were exhibited in figure 5.3. The analysis was completed 
in triplicate, the error bars represent the standard deviation of the mean ∆∆Ct value. 
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5.4 Discussion 
While the development and analysis of in vitro models of resistance has been shown 
to be helpful in understanding mechanisms of resistance and in therapy regime 
development, some concerns have more recently been raised as to whether they 
provide a realistic picture of what occurs in vivo. Gillet et al., 2011 [12] have 
provided evidence that suggests that characterisation experiments carried out on both 
in vitro cell-based models and tumour samples resulted in very different outcomes. 
In particular they looked at the expression of the Multi Drug Resistance (MDR) 
transcriptome using RT-PCR assay technology. The MDR transcriptome is a well 
characterised and extensively researched group of 380 genes associated with aspects 
of MDR. The study investigated the expression of genes associated with this 
mechanism in six different cancer types (ovarian, glioblastoma, colorectal, breast, 
metastatic melanoma and leukaemia) using the NCI-60 [13] cell line panel and 
clinically relevant samples. One of the outcomes of the study indicated that the cell 
lines had been highly selected for expression of a number of genes that were 
associated with MDR. They suggested that this expression was as a result of the cells 
adapting to their “new” environment [14]. It also highlighted that the cell culture 
models did not reflect what clinical samples did in relation to the MDR gene 
expression patterns. 
While this study does show some limitations to the applicability of in vitro cell 
models of resistance, until a more easily developed and cultured model is available, 
it will continue to be utilised by researchers to identify the mechanism by which 
acquired resistance is established [15].  
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Summarising the gene changes in chapter three and four, where the cell lines were 
sensitive to the targeted therapies, there was an increase in the differential expression 
of RB1CC1, FOXO3a, NR3C1 and ERBB3, while CCND1 was shown to be 
differentially down-regulated in response to the HER2 targeted treatments. When the 
expression of these five genes was evaluated in response to lapatinib, afatinib and 
neratinib in the lapatinib-resistant, SKBR3-L, cell line, the trend that was exhibited 
in responsive cell lines was not evident at all. However, it should be taken in to 
account that the Plasmocin treatment that was applied to the SKBR3-L cells to 
eliminate a mycoplasma contamination may have impacted the cells response to the 
drugs. This was supported by the analysis of the parental cell line and the expression 
of the genes before and after the treatment with Plasmocin. Mycoplasma 
contamination has been shown to have an impact on the expression of different 
genes, eg oncogenes and tumour suppressor genes [16] however, there is evidence to 
support our assumption that once cells have been treated with plasmocin or other 
anti-mycoplasma treatment, the function of these genes can be restored [17, 18].  
Gene expression changes associated with lapatinib resistance have not been 
extensively researched. Using qRT-PCR methodology, Penzvalto et al. [19] have 
identified three genes associated with resistance to lapatinib. The three genes were 
FURIN, ME1 and TMOD3. There are no published reports linking NR3C1 and 
RB1CC1 with lapatinib resistance. Depression of FOXO3a expression increased ER 
transcriptional activity and increased localisation of ERBB3 have all been proposed 
as potential mechanisms of acquired resistance to lapatinib [20-22]. As an important 
oncogene and regulator of cell cycle progression CCND1 and a number of the genes 
single nucleotide-polymorphisms (SNPs) has recently been associated with clinical 
response to lapatinib in combination with capecitabine [23]. Any dysregulation of 
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the gene might possibly have a negative impact on the response of the patient to the 
therapy.  
A limitation of this study is that only one cell line model was used. The mycoplasma 
contamination would also have had an impact on the results. In order to fully 
understand the effect of acquired resistance on the expression of the five genes 
indicative of response to HER2 targeting therapies, multiple cell lines would need to 
be treated in order to develop acquired resistance to lapatinib and also possibly 
additional targeted therapies such as afatinib or neratinib. As a back-up, multiple 
flasks would need to be treated individually with identical treatments so that in the 
event of a contamination there would be another flask that is undergoing treatment. 
Routine mycoplasma testing would also need to be completed. 
However, these preliminary results do give an indication that the gene expression 
pattern that was exhibited in the responsive cell lines is not evident in the acquired 
resistant SKBR3-L cells following treatment with lapatinib, afatinib and neratinib. 
The fact that there was a difference between the expression pattern, even in this one 
responsive cell line and its acquired resistance counterpart, strengthens the 
hypothesis that this panel of five genes provide a strong marker of response to HER2 
targeted therapies in sensitive cell lines undergoing a treatment with such agents.  
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6. In vivo evaluation of tumour gene 
expression in response to targeted 
therapies 
 
 
 
 
 
 
 
186 
 
6.1 Introduction 
 
While in vitro analysis has proven to be extremely useful in the cancer research 
setting, is has been clearly established that the use of these immortal cell lines does 
not give a fully clinically relevant picture in regards to changes in protein or gene 
expression [1] and as such has significant limitations. Cancer cell lines are typically 
grown in a monolayer or in suspension and cultured in plastic flasks. Some argue 
this can cause changes that would not occur in an in vivo setting and that these 
changes could have varied effects on the targets that are being examined. By using in 
vivo models, where tumours are cultured in immune compromised animals, such as 
nude mice or severe combined immune-deficient mice (SCID mice), researchers are 
able to determine if the micro-environment of the animal would have an impact, 
either negatively or positively, on the results that they have found in the in vitro 
setting [2]. Nude and SCID mice are immune compromised by their inability to 
generate enough T lymphocytes, in the case of nudes or the inability to produce any 
B or T lymphocytes which are vital in mounting an immune response, as is the case 
for SCID [3]. It is due to these immune alterations that allow for the implanted 
“foreign” cells to grow and develop the xenograft models. Xenografts in these 
immune-compromised mice can be generated in a number of ways. Methods include 
injection of a cell line, either sub-cutaneous or intra-peritoneal injection, or 
implantation of a sample of patient material. Once these cell lines or patient-derived 
materials have developed tumours, they can be passaged into further animals. Such 
tumour models much more closely imitate human tumours in key ways since they 
have a blood supply and are three dimensional but do, however, have some 
limitations. Murine stroma can infiltrate the human tumour where the characteristics 
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of the malignancy can be affected by the murine micro-environment; the blood 
supply to the tumour is supplied by the murine host which can have different 
characteristics to humans in terms of hormones, growth factors etc, [4]. There have 
been some studies that have indicated that the pharmacological response seen in the 
mice models does not always correspond to that seen in humans [5,6]. 
Cognisant of such limitations, we sought to advance our in vitro findings with a pilot 
in vivo examination. This pilot in vivo study aimed to determine if the gene changes 
that were described in chapter 3 in response to lapatinib treatment remained when 
examined in tumours formed from the BT474 cell line in SCID mice.  
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6.2 Materials and methods 
 
As laid out in more detail in section 2.13, the following methods were used in the 
process of the in vivo study.  
The cell based tumours were developed by sub-cutaneous implantation of the BT474 
cell lines in eight SCID mice. Once tumours had developed in these animals, three 
were sacrificed and the tumours were used for implantation into 14 SCID mice, for 
further growth. Three of the remaining animals underwent treatment with either a 
vehicle or lapatinib at a concentration of 200mg/kg. Following five days treatment, 
the animals were sacrificed and the tumours were removed for further analysis using 
qRT-PCR.  
The 14 mice implanted with tumours from the donor mice were allowed to develop 
tumours. Animals were monitored daily and once the tumours were palpable, they 
were measured twice weekly to determine the tumour volume. There were three 
treatment conditions in the tumour implanted group of mice, (1) vehicle (0.5% 
hydroxyl-propyl-methyl-cellulose/0.1% Tween 80), (2) one day lapatinib treatment 
with 200mg/kg and (3) five day treatment with 200mg/kg. Once the treatment was 
completed, the tumour, as well as organs tissue and skin were snap frozen for 
analysis with qRT-PCR.  
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6.3 Results 
 
BT474 cells were selected for this study has they had been used successfully in a 
large number of in vivo studies. They were also the most lapatinib-sensitive cell lines 
that were in the panel that was used in previous experiments.  
Figure 6.1 provides a flow chart of the course of the experiment and the number of 
animals used in each arm.  
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Figure 6.1: Schematic of in vivo experiment. Outline of the steps involved in the generation 
of the cell-line derived tumours and tumour xenografts used to evaluate the gene expression 
pattern identified in chapter 3 in response to lapatinib. 
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6.3.1 Generation of the cell line and tumour-derived xenografts in SCID mice 
 
The outcome for all of the animals that were treated in the study is detailed in table 
6.1 and 6.2. It was necessary to cull two animals in order to determine the progress 
of the tumours.  
Table 6.1: Assignment of animals used for the development of BT474 cell line 
derived tumours. 
Animal number n=8 Outcome during investigation 
2/8 Culled for exploratory surgery 
3/8 Used for tumour donation for the F2 phase of the study. 
Tumours had been growing for 35 days at point of removal 
for implantation 
3/8 Of the 3 animals, 2 of them had developed tumours. 1 of 
the tumoured mice and the mouse with no tumour were 
treated with 200mg/kg of lapatinib for 5 days 
The remaining mouse with a tumour was treated with the 
vehicle for 5 days.   
 
Table 6.2: Assignment of animals used in the development of tumour derived 
xenografts.  
Animal 
Number n=14 
Donor Mouse Treatment Animals survived 
to end of 
experiment 
5/14 Donor 3 and 1 
sample from 
donor 2 
1 day 200mg/kg  4/5 
5/14 Donor 2 5 days vehicle 3/5 
4/14 Donor 1  5 days 200mg/kg 4/4 
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Figure 6.2 shows images of the tumour-derived xenograft models for the 11 
remaining animals of F2 phase of the study. It should be noted that the size of the 
tumours was quite small, at the time of dissection they were no more than 100mm
3
. 
For comparison, in an additional study carried out by the group, tumours were 
developed using a DLKP-variant lung cancer cell line. After 30 days of growth these 
tumours typically reached a volume of approximately 1500mm
3
 (data not shown). 
The tumours were derived in the same mouse model (SCID) and the same cell line 
concentration was implanted in this study. These cells did not require estrogen for 
proliferation so the mice were not implanted with estrogen pellets prior to cell 
implantation. The presence of increased vasculature in the BT474-implanted mice is 
visible in figure 6.2, in particular in images C, I and J (highlighted with yellow 
arrows). This vasculature was a sign that the implanted tumour sections had begun to 
proliferate. In a number of the images slightly enlarged lymph nodes are also visible, 
in particular, images A, D, H, I and J. Once these enlarged lymph nodes were 
visualised during dissection, they were also removed and snap frozen in liquid 
nitrogen for qRT-PCR analysis. It was hoped that analysis of these nodes would give 
an indication if cells from the implanted tumour had travelled to the lymph system of 
the mice and as a result could form potential metastasis.  
Another issue that may have impacted the size of the tumours was the formation of 
bladder stones in animals as a result of the estrogen pellets that were implanted to 
maintain the growth of the tumours. BT474 cells are estrogen dependent and in order 
for them to continue to grow in vivo estrogen pellets were implanted into the 
shoulders of the animals 24 hours prior to the sub-cutaneous injection of cells or the 
implantation of a tumour fragment.  This is a standard approach for the generation 
and maintenance of such tumours [7, 8].  In F1 phase of the study, which examined 
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the growth of tumours derived from the cell line, approximately 19-21 days 
following the implant of the cells, deterioration in the health of the animals was 
noticed. They had begun to lose weight and there was a hardening around the 
bladder area. During exploratory surgery on two of the animals, a build-up of a 
significant volume of a hardened white crystalline material was found in the bladders 
of the animals (Figure 6.3). On a detailed examination of the literature in this field, 
this adverse effect was also identified by a number of other groups using estrogen 
dependent cell line-derived tumours [8, 9]. The bladder sac had also increased in 
size. Following discovery of this adverse effect of the estrogen tablets, the animals 
were given sub-cutaneous injections of sterile saline in an attempt to delay the build-
up of this material in phase 2 of the study through increased flushing of the bladder. 
The animals were also closely monitored for any signs of distress as well as palpated 
daily for any hardening in the region of the bladder.   
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 A B  C  
 D  E  F  G 
H   I  J  K 
 
Figure 6.2: Location of BT474-derived tumours following subcutaneous implantation in the 
surviving animals following treatment with either vehicle, lapatinib 200mg/kg for 1 day or 
lapatinib 200mg/kg for 5 days. Images A-C indicate the tumours that were present in the 
mice that were treated with the vehicle,  images D-G indicate the tumours that were present 
in the mice treated with lapatinib 200mg/kg for 1 day and images H-K indicate the tumours 
present that were present in the mice treated with lapatinib 200mg/kg for 5 days. The red 
arrow indicated the location of the implanted tumour. Increased vasculature is clearly visible 
around the tumour and the adjacent lymph node (highlighted by the yellow arrows).  
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  A 
  B 
  
Figure 6.3: In situ visualisation of enlarged bladders (and the dissected bladders) that 
occurred following supplementation of animals with estrogen pellets to support the growth 
of the tumours. A white crystalline substance was found to have been deposited in the 
bladders of the mice approximately 19-21 days following the implantation of the estrogen 
tablets. The extent of the build-up was not known until an exploratory surgery was 
performed on the two of the animals affected which are shown in A and B.  The only 
external indication that there was an issue was a swollen abdomen on the affected animals 
and the solid mass could be felt when the area surrounding the bladder was palpated.  
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6.3.2 Isolation of RNA and Taqman RT-PCR of snap frozen tumour samples 
 
Two methods of RNA extraction from the tumour and tissue were optimised 
(homogenisation using a mortar and pestle in combination with the Qiagen 
Qiashredder or the Qiagen automated Tissue Lyser) as outlined in section 2.7. These 
two methods are routinely used for the homogenisation of tumour samples for 
analysis [10]. Following RNA extraction using either method of tissue 
homogenisation, the RNA concentration in each sample was evaluated using a 
nanodrop. Two tumour samples were used for the optimisation of the two methods. 
When the extraction process was completed using the tissue lyser method in the 
autolyser for 20 minutes, it was evident that the tumour sample was not fully 
homogenised.  Although the automated tissue lyser would have allowed for 12 
samples to be homogenised at once, for the purpose of this study, the tumour and 
tissue samples were homogenised using liquid nitrogen in a mortar and pestle in 
combination with the Qiagen Qiashredder method as it ensured that all of the tissue 
was homogenised and it was also a faster method to use.   
Once the samples were homogenised they underwent extraction using the Qiagen 
RNeasy extraction kit that had been used for all of the in vitro cell line samples. The 
samples were quantified using the nanodrop in order to evaluate concentration of 
RNA for the reverse transcription reactions. It was necessary to concentrate the 
samples using the Maxi dry vacuum concentration system. All samples were 
concentrated so as to prevent any bias in the quality of the samples. Table 6.2 
outlines the average ng/µL concentration of RNA found for each of the tumour, 
lymph node, lung and skin samples from each of the treatment groups. Each sample 
was quantified twice and the standard deviations are also reported. It should be noted 
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that the samples for the tumour from mouse 2 and mouse 3 from the 5 day lapatinib 
treated group did not contain an accurately quantifiable concentration of RNA as 
concentrations below 10ng/µL measured by the nanodrop were not considered to be 
reliable. 
A number of internal controls were utilised throughout this analysis. On each 96 well 
Taqman plate there were 3 controls; no RT, no template control (NTC) and a pooled 
control. The no RT control was prepared at the same time as the RNA was 
undergoing reverse transcription. It contained no multiscribe reverse transcriptase. 
The no RT control was used to determine that there was no genomic DNA 
contamination in the RNA. DNase treatment during the RNA extraction protocol and 
correct handling of the samples would also aid in reducing genomic DNA 
contamination. The NTC control contained a gene assay and the universal Taqman 
mastermix but no target cDNA and was used to determine if there was any 
contamination of the reagents used in the qRT-PCR. The final control was the 
analysis of a pooled sample. Once RNA quantification was completed, 1µL of each 
of the RNA samples was pooled together and it underwent reverse transcription. A 
gene assay was chosen at random and this assay was analysed on each plate using 
the pooled sample. For the purpose of this study, FOXO3a was used for this control. 
As expected, on all of the plates, it was expected that this pooled sample  had the 
same Ct value. This control exhibited a Ct value of ~26 on all plates tested indicating 
that there was no intra-plate variability and that the machine was working 
comparably on different days and different plates. 
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Table 6.3: Quantification of extracted RNA from tumour, lung and skin 
samples 
 
Sample ID ng/µL ± SD 
F2 samples   
Tumour vehicle m1 29.09 0.099 
Tumour vehicle m4 32.63 0.163 
Tumour vehicle m5 25.115 0.318 
Skin vehicle m1 106.95 0.085 
Skin vehicle m4 137.09 2.659 
Skin vehicle m5 47.86 0.156 
Lung vehicle m1 298.38 2.036 
Lung vehicle m4 204.54 1.259 
Lung vehicle m5 255.92 0.969 
Tumour 1 day  m1 63.40 0.247 
Tumour 1 day m2 45.29 0.127 
Tumour 1 day m3 67.07 0.057 
Tumour 1 day m4 52.63 1.499 
Tumour 5 day m2 
#
 ----- ----- 
Tumour 5 day m3 
#
 ----- ----- 
Tumour 5 day m4 46.5 0.849 
Tumour 5 day m5 25.31 0.495 
Lymph node 5 day m2 101.05 3.521 
Lymph node 5 day m3 89.29 0.325 
Lymph node 5 day m4 144.05 0.933 
Lymph node 5 day m5 135.6 0.714 
Skin 5 day m2 89.83 1.322 
Skin 5 day m3 139.68 0.269 
Skin 5 day m4 109.5 0.820 
Lung 5 day m2 171.28 2.206 
Lung 5 day m3 393.84 2.652 
Lung 5 day m4 161.69 1.421 
Lung 5 day m5 208.71 0.403 
Exploratory animal 
Samples 
  
Cell derived tumour vehicle 14.82 0.078 
Cell derived tumour 5 day 10.30 0.219 
# indicates that the RNA from these two samples could not be accurately determined due to 
the concentration being too low. n= 2  
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As depicted in figure 6.1, the F1 phase of the in vivo study involved the sub-
cutaneous implantation of 5x10
6
 BT474 cells per mouse in eight SCID mice. Of 
these eight animals three were used as donors for arm 2 of the study, two were 
sacrificed for investigation purposes and the remaining three animals were treated as 
a pilot to give experience of the treatment schedule and demonstrate that sampling 
would be possible and likely to generate viable data post treatment in the second arm 
of the study. Unfortunately, of the three remaining animals, only two of them had 
developed tumours. Two of the mice (one of which had no tumour growth) were 
treated with 200mg/kg of lapatinib for 5 days and the remaining mouse was treated 
with vehicle alone for 5 days. Following sacrifice, the tumours were analysed using 
qRT-PCR. Of the eight genes determined to be differentially expressed in response 
to lapatinib in the panel of cell lines in chapter 3, five of them; RB1CC1, FOXO3a, 
NR3C1, ERBB3 and CCND1 provided a more compelling response pattern in 
response to lapatinib in chapter 4. It was these five that were evaluated in the in vivo 
setting. 
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6.3.3 Gene expression changes in response to lapatinib in cell line derived 
tumours  
 
The tumour cells that were injected sub-cutaneously in the mice, were anticipated to 
be supported by the murine stroma [4, 6, 11]. As the cells that were injected were 
derived from a human tumour it was expected that the expression profile of these 
would be maintained. Of the five genes that we had previously examined in the in 
vitro experiments, it was found that only the primer for ERBB3 was human specific, 
while the remaining four primers employed had the ability to detect both human and 
mouse variants of the gene. In order to determine if there was any infiltration of the 
murine stroma into the human cell, human specific assays for the genes were 
sourced. There was no human specific assay for CCND1 available; however for all 
other genes, human specific assays were purchased. The endogenous control assay 
for GAPDH was also determined to be human specific. The assays that were not 
human specific, would have been expected to detect expression of the gene in 
question in both the human and murine tissue.   A mouse specific assay for both 
FOXO3a and GAPDH were also purchased so as to determine the expression of 
these genes in the mouse tissues. It was expected that there would be no differential 
expression of these genes following treatment with lapatinib, as the mouse tissue 
should not respond to lapatinib treatment. 
From the in vitro work that was performed in chapters three and four, the pattern that 
had been observed from the cell lines showed an increase in the differential 
expression of the RB1CC1(H/M), FOXO3a(H/M), NR3C1(H/M) and ERBB3(H) 
genes and a decrease in the differential expression of CCND1(H/M) in response to 
lapatinib. This pattern was not evident in the single cell line-derived tumour in this 
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pilot experiment.  As shown in figure 6.4. FOXO3a(H/M), CCND1(H/M) and 
FOXO3a(H) showed no change in the expression of the genes of interest between the 
5 day 200mg/kg lapatinib (single tumour) and the vehicle alone treatments (single 
tumour). The genes were considered unchanged if the RQ value was less than 2. 
Decreases in gene expression following the treatment were seen in RB1CC1(H/M), 
NR3C1(H/M), ERBB3(H), RB1CC1 (H), NR3C1(H) and FOXO3a (M). The Ct values 
for the GAPDH (H) endogenous control were equivalent to the values expressed in 
the cell line in vitro analysis with values of 20 and 22 for the untreated and 5 day 
lapatinib treated animals respectively. As there was only one replicate of each 
treatment these results could not be conclusively analysed but the experiment did 
prove that sufficient high quality RNA could be generated to permit accurate gene 
expression measurement. 
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Figure 6.4: A summary of the changes in gene expression in a BT474 cell line xenograft 
tumour from an animal treated with  lapatinib (200mg/kg) for 5 days, when compared to the 
gene expression data from a non-drug treated tumour. (H) indicates the human specific gene 
assay.  (M) indicates the murine specific assay.  (H/M) indicates that this assay detects both 
human and murine gene.. The control animal was treated with vehicle ((0.5% hydroxyl-
propyl-methyl-cellulose/0.1% Tween 80) for 5 days, the tumour was then excised 
and expression of the relevant genes calculated. The test animal was treated with 
200mg/kg lapatinib in the same vehicle for 5 days. Both treatments were 
administered using oral gavage. There was no correlation between the in vitro pattern that 
was discussed in chapter 3 and the in vivo pattern from this pilot study. n=1 
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6.3.4 Gene expression changes in response to lapatinib in tumour derived 
xenografts 
 
As outlined in figure 6.1, the F2 phase of the study examined gene expression  
changes in tumour-derived xenograft models. 14 animals were implanted with 
fragments from tumours derived from the BT474 cell lines in arm 1. Once split into 
three groups, the tumours were allowed to develop and two groups were then treated 
with 200mg/kg of lapatinib for one or five days with the third group treated with 
vehicle (0.5% hydroxyl-propyl-methyl-cellulose/0.1% Tween 80) alone for 5 days.  
Figure 6.5 shows the differential gene expression changes following one and five 
days 200mg/kg lapatinib treatment. It should be noted that not all of the animals in 
each group of the experiment showed expression of the genes and that the graphs 
below show a mean expression change from those animals that did. Table 6.4 
outlines the number of individual Ct values for each gene at each treatment 
conditions that were included in the calculation of the relative expression of the 
genes (Individual Ct values can be found in appendix 3). 
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Table 6.4: Number of individual Ct values for each gene used in the RQ 
calculation 
 Number of Ct values for each gene used in 
the RQ calculation 
 Vehicle /3 1 Day/4 5 Day/4 
RB1CC1(H/M) 2 3 3 
FOXO3a (H/M) 3 4 4 
NR3C1(H/M) 2 ND ND 
ERBB3(H) 2 3 3 
CCND1(H/M) 3 4 4 
RB1CC1 (H) 2 3 2 
FOXO3a (H) 2 2 4 
NR3C1 (H) 2 4 2 
GAPDH (H) 2 4 4 
FOXO3a (M) 3 4 4 
GAPDH (M) 3 4 4 
 
All genes showed a differential upregulation following 1 day of treatment with 
200mg/kg lapatinib with the exception of NR3C1(H/M) where no expression was 
detected in any sample. FOXO3a(H/M), CCND1(H/M) and NR3C1 (H) showed the 
highest levels of differential expression. The upregulation of CCND1(H/M) was 
unexpected as it has been downregulated in response to lapatinib in all of the other 
studies completed. The calibrator sample for all of the RQ calculations was the 5 day 
vehicle treatment.  
 In the in vitro experiments, RB1CC1(H/M) FOXO3a (H/M), NR3C1(H/M) 
ERBB3(H) were found to be up-regulated in response to lapatinib and CCND1(H/M) 
was found to be down-regulated in response to lapatinib in the BT474 cell line. In 
comparison in the in vivo experiment, all of the genes with the exception of 
NR3C1(H/M) which was not expressed in the 1 day lapatinib treated xenografts, 
were all differentially up-regulated in response to lapatinib.  
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Figure 6.5A showed the differential expression of the genes in response to 1 day 
treatment of lapatinib. There was no RQ value for NR3C1 determined as there were 
no Ct values detected for the gene in the treated animals. It is possible that no signal 
could be detected using this probe due to stromal contamination of the samples. This 
could possibly be evidenced by the finding that the FOXO3a(H/M) assay showed a 
higher level of expression than that of the human specific assay. The Ct values for 
the FOXO3a (H/M) were slightly lower than that of the human specific assay 
(Appendix 3) which could be attributed to the higher differential expression for the 
non-specific assay. There was also some biological variability in the Ct values for the 
FOXO3a (H) vehicle control group as well as the 1 and 5 day lapatinib treatment 
groups which could account for some of the discrepancies in the RQ values 
exhibited.  Interestingly, the mouse specific gene was also shown to be differently 
expressed. There was a high magnitude of up-regulation in the CCND1(H/M) and the 
NR3C1(H). The CCND1(H/M) up-regulation was an unexpected result as down-
regulation of the gene in response to lapatinib has been identified by a number of 
studies [12, 13].  
Figure 6.5B shows the expression of the panel of genes in response to 5 days 
treatment of lapatinib. As with the 1 day lapatinib treatment, all of the genes were 
shown to be up-regulated. However, in comparison to the 1 day lapatinib treatment, 
there were some differences in the expression of the genes following the 5 day 
treatment. There was a reduction in the magnitude of FOXO3a(H/M), CCND1(H/M) 
and NR3C1(H). The levels of RB1CC1 (H/M), ERBB3(H), and FOXO3a(H) 
remained the same. A relative expression for the NR3C1(H/M) assay was evaluated, 
however, there was only one animal in the 5 day lapatinib treatment group that 
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expressed detectable levels of the gene, so no standard deviation value could be 
evaluated. 
All Ct values can be found in appendix 3.   
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Figure 6.5: Relative changes in mean differential expression of the panel of genes following 
1 and 5 days lapatinib treatment in tumour derived xenografts. The expression of the genes 
was evaluated relative to the expression of the same genes in the vehicle treated animals. 
The n values (number of biological replicates) for each gene expression measurement can be 
found in table 6.4. (H) indicates the human specific gene assay, (M) indicates the murine 
specific assay (H/M) indicates that this assay detects both human and murine gene. Control 
animals were treated with vehicle, (0.5% hydroxyl-propyl-methyl-cellulose/0.1% 
Tween 80) for 5 days.  Test group (A) was treated with 200mg/kg lapatinib 
suspended in vehicle for 1 day (A) and group (B) treated with the same agent for 5 
days. Treatments were administered using oral gavage. The error bars represent the 
standard deviation of the mean ∆∆Ct value.  
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6.3.5 Gene expression changes in response to lapatinib in lymph-nodes, lung 
and skin 
 
In addition to the tumours, the lymph-nodes, lung and skin tissue of the vehicle and 5 
day lapatinib treated mice were assessed for the gene expression pattern. The lymph-
nodes were examined as it was observed that in a number of the mice examined that 
the lymph-nodes were enlarged (Figure 6.6). The lung tissue was examined, as it is a 
normal tissue, and as such the genes should not be differentially expressed. The skin 
was evaluated as a known adverse effect of lapatinib treatment in humans is skin 
irritation [14-16] and it has been observed in some studies, that patients who develop 
a rash/skin irritation have an increase in life expectancy [17]. 
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A   B 
Figure 6.6: Images illustrating the enlarged lymph-nodes that were associated with the 
tumour implantation that were observed in the vehicle(A) and 5 day lapatinib (B)-treated 
mice. The blue arrow highlights the enlarged lymph-node. The yellow arrow indicates the 
implanted tumour. 
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Following extraction of the RNA from the tissue samples (concentration of RNA can 
be found in table 6.3), Taqman RT-PCR was completed on the samples. In all of the 
samples, it was not possible to evaluate the relative expression of the following 
genes, RB1CC1(H/M), FOXO3a(H/M), NR3C1(H/M), ERBB3(H), CCND1(H/M), 
RB1CC1(H), FOXO3a(H) and NR3C1(H) as no Ct  values for these genes were 
detected in the samples, with the exception of FOXO3a(H/M) and CCND1(H/M) (Ct 
values can be found in appendix 3). There was also no detectable Ct value for the 
GAPDH(H) which is used to normalise the expression of the gene in the Livak 
method[18]. 
The murine specific FOXO3a and GAPDH did, however, have detectable Ct values 
and the relative gene expression was calculated. Figure 6.7 illustrated that following 
the treatment of lapatinib for 5 days, the gene was considered to be unchanged in 
response to the lapatinib treatment in the three tissues as they had an RQ value that 
was below 2.  
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Figure 6.7: Changes in mean relative murine FOXO 3a gene expression in response to five 
days of lapatinib treatment from mouse skin, lung and lymph-nodes tissues in comparison to 
untreated tissue for the same regions The error bars represent the standard deviation of the 
mean ∆∆Ct value. 
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6.4 Lapatinib quantification in plasma using LC-MS. 
 
In order to evaluate the level of drug that was present in the animals system, drug 
quantification was completed. Dr Sandra Roche completed the analysis. Blood 
samples were taken from the animals before they were sacrificed and the plasma was 
separated from the whole blood by centrifugation for 15 minutes at 2000g. The 
plasma was then stored at -80°C until ready for analysis. There were no samples 
collected for two mice (C4M3 or C4M4 day lapatinib treatment) as blood could not 
be sampled from the animal. The method was completed as set out in section 2.13.6.  
Duplicate technical samples were taken from each of the plasma samples, with the 
exception of the 1 day lapatinib treated mouse 4 as there was insufficient plasma 
volume, and were analysed. Table 6.5 shows the lapatinib concentrations that were 
determined in the plasma samples. There are no standard deviations as these 
concentrations were determined based on only two readings.  
 
Table 6.5: Lapatinib plasma concentration as determined using LC-MS. 
 
Treatment Mouse ID Plasma Concentration 
(ng/mL) 
±SD (n=2) 
Vehicle B4M1 below limit of detection n/a 
Vehicle B4M4 below limit of detection n/a 
Vehicle B4M5 below limit of detection n/a 
1 day Lapatinib A4M2 106.44 9.18 
1 day Lapatinib A4M3 5556.50 2331.04 
1 day Lapatinib A4M4 42.13 n/a * 
1 day Lapatinib A4M5 33.63 6.11 
5 day Lapatinib C4M2 51.39 3.53 
5 day Lapatinib C4M3 98.61 7.44 
*indicates that there was only one replicate analysed so no SD could be determined 
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The plasma concentrations of lapatinib in the vehicle samples were below the limit 
of detection, which was to be expected as no lapatinib was given to the animals. In 
the 1 day lapatinib treated A4M3 there was extremely high level of lapatinib in the 
plasma, with a concentration that was >5000ng/mL. This was an unexpected result 
and could not be explained. The two technical readings of these samples both 
showed high level of lapatinib in the plasma. It is possible that there was some form 
of sample handling error that could have resulted in the reading of a high level of 
lapatinib in this plasma sample. In addition to this it is also possible that the blood 
sample did not have sufficient anticoagulant in the tube during collection and as a 
result there was some clotting of the blood sample. The remaining samples all had 
levels that were between 33 (A4M5) and 106  (A4M2) ng/mL.  
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6.5 Discussion 
 
The use of xenograft models has gained importance in particularly in the clinical trial 
setting[19]. In the course of this in vivo study, two approaches were employed, a cell 
line-derived tumour as well as the implantation of a tumour fragment from a donor 
mouse into a recipient mouse.  
The BT474 cell line that was selected to generate the cell line-derived tumour had 
been successfully used in previous HER2+ tumour xenograft experiments in the 
literature. [20-23]. As the most lapatinib sensitive cell line in our breast cancer cell 
lines panel from the in vitro studies from chapter 3 and 4, it was deemed the most 
suitable for the in vivo investigation. In culture, the cell line has a tendency to be 
slow growing and can take a number of weeks to become confluent following 
thawing [24]. When the cells were implanted it was discovered that the tumours 
derived from these cells were also slow growing as, after 23 days, the tumours had 
only reached a volume of approximately 100mm
3
. This tumour volume was in line 
with what other BT474  in vivo studies determined at this time point [25, 26]. In 
comparison to an unrelated study that used the same method this tumour volume was 
quite small as at the same time point, the volume of tumours derived from the DLKP 
cell line had reached over 400-500mm
3
. In addition to the small tumour size, the 
mice suffered an unusual and potentially life threatening reaction to the estrogen 
pellets that were implanted in order to maintain the growth of the estrogen-dependent 
BT474 cells.  
The pellets were implanted 24 hours prior to the cells to allow the mice to recover 
from the anaesthesia needed for this procedure prior to tumour cell implantation. 
During daily monitoring it was discovered that a number of the mice had significant 
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hardening in the bladder region, approximately 20 days post implantation of the 
pellet and, upon closer observation, it was noticed that they were not producing 
normal volumes of urine. It was also observed that the urine that was produced was 
extremely dark in colour and was causing staining of the fur. It was decided that an 
exploratory surgery would be undertaken in order to determine the cause of these 
symptoms. Upon dissection of the chosen mouse, it was discovered that the bladder 
has become blocked with a large deposit of crystalline material that was preventing 
the animal from urinating (Figure 6.3). This adverse effect had not been described by 
the producer of the pellet, however, when a detailed literature search was performed 
it was found that this effect has been observed by a number of other researchers [8, 
27-29]. Kang et al., [9] described, that by using lower doses of the estrogen pellet 
that the number of deaths that they had observed could be reduced but that the lowest 
dose of the estrogen pellet that was available still resulted in some deaths. They also 
described similar build ups in the bladder, which coincide with the timeline that the 
mice within our study exhibited these adverse effects. 
In conjugation with these adverse estrogen effects and the slow growing nature of 
the tumours, it was not possible to leave the animals any more than 35 days post 
implantation with the cell line before they were sacrificed for use in the tumour-
derived model or before the 5 day lapatinib treatment could be initiated. If the 
animals were left any longer, it was feared that this could cause undue suffering and 
could also possibly result in them succumbing to death from the bladder stones and 
the loss of the experimental material. The saline treatment that was given to the 
animals, while it may have provided the animals with increased hydration, did not 
prevent or slow down the crystalline build-up that was found in the bladders. As the 
experiment progressed, it was hypothesised that prolonged use of this palliative 
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method might also possibly cause increased harm to the animals as it was increasing 
their fluid intake, which they did not have the ability to adequately  relieve due to the 
bladder blockage.  
The gene expression pattern that was determined for the cell line-derived tumours 
was evaluated using RNA extracted from a tumour from a vehicle treated mouse and 
a tumour from a 5 day lapatinib treated mouse. From the cell line analysis, it was 
expected that we would see an up-regulation in expression of RB1CC1(H/M), 
FOXO3a(H/M), NR3C1(H/M) and ERBB3(H) and a down-regulation in the 
expression of CCND1(H/M) in the lapatinib treated tumours. However, in this initial 
pilot with only material from one control and one test animal this pattern was not 
evident. The anticipated down-regulation of CCND1(H/M) was evident but all of the 
remaining genes were also all down-regulated. There are a number of rationales for 
why this may have been the case. It is possible that the tumours did not respond to 
the treatment and if that was the case, the response that was evident would coincide 
with profile of non-responding cell lines to lapatinib treatment. This non-response 
could have been due to drug preparation issues or possibly due to issues with the 
absorption of the drug. Due to the small size of the tumour, it was not possible to use 
some of the material to evaluate the levels of the drug in the tumour using LC-MS as 
described in section 6.4. This analysis would have allowed us to determine that there 
was sufficient drug present in the tumour to affect gene expression.   All previous 
analysis was done on triplicate cell line sample measurements for each gene; this 
analysis was only completed on one tumour sample and hence the finding could be 
subject to significant inaccuracy. In addition to the five assays that were used in the 
in vitro experiments, three human specific assays for RB1CC1(H), FOXO3a(H) and 
NR3C1(H) and one mouse specific assay FOXO3a (M) were also employed in the 
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analysis. These human specific assays were used in the hope of distinguishing 
tumour (human cells) from murine gene expression, and thereby help evaluate the 
tumour specificity of lapatinib-induced gene expression changes   
The probes used throughout the analysis were either human specific, murine specific 
or cross-reactive for both species. The original Taqman probes that were used in the 
in vitro analysis were (unintentionally) a mixture of human specific and cross-
reactive probes. Human specific probes were employed for the in vivo analysis to 
help evaluate the effect of potential murine stromal contamination of the tumour 
material. The species specific probes, although targeting the same genes as the cross-
reactive probes, target a different region of the gene sequence that has not been 
conserved in the different species. The targeting of the different region could account 
for some of the variability that was exhibited in the gene expression in the tumour 
derived xenograft samples following lapatinib treatments.  
Another objective of this arm of the study was to determine if the mice could cope 
with the dose of lapatinib they would receive for 5 days. The half-life of lapatinib 
has been determined to be approximately 24 hours and a steady state level of 
lapatinib occurred after five to seven days in human patients [30, 31]. It was these 
aspects of the pharmacology of lapatinib that determined the time points in the 
lapatinib treatment of 1 and 5 days. 200mg/kg was the maximum drug dose 
administered. There have been a number of in vivo studies where varying doses of 
lapatinib have been admistered [23, 32-35]. Had there been sufficient animals to use, 
it would have been ideal to conduct a dose range experiment on a number of 
different animals to evaluate any dose dependent correlations in the gene findings.  
However, due to time and experimental limitations our dose regime was based on 
previous literature. A dose of 200mg/kg was selected as literature suggested it would 
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provide a sufficient dose of the drug to infiltrate the tumour while being of limited 
toxicity to the mice over durations longer than we proposed to use. It was 
hypothesised that exposure of the tumours to this drug level for the durations chosen 
(particularly for the five day duration) should be roughly consistent with the 
maximal durations previously evaluated in vitro and result in maximal gene 
expression changes. 
The xenograft study, involved 14 mice that underwent treatment with the vehicle 
alone, lapatinib for 1 day or lapatinib for 5 days. As the estrogen pellets were also 
required in F2 phase of the study, where the tumour fragments from donor mice were 
transplanted into recipient mice, sub cutaneous injections of saline were given to the 
animals from approximately day 10 post implantation in order to encourage urine 
production, in the hope that extra fluid delivery would “flush” the bladder, 
preventing or delaying development of the bladder issues. Unfortunately all of the 
mice within each of the three treatment groups (vehicle, 1 day lapatinib treatment 
and 5 day lapatinib) developed the same bladder issues as those in the F1 phase of 
the study. As a result of this, the animals were treated with either vehicle or 1 or 5 
day 200mg/kg of lapatinib using oral gavage before the tumours had sufficient time 
to develop into larger tumours. All genes showed a differential upregulation 
following 1 day of treatment with 200mg/kg lapatinib with the exception of 
NR3C1(H/M) where no expression was detected in any sample. FOXO3a(H/M), 
CCND1(H/M) and NR3C1 (H) had the highest levels of differential expression. The 
upregulation of CCND1(H/M) was unexpected as it has been downregulated in 
response to lapatinib in all of the other studies completed.  When examining the 
differential expression of the genes following 5 days treatment with lapatinib, there 
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was a change in the level of expression when compared with the values from the 1 
day lapatinib treated tumours.  
There was a significant biological variation between the Ct values for the genes 
between each mouse which accounts for the large standard deviation values that are 
present (appendix 3).  The variation in the tumour response could be explained by 
differences in the tumour section that was implanted into the mice. The tumour that 
was generated by injecting BT474 cells sub-cutaneously into the mouse, was cut up 
in order to be transplanted into the donor animals. It is possible that there were 
differences in the characteristics of the different sections such as the relative level of 
murine stroma infiltration or a concentrated pocket of cells that could explain the 
biological variation. The size of the tumours could also have had an impact on the 
tumour response. The tumours that developed were quite small in size in comparison 
to the tumour that developed following implantation with the BT474 cells. As a 
result of the small size it is possible that there was limited amount of human tissue 
from which RNA could have been extracted. When the tumours were being dissected 
from the mice there were small amounts of murine tissue extracted simultaneously. 
This murine tissue contamination could have reduced the signal for the human 
specific probes.     
LC-MS/MS analysis was employed to measure the concentration of lapatinib in 
plasma samples from the animals. Measurements of the drug (table 6.5) indicated 
that there were measureable levels of the drug in the animals system following the 
oral gavage administration. In order to confirm that sufficient levels of the drug were 
present in the tumour, this analysis would need to be completed on tumour samples 
following treatment. Unfortunately this was not possible due to the small size of the 
tumours. It was believed that the levels measured in the blood indicated that 
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sufficient levels were present, that the tumour had internalised the drug to affect gene 
expression within the cancer cells. 
Examination of the gene expression changes in the lymph-nodes, the lung and the 
skin following 5 day lapatinib treatment was completed to determine if there was any 
similarity of the expression pattern in other animal tissue samples. As anticipated, it 
was not possible to determine the relative expression of the genes, including the 
endogenous control, GAPDH, that were targeted by the human specific assays in 
these murine tissues.. It was possible to evaluate Ct values for the FOXO3a(H/M) 
and CCND1(H/M) but as there as there was no GAPDH Ct values, it was not possible 
to generate relative expression data. Ct values for the murine specific FOXO3a and 
GAPDH were detected and hence the relative expression of the murine gene variants 
was measurable. In all of the tissue samples the gene expression was determined to 
be unchanged after lapatinib treatment as the RQ values were below 2 indicating that 
this normal tissue was not responsive to the circulating drug.  
It was promising to see that it was possible to evaluate the gene expression changes 
in both the cell line and tumour-derived xenograft models and with proportionately 
small amounts of tumour material.  In order to fully examine the gene changes in this 
in vivo setting it would be critical to repeat this experiment with a number of 
changes. At the initial implantation and generation of the tumours, it would be 
important to monitor and possibly reduce the dose of the estrogen that is required for 
the experiment or else use a non-estrogen-dependent HER2+ model for the 
xenografts. Kang et al., [9] has shown that low dose estrogen can still maintain and 
support growth of the receptor-dependent cell lines and can extend the life 
expectancy of the animals. It has also been shown that introducing the estrogen in 
the water could be a plausible way to ensure dosing of the animals at a low dose 
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[36]. It has also be shown that it may not be necessary to use estrogen to maintain the 
tumour growth [37]. The strain of mice that was used may also be important to look 
at. Although SCID mice have been evaluated as being more immune-compromised 
than nudes, they are not the only suitable model that could be used. They have been 
shown to have a tendency to develop lymphomas, which could impact results of the 
study [38]. Nude mice have been shown to be comparable for the generation of 
xenograft models [36, 39, 40]. Nude mice tend to have some other practical 
limitations though as they have been shown to not support metastasis studies[41], 
while SCID mice appear to be more supportive of metastasis studies [3].  A slightly 
larger cohort of animals would also need to be used for each treatment group, giving 
tighter statistical findings to the results and also that biological variation could be 
examined more. It would also be important to blind the study and RNA analysis. 
Blinding the study would mean that animals were transplanted with tumour sections 
from differing sources. If this was to be completed in human studies, it would 
involve treating tumour samples from different patients under the same treatment 
conditions and determining the mean relative gene expression.    
It was not possible to detect a signal for the endogenous control in the lymph-node, 
lung and skin tissue samples. There were also biological variations in the Ct values 
that were determined for the tumour samples. It would be necessary to optimise the 
expression of a more suitable endogenous control for any further study. Further 
control genes such as TFRC, ABL and PSMC4 as evaluated by McNeal, R.E et 
al.,[42] may be more suitable, however, optimisation would have be undertaken.   
In principle, this study indicated that the experimental approach is appropriate for the 
evaluations we were attempting. Tumours were developed using both breast cancer 
cell lines and also secondary tumour implants derived from those cell lines. The 
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mouse strain that was utilised, SCID, successfully supported tumour culture, with 
nearly a 100% tumour growth success rate. It was also evident that the mice could 
tolerate the dose and treatment regime of the targeted therapy lapatinib. Successful 
RNA extraction and Taqman RT-PCR analysis were completed on the tumour 
material.  Inclusion of a patient derived xenograft (PDX) model could also provide 
interesting data as it provides a more realistic representation of a human tumour due 
having been less modified by culture and since such tumours typically demonstrate a 
presence of human stromal tissue. Further in vivo studies would be required in order 
to fully examine the effect of the lapatinib on the gene expression pattern; however 
the preliminary results described here are a strong foundation to build additional 
studies on. These results do show a consistency with the initial premise of the 
experiment, which was to evaluate if the gene pattern identified in vitro can be assed 
in an in vivo model.  
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7. Discussion 
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7.1 Discussion 
 
The aim of this project was to employ bioinformatics and in vitro and in vivo 
techniques to understand the molecular effect of targeted therapies on a panel of 
breast cancer cell lines. By investigating molecular gene expression changes, it was 
hoped to identify potential markers of response to a panel of HER2 targeted 
therapies. Development of novel targeted drugs is a major focus for the 
pharmaceutical industry; however, there is enormous need to identify a means to 
characterise which patients will benefit from treatment, thereby making such agents 
more useful and cost effective.  It was hoped that if we could identify markers of 
response this might be part of a potential route to ensure that only patients that will 
benefit from these expensive targeted therapies will receive the treatment.  
Extensive bioinformatic interrogation of microarray data from two HER2-positive 
lapatinib-sensitive cell lines treated with varying concentrations of lapatinib resulted 
in a list of 512 genes which were significantly altered in response to the drug. This 
list was generated using the Co-inertia analysis (CIA) technique, a multi-variant data 
analysis method that allows for the identification of trends or co-relationships in 
gene expression across multiple datasets which contain the same samples. This was 
the first time the analysis method had been applied to breast cancer cell lines or 
cellular drug response data.  From this list of 512 targets, a subset of 19 genes was 
examined using RT-PCR with five genes being shown to be differentially expressed 
in response to lapatinib and their magnitude of expression change was proportional 
to the sensitivity of the cell lines to the targeted drug [1]. When these five genes 
(RB1CC1, ERBB3, NR3C1, FOXO3a and CCND1) were examined in response to 
additional HER2 targeted therapies (afatinib, neratinib and traztuzumab), they 
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showed a similar gene expression pattern, indicating that the pattern identified has 
the potential to predict not only response to lapatinib but also, more broadly, HER2 
targeting therapies [2]. The gene expression pattern was not present when it was 
evaluated in a cell line (SKBR3-L) that has developed acquired resistance to 
lapatinib. When combined with our findings from a series of intrinsically sensitive 
and resistant cell models, this result suggested that the gene expression pattern has 
the potential for differentiating cell lines that are responsive, insensitive or have 
become resistant to lapatinib. Finally, when evaluated in a pilot in vivo study, the 
gene expression pattern was also largely evident in a xenograft model following 
treatment with lapatinib for both 1 and 5 days.  
The results generated from this project suggest that measuring gene expression 
changes in tumours treated with HER2-targeting drugs may have the potential to be 
utilised as a rapid, sensitive predictive marker of response to such therapies.  More 
generally, such an approach might potentially be adaptable to examination of the 
drug response of tumours to various drug treatments. In using this approach to 
determine response to therapies, it could be possible to avoid treating patients with 
expensive drugs that they will receive no benefit from and which could cause 
potentially serious side effects without any likely benefit. This could greatly improve 
overall treatment efficiency and efficacy. 
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7.2 Current state of the art in predictive cancer diagnostics 
 
7.2.1 Diagnostically Predictive Microarray technologies 
 
In examining the currently available prognostic or predictive biomarker approaches, 
there is clear diversity in the methodologies that have applied using each specific 
technology. 
Microarray technology has been utilised by a number of different groups that have 
identified gene expression patterns that can be used as either prognostic or predictive 
indicators of patient response. Oncotype DX, which involves a 21 gene signature, 
has been used in a prognostic manner to identify patients that are at risk of a 
recurrence of disease[3]. In the TAILOR X clinical trial the Oncoytpe gene 
expression signature was utilised to identify patients that would benefit from the 
inclusion of chemotherapy in their treatment regime[4]. MammaPrint uses a similar 
methodology [5] and in their approach a 70 gene signature has been used to  predict 
patients that were likely to suffer from metastasis from their original tumour. This 
assay is employed in the MINDACT trial, as with the TAILOR X trial, to predict 
which patients would benefit, from the inclusion of chemotherapy in their 
treatment[6]. Of interest, it has been suggested that the number of genes in both of 
these tests could be reduced as more detailed analysis has indicated that several do 
not make major contributions to the final therapeutic assessment and clearly in 
reducing the number of genes analysed there is potential to  reduce the cost of the 
test [7].  
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7.2.2 Diagnostically predictive gene mutation tests 
 
Examination of tumoural genetic mutations has also come to forefront of attempts to 
predict patients that will respond to certain chemotherapeutic or targeted therapies. 
The MassARRAY platform developed by Sequenom has been used to identify 
specific gene mutations that have been validated to predict to response to certain 
therapies. In combining PCR amplification steps with mass spectrometry (MALDI-
TOF) detection, the MassARRAY analyser 4 system has the capability of high 
throughput analysis of a large number of patient samples. In utilising this technology 
the following studies were able to determine the most suitable treatment regimens for 
patients based on the presence of gene mutations. Brevet, M et al., [8] utilised the 
MassARRAY technology to evaluate the presence of EGFR mutations in order to 
predict who would have an improved overall survival following erlotinib treatment, 
an EGFR inhibitor. Parker WT et al.,[9] determined that identification of BCR-ABL 
gene mutations following failure to respond to imatinib treatment in leukaemia 
patients, could predict which second line treatment would be the most suitable. Su, K 
et al.,[10] used the MassARRAY technology to identify the presence of the T790M 
mutation in lung cancer. Presence of this mutation has been associated with 
resistance to the EGFR inhibitors erlotinib and gefitinib. Identifying the presence of 
this mutation prior to or soon after beginning treatment could guide a more suitable 
treatment regime.  
With the advances in sequencing technologies, the ability to characterise a patient’s 
genomic tumour signature (including mutations etc.) more directly has become much 
easier and cheaper [11]. Next generation sequencing has proven to be a valuable tool 
in the deep sequencing of the tumour genome[12]. This high throughput technology 
  
231 
 
has the capability to sequence hundreds if not thousands of DNA sequences 
concurrently, cutting down on the time necessary to undertake this type of analysis 
[13].  It has the ability to be utilised in a number of studies, including SNP (small 
nucleotide polymorphisms), gene insertion and mutation, and copy number mutation 
analyses [11, 14]. While the technology has vastly improved in the last decade, there 
is still more work to be done before such technology can  form the basis of a routine 
diagnostic and deep sequencing of a cancer genome results in an extremely rich data 
set, which requires expert analysis or would not be clinically useful [15]. That being 
said, this technique has the capability to identify small somatic gene mutations that 
could have huge clinical implications in relation to suitable treatment options [16]. 
RNA-sequencing, also known as RNA-seq utilises next generation sequencing 
technologies and applies them to sequencing RNA transcripts. In using this method, 
researchers can investigate alternative gene splicing [17], post-translational changes, 
changes in gene expression [18], ribosomal changes [19] and examine different RNA 
populations such as miRNA and tRNA.  
 
7.2.3 Ex vivo diagnostic approaches 
 
In addition to these molecular biological approaches to evaluate tumour response, an 
ex-vivo methodology has also been developed to assess a patients response to 
different therapies[20]. Precision Therapeutics Inc. have developed ChemoFX to 
evaluate the response of patient samples to possible treatment regimens at varying 
drug concentrations using core biopsy samples [21]. Briefly, a primary culture is 
prepared from the patient biopsy by mincing the samples, which are then seeded to a 
culture flask with the correct medium and cultured until confluent. The cells are then 
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seeded to a 384 well plate and incubated for 72 hours with the relevant drug 
treatments. Survival fractions are calculated using untreated cells as controls and 
dose response curves are generated to evaluate the response index of the treatments. 
While this method was initially developed for the evaluation of the sensitivity of 
gynaecological cancers such as ovarian [22, 23] and cervical [24] cancer, this assay 
has also been applied to a number of breast cancer studies[25-28]. 
 
7.2.4 Sample preparation challenges  
 
When examining the different approaches for assessing predictive biomarkers, a 
common challenge that seems to affect all researchers is the quality of the samples 
on which the test will be performed. This challenge also relates to the validation and 
optimisation that is required in the preclinical evaluation of these markers. 
Historically FFPE tissue samples are the most common archival samples available, 
however, recent studies have indicated that this method of preservation is not 
conducive to the high quality RNA extraction necessary to evaluate mRNA and gene 
expression [29-31]. While there can be practical challenges with gene expression 
analyses from this type of material, it should be noted that while mRNA can be 
degraded in FFPE tissues, miRNA is generally not as impacted and as such archival 
material can be useful in miRNA studies.[32] While flash frozen samples would be 
more suitable for this type of analysis, the capability of hospitals to complete this 
method of preservation and store the collect samples is extremely restricted. In the 
Sequenom and Oncotype DX methodologies described in preceding paragraphs, 
FFPE is the recommended source material, while fresh tissue samples are preferred 
for the Mammaprint and ChemoFX methods.  The Sequenom method is a DNA 
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based technology and as DNA is not  as sensitive to degradation, FFPE tissues can 
be used successfully in this analysis. 
 
7.2.5 Regulatory relevance of companion diagnostics 
 
The drive to provide diagnostic tests for response to therapy has been continually 
increasing. The FDA have recently issued a directive, 21CFR809, calling for all 
pharmaceutical companies to incorporate companion diagnostics into their clinical 
and regulatory strategies[33] . Biomarker analysis and diagnostic development will 
now be required in conjunction with the pre-clinical and clinical trials with drug 
development [34]. However, it is not just regulatory bodies that are calling for 
companion diagnostics, national health services are also looking for tests that will 
indicate which patients will benefit from targeted therapy treatments. The National 
Centre for Pharmacoeconomics (NCPE) in Ireland and the National Institute of 
Health and Care Excellence (NICE) in the UK are responsible for determining if a 
drug should be made available to patients. Most of newly developed targeted 
therapies are expensive and have been seen to work in only a limited subset of 
potential patients. Without a companion diagnostic to determine which patients will 
benefit from treatment with these costly drugs, many of these therapies are not 
recommended to be made available for patients. In Ireland, the NCPE recently 
announced that it would not support the use of pertuzumab for treatment in HER2 
positive metastatic breast cancer patients due to cost. The monoclonal antibody has 
proven to be extremely successful in clinical trials when combined with trastuzumab 
[35]. In the UK, NICE announced that it would not support the use of lapatinib in 
patients with HER2 positive metastatic breast cancer. Without the ability to evaluate 
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who will benefit from treatment with the TKI, they determined that it was not cost 
effective to recommend the treatment [36]. These are just two examples of how, due 
to inability to determine benefit from treatment, successful therapies are not being 
utilised to their full capacity.  
In the area of HER2-targeted therapies, there are currently a limited number of 
approved companion diagnostics and none of these can be used to evaluate tumour 
response. The approved kits use either immunohistochemistry (IHC), fluorescent in 
situ hybridisation (FISH) or chromogenic in situ hybridisation (CISH) to evaluate 
HER2 status and expression [37].  However, only a subset of all HER2 
overexpressing patients will respond to HER2 targeting therapies. More broadly in 
the larger cancer field, utilisation of cancer gene expression changes as potential 
markers of response has been applied to a limited number of experimental studies. 
Wang, XD et al., [38] identified potential predictive gene expression markers of 
response to dasatinib which correlated with sensitivity of the cell lines used in their 
study. A similar approach, where gene expression changes were evaluated before 
and immediately after the start of treatment, was used by Modlich, O et al.,[39]. This 
group sought to determine if a comparison of gene changes before and after 
treatment could predict response to neoadjuvant chemotherapy regimens in patients 
with primary breast cancer. Their initial analysis indicated that this approach could 
be utilised for this purpose but that additional studies would need to be completed in 
order to fully evaluate which genes would be most suitable as markers.  
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7.2.6 Context of this work to the predictive diagnostic field 
 
The evaluation of gene expression changes has been used by a number of the 
methods described above; however, none of the commercial kits evaluate gene 
changes after a treatment has been given. All of the methods described above employ 
gene expression changes to determine if a patient should be given a treatment or not, 
but do not evaluate if the patient should remain on the treatment already started. The 
gene expression pattern described in this thesis has the potential to be utilised in 
determining if a patient should continue to respond to a HER2-targeting treatment 
that they have recently been given or not. For most clinicians the only indicator for a 
patient to be given one of the HER2 targeted therapies is that they demonstrate 
amplification of the HER2 gene. However, as indicated in previous chapters 
summarising the literature and the in vitro results described in chapters 3 and 4, the 
presence of HER2 is not necessarily an indicator of ultimate patient response to 
therapy.  In our models this is illustrated, for example, with our use of the 
MDAMB453 cell line which over-expressed HER2 but has an innate resistance to 
the effects of lapatinib.  
While this preliminary work has both demonstrated that there are clear alterations in 
the expression of a specific set of genes in response to HER2 inhibitor treatment in 
sensitive cells and possibly more broadly that this concept might therefore be 
adaptable to other agents, further research will be needed to take this to the stage of 
being a useful diagnostic.  In addition, while the findings of our in vivo study support 
our general hypothesis, there were practical challenges in our first experiment in this 
area.  Overcoming the estrogen-related bladder issues and thereby generating a larger 
amount of tumour material for evaluation in larger groups of animals will make for a 
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much clearer and more therapeutically-relevant understanding of our findings.  
Functional validation of our genes of interest will confirm their role in the cellular 
HER2 inhibitor response. It is also possible that there may be more suitable gene 
targets from the original list of 512 genes described, in particular from the 19 genes 
which were more closely examined in chapter 3. The roles of PIK3C3, CDKN1B 
and ALDH3A2 may warrant examination in parallel with our five gene response in 
any future in vivo study to determine if they may provide additional response 
information. A patient-derived xenograft, which has much closer architecture and 
biological characteristics to that of a human tumour, would also help to assess the 
relevance and significance of the gene expression changes described. 
One of the challenges that will have to be assessed in order to turn these gene 
changes into a useful diagnostic will be how the tumour samples will be taken and 
processed in a conventional patient/clinical context. As described in chapter 3, the 
minimum amount of RNA that is necessary to complete this type of analysis is as 
low as 20ng. A needle biopsy of a patient tumour would provide sufficient tumour 
material; however, processing of the sample will likely be very important. As the 
analysis is RNA-based, preventing contamination with genomic DNA and RNase 
degradation will be vital to ensuring that the quality of the sample remains at as high 
a standard as possible so that these contaminations do not interfere with the outcome 
of the analysis. So too will be our ability to utilise just tumour material, as our 
research has clearly shown that the response will not be evident in non-tumour 
material and a gene expression change signal could therefore be “crowded out” by 
RNA from non-tumour material. The capacity to use an automated processing step 
would remove some of the opportunity for these types of contamination to enter the 
samples. It appears likely that it will be necessary to complete a second biopsy of the 
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patient tumour within approximately one week of the treatment regime beginning 
which could cause some issues. In addition to patient discomfort and practical 
challenges with resampling from the same area, intra-tumour heterogeneity could 
have an impact on the analysis so it would be important that the second biopsy be 
taken close to the first one. It is conceivable that a second biopsy might not be 
required if the primary material could be kept alive and treated with clinically 
relevant concentrations of the test agent. Sampling of the gene expression before and 
after treatment would then be possible without having to go back to the patient and 
the associated inherent challenges of that approach.  Further in vivo investigation 
could help to remedy some of these challenges and fine tune the optimal approach. A 
suitable gene analysis platform would also need to be chosen. As there may only be 
five genes in the expression pattern, use of microarray technology and next 
generation sequencing would be an inefficient use of these platform types as well as 
being costly.  
In conclusion, there is an enormous imperative on biomedical science to identify 
diagnostics which predict or very rapidly measure tumour response in a patient if we 
are to improve the pharmacoeconomic viability of the emerging raft of new cancer 
pharmaceuticals and improve the selectivity of cancer treatment for our community. 
The work outlined in this thesis has identified a gene pattern that is predictive of 
response to HER2-targeted therapies in cell line models and a cell line derived 
xenograft. Using a multi-disciplinary approach which incorporated an emerging 
bioinformatic technique and molecular biological methods, the gene expression 
targets were successfully interrogated in a panel of cell lines with varying sensitivity 
to lapatinib and also in response to a number of different anti-HER2 therapies. By 
examining the genes in cells with varying sensitivities, we were able to determine if 
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the sensitivity of the cells to the treatment had an impact on the gene expression 
response, and hence whether the extent of alterations in our gene expression 
response could be used to predict the ultimate response of cells. In these HER2-
expressing cell line models, lapatinib, neratinib, afatinib and trastuzumab treatment 
generated a characteristic and specific gene expression response, proportionate to the 
sensitivity of the cell lines to the HER2 inhibitor. Characterisation of the induced 
changes in expression levels of these genes may therefore give a valuable, very early 
predictor of the likely extent and specificity of tumour HER2 inhibitor response in 
patients, potentially guiding more specific use of these agents.  Adoption of such an 
approach in the investigation of other therapeutics may also point the way for a 
whole new route and rapid methodology to assess treatment response. 
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7.3 Future Work 
 
 In order to functionally validate the gene targets, an siRNA study should be 
completed. By examining the toxicological impact of knocking down the 
genes in the cell line sub panel (BT474, SKBR3 and MDAMB453) the 
causative or associative role of the genes in response to lapatinib will be 
more apparent. This relevance and toxicological impact might also be 
examined  and assessed by looking at induced alterations in theexpression of 
genes (and their associated proteins) and even the targets of those genes 
downstream of the siRNA gene target.. A proteomic study using mass 
spectrometry methodology should be able to identify any major changes in 
the levels of such proteins. These roles should also be evaluated in the cell 
line panel in response to the additional HER2 targeted therapies (afatinib, 
neratinib and trastuzumab). This functional study will help to indicate if 
sensitivity of the cell lines to the targeted therapies has any impact on the 
roles of the genes in their response.   
  It would be informative to investigate the relevance of our gene expression 
pattern in HER2 over-expressing cell lines with acquired resistance to 
additional targeted therapies such as afatinib, neratinib or trastuzumab.  
 To further inform the in vivo results generated in this thesis the following 
adaptations of the described in vivo study (chapter 6) should be undertaken. 
Throughout the course of the experiment, the presence of the estrogen pellets 
resulted in bladder issues developing in a large percentage of the animals and 
this greatly impacted on our need to prematurely excise and analyse the 
tumours when it would have been preferable to leave them develop to a 
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larger size.  In order to determine if estrogen supplementation is necessary to 
support the growth of the tumours and if implantation was the most suitable 
administration method, a further study in which one group would not be 
given any estrogen supplementation, while another group would be given 
estrogen but in their water will be necessary. The in vitro identification of the 
gene expression pattern has indicated that this response pattern is indicative 
of response to not just lapatinib treatment but also additional HER2 targeted 
therapies. To evaluate that this observation translates to the in vivo setting, 
study evaluating gene expression response to these additional therapies 
should be carried out. Evaluation of the gene pattern in a HER2 positive 
patient-derived xenograft (PDX) should further inform the results that have 
already been generated in this study. A PDX better represents the molecular 
characteristics of the original tumour and reproduces more effectively the 
architecture of the primary tumour compared to cell line derived xenografts.  
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Appendix 1: Relative Expression (RQ) and Standard Deviation (SD) Values for breast cancer cell lines in response to lapatinib. (n=3) 
  12 Hours Lapatinib Preseeded Plates (Figures 3.6 and 3.7) 
  BT474 SKBR3 EFM192A HCC1954 MDAMB453 MDAMB231 
 RQ SD RQ SD RQ SD RQ SD RQ SD RQ SD 
RB1CC1 5.002 0.925 2.612 0.707 2.516 0.671 1.303 0.223 -1.273 0.595 -1.219 1.512 
FOXO3a 4.702 0.644 2.869 0.588 2.189 0.660 1.729 0.245 -2.226 0.543 -1.078 1.373 
NR3C1 4.215 0.699 2.624 0.746 3.446 0.123 1.285 1.337 -1.342 0.330 -1.097 0.378 
ERBB3 3.524 0.051 2.794 0.659 1.466 0.681 1.477 0.665 -1.118 0.416 -1.132 1.260 
PIK3C3 2.474 0.491 3.198 0.737 1.286 0.666 -1.036 0.642 1.066 0.338 -1.007 0.370 
ALDH3A2 3.370 0.279 2.593 0.732 1.369 0.220 -1.333 0.225 -1.123 0.715 1.246 0.481 
CDKN1B 2.366 0.351 3.044 0.428 1.316 0.504 1.113 0.753 -1.471 0.091 1.058 0.490 
CCND1 -3.256 0.412 -5.711 0.637 -2.180 0.217 -1.781 0.583 -1.341 0.182 -1.060 0.906 
  
  6 hour Lapatinib Treatment (Figure 3.9)  12 hour Individual Assay Lapatinib Treatment 
(Figure 3.8) 
  BT474 SKBR3 MDAMB453 BT474 SKBR3 MDAMB453 
  RQ SD RQ SD RQ SD RQ SD RQ SD RQ SD 
RB1CC1 18.021 1.119 10.172 0.773 1.592 0.218 37.214 1.007 5.339 1.162 1.221 0.724 
FOXO3a 6.235 1.069 2.974 0.304 -2.924 0.675 12.809 0.666 2.194 0.773 1.007 0.708 
NR3C1 6.871 0.613 2.791 0.726 -2.122 0.193 9.601 0.869 1.925 0.780 1.244 0.418 
ERBB3 6.096 0.576 4.518 0.478 -3.081 2.139 4.305 1.125 2.836 0.701 1.462 0.641 
PIK3C3 2.510 0.543 2.955 0.140 1.073 0.366 15.407 0.875 1.954 0.361 1.669 0.300 
ALDH3A2 3.468 0.456 4.040 0.571 -1.018 0.439 7.632 0.482 2.118 0.684 1.127 0.378 
CDKN1B 4.016 0.402 4.615 0.728 -1.387 0.317 4.362 0.612 3.205 0.762 -1.311 0.273 
CCND1 -3.614 0.959 -5.839 0.758 1.360 0.689 -2.031 1.478 -3.875 0.584 1.415 0.404 
246 
 
 
  24 hour Lapatinib Treatment (Figure 3.9)  36 hour Lapatinib Treatment (Figure 3.9) 
  BT474 SKBR3 MDAMB453 BT474 SKBR3 MDAMB453 
  RQ SD RQ SD RQ SD RQ SD RQ SD RQ SD 
RB1CC1 21.757 1.110 17.309 1.141 1.339 0.351 15.088 1.191 32.812 1.701 1.004 0.331 
FOXO3a 11.884 0.794 9.169 0.689 -2.113 0.448 8.433 1.681 13.244 0.929 -3.492 0.665 
NR3C1 9.603 0.458 3.216 0.901 -2.034 0.200 5.765 1.604 5.115 1.082 -2.618 0.109 
ERBB3 10.730 0.500 7.260 0.681 -1.036 0.271 8.789 0.693 9.645 0.781 -1.619 0.251 
PIK3C3 6.253 0.665 4.064 0.345 -1.072 0.380 5.406 0.732 5.615 0.839 -1.035 0.413 
ALDH3A2 11.307 0.355 5.334 0.758 -1.584 0.345 7.614 1.267 7.578 0.840 -2.436 0.495 
CDKN1B 7.358 0.887 5.565 0.707 -1.274 0.172 5.543 1.107 6.683 0.816 -1.268 0.279 
CCND1 -1.637 1.857 -3.465 0.535 1.082 0.335 1.117 0.655 -2.197 0.678 -1.032 0.408 
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RQ values for remaining 11 genes not used for further evaluation. 
 BT474 SKBR3 EFM192A HCC1954 MDAMB453 MDAMB231 
AKT1 -1.454 -1.580 -1.567 1.013 1.091 1.289 
BID -1.212 -2.017 -2.367 1.219 -1.288 -1.108 
E2F3 -1.697 -3.013 -2.574 -1.006 1.025 1.192 
EIF4E -1.218 -1.802 1.028 1.001 -1.038 1.003 
FKBP4 -1.155 -1.664 -1.759 -1.207 1.297 1.456 
MAPK9 -1.301 -1.478 -1.212 -1.124 -1.289 1.202 
PARP2 1.359 -1.316 -1.238 -1.355 1.000 -1.050 
PSMD13 1.159 1.362 -1.369 -1.453 -1.199 1.228 
SLC29A1 1.265 -2.071 -1.365 -1.812 -1.269 -1.014 
TFPT -1.086 1.362 -1.728 -1.443 -1.268 1.062 
CBFA2T2 1.850 2.812 1.101 1.135 1.024 1.366 
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Appendix 2: Relative Expression (RQ) and Standard Deviation (SD) Values for breast cancer cell lines in response to additional treatments (n=3) 
 12 Hour Neratinib Treatment (Figure 4.1) 36 Hour Neratinib Treatment (Figure 4.3) 
 BT474 SKBR3 MDAMB 453 BT474 SKBR3 MDAMB 453 
 RQ SD RQ SD RQ SD RQ SD RQ SD RQ SD 
RB1CC1 19.971 0.986 10.704 1.293 2.014 0.610 8.827 0.879 4.058 1.185 -0.844 0.667 
FOXO3a 8.924 0.647 3.916 0.786 -1.752 0.777 8.416 0.791 3.444 0.713 -1.402 0.506 
NR3C1 7.803 0.528 2.664 0.807 -1.645 0.712 5.225 0.371 1.707 0.834 -1.198 0.207 
ERBB3 8.619 0.142 5.040 0.602 -1.240 1.343 5.669 0.102 2.574 0.730 -1.369 0.092 
PIK3C3 3.684 0.055 3.221 0.417 1.055 1.560 2.194 0.256 1.215 0.448 -2.233 0.264 
ALDH3A2 5.975 0.301 4.409 0.691 1.342 0.067 4.145 0.106 1.643 0.814 -1.228 0.379 
CDKN1B 5.011 0.230 4.919 0.721 1.098 0.516 2.771 0.301 1.413 1.034 -0.967 0.408 
CCND1 -3.189 0.767 -3.725 0.695 1.091 0.825 -3.903 1.026 -3.657 0.631 -1.585 0.357 
 
  12 Hour Afatinib Treatment (Figure 4.2) 36 Hour Afatinib Treatment (Figure 4.3) 
  BT474 SKBR3 MDAMB 453 BT474 SKBR3 MDAMB 453 
 RQ SD RQ SD RQ SD RQ SD RQ SD RQ SD 
RB1CC1 25.653 0.929 4.827 1.262 1.266 0.423 27.855 0.955 10.790 1.301 -1.454 0.309 
FOXO3a 9.394 0.900 1.367 0.758 -1.104 0.496 33.545 0.823 14.978 0.863 -1.320 0.291 
NR3C1 10.966 0.583 3.512 0.838 1.129 0.278 87.956 0.631 24.008 0.864 3.540 0.283 
ERBB3 12.165 0.297 2.481 0.769 1.147 0.382 14.999 0.324 5.581 0.779 -1.875 0.235 
PIK3C3 26.396 0.218 1.760 0.522 1.280 0.650 6.054 0.374 2.652 0.381 -1.836 0.299 
ALDH3A2 15.982 0.162 2.275 0.885 -1.144 0.689 26.450 0.231 7.645 0.681 -2.716 0.385 
CDKN1B 7.955 0.324 2.675 0.868 -1.513 0.484 9.270 0.481 4.993 0.789 -1.497 0.245 
CCND1 -1.589 1.020 -6.070 0.645 1.606 0.429 -1.452 1.017 -2.512 0.656 1.130 0.379 
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  12 Hour Lapatinib with Capecitabine(Figure 4.5) 12 Hour trastuzumab Treatment (Figure 4.6) 
  BT474 SKBR3 MDAMB 453 BT474 SKBR3 MDAMB 453 
  RQ SD RQ SD RQ SD RQ SD RQ SD RQ SD 
RB1CC1 17.814 0.462 4.412 1.129 1.221 0.724 7.895 1.660 3.810 1.219 -1.217 0.079 
FOXO3a 6.673 0.232 1.483 0.829 1.007 0.708 3.077 0.856 1.001 0.796 -1.306 0.404 
NR3C1 8.756 0.463 3.853 0.797 1.244 0.418 4.419 0.636 2.202 0.757 -1.111 0.385 
ERBB3 7.562 0.518 2.276 0.796 1.462 0.641 3.970 0.328 1.655 0.743 -1.135 0.361 
PIK3C3 15.263 0.395 1.991 0.361 1.669 0.300 15.626 0.371 1.445 0.330 1.193 0.532 
ALDH3A2 10.575 0.769 2.050 0.814 1.127 0.378 8.125 0.294 1.689 0.695 -1.386 0.366 
CDKN1B 5.351 0.754 2.172 0.748 -1.311 0.273 4.783 0.322 1.999 0.663 -1.794 0.059 
CCND1 -2.591 0.607 -7.175 0.620 1.415 0.404 2.167 1.000 -1.362 0.628 1.897 0.300 
 
  12 Hour Dasatinib (Figure 4.7) 12 Hour Gefitinib Treatment (Figure 4.8) 
  BT474 SKBR3 MDAMB 453 BT474 SKBR3 MDAMB 453 
  RQ SD RQ SD RQ SD RQ SD RQ SD RQ SD 
RB1CC1 5.288 1.136 2.004 0.744 -1.783 0.346 1.250 0.968 2.350 1.169 -2.992 0.311 
FOXO3a 1.940 0.952 -1.412 0.752 -4.184 0.577 2.331 0.841 -2.402 0.786 -11.118 0.424 
NR3C1 6.206 0.843 2.599 0.655 -1.003 0.326 -2.216 0.700 -1.418 0.806 -4.514 0.304 
ERBB3 1.616 0.366 -1.497 0.803 -3.810 0.557 -3.723 1.090 -1.320 0.591 -6.019 0.227 
PIK3C3 1.676 0.460 -1.109 0.363 -2.230 0.256 -2.670 0.369 -1.703 0.395 -3.741 0.437 
ALDH3A2 1.680 0.362 -1.102 0.763 -5.904 0.189 -1.080 0.232 1.074 0.657 -5.986 0.408 
CDKN1B 2.718 0.521 1.495 0.777 -2.434 0.299 -2.328 0.536 -1.305 0.630 -5.503 0.308 
CCND1 1.360 1.096 1.093 0.457 1.079 0.274 -13.438 1.221 -3.787 0.515 -2.801 0.319 
             
                     
 250 
 
  12 Hour Epirubicin Treatment (Figure 4.9) 
  BT474 SKBR3 MDAMB 453 
  RQ SD RQ SD RQ SD 
RB1CC1 -1.358 1.232 1.278 1.229 -4.842 0.050 
FOXO3a 1.102 1.122 -4.068 0.794 -13.298 0.349 
NR3C1 -4.982 0.885 -2.224 0.859 -6.321 0.323 
ERBB3 -4.757 0.614 -2.084 0.614 -14.388 1.320 
PIK3C3 -4.172 0.660 -2.195 0.391 -5.285 0.588 
ALDH3A2 -2.857 0.493 -1.569 0.743 -8.458 0.480 
CDKN1B -3.161 0.822 -1.679 0.751 -8.046 0.296 
CCND1 -6.443 1.399 -3.583 0.629 -3.212 0.328 
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Appendix 3:  
Ct values for each of the genes in the vehicle, 1 day lapatinib and 5 day lapatinib treatment in each animal. 
 Vehicle  1 day lapatinib treatment  5 Day lapatinib treatment 
 Ct m1 Ct m4 Ct m5  Ct m1 Ct m2 Ct m3 Ct m4  Ct m2 Ct m3 Ct m4 Ct m5 
RB1CC1 (H/M) * 32.998 28.215  * 34.625 33.771 32.855  32.075 35.455 31.298 * 
FOXO3a (H/M) 30.658 30.134 29.307  30.569 31.204 29.922 31.461  32.312 30.135 29.675 31.968 
NR3C1 (H/M) * 34.563 30.030  * * * *  32.961 * * * 
ERBB3 (H) * 32.114 27.573  * 33.444 32.461 31.467  30.999 34.730 30.742 * 
CCND1 (H/M) 31.068 29.467 28.485  29.458 31.405 29.007 30.808  31.857 30.007 29.540 31.880 
RB1CC1 (H) * 33.047 28.901  * 33.813 33.439 32.331  32.025 * 31.351 * 
FOXO3a (H) * 30.932 26.789  * * 34.199 30.157  30.061 33.753 29.511 33.803 
NR3C1 (H) * 33.753 28.597  33.286 29.970 29.489 32.502  31.079 * 33.344 * 
FOXO3a (M) 30.653 27.876 29.459 
 
28.004 28.549 27.877 28.462 
 
30.407 28.420 28.105 28.849 
GAPDH (M) 21.913 21.509 25.816  22.622 23.498 23.621 23.531  26.930 22.752 22.452 25.417 
              
              
GAPDH * 26.488 21.843  31.096 28.556 28.153 26.577  26.651 28.845 24.570 31.921 
*indicates that the Ct values was above 35 and as such was not considered expressed and was excluded from the calculations. 
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 Skin Ct values 
 Vehicle 5 Day lapatinib treatment 
 Ct m1 Ct m4 Ct m5 Ct m2 Ct m3 Ct m4 Ct m5 
FOXO3a (H/M) 29.19784 30.5586 30.87789 29.6879 28.15496 28.67739  * 
CCND1(H/M) 29.92199 30.90163 31.42274 30.681 29.507 29.628  * 
 Lung Ct values 
 Vehicle 5 Day lapatinib treatment 
 Ct m1 Ct m4 Ct m5 Ct m2 Ct m3 Ct m4 Ct m5 
FOXO3a (H/M) 27.51486 28.1907 28.1907 27.51962 27.42548 27.72178 27.54139 
CCND1(H/M) 27.65937 27.95 27.92429 28.22269 27.47478 27.96587 27.6164 
 Lymph-node Ct values 
 Vehicle 5 Day lapatinib treatment 
 Ct m1 Ct m4 Ct m5 Ct m2 Ct m3 Ct m4 Ct m5 
FOXO3a (H/M)  #  # #  29.52675 29.16434 29.41843 29.07615 
CCND1(H/M)  # #   # 28.44526 28.44598 28.3298 28.10955 
*indicates that the Ct values was above 35 and as such was not considered expressed and was excluded from the calculations. 
#indicates that RNA extraction was not completed on these samples 
 
